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The aim of my Ph.D. thesis is to develop trigger-responsive prodrug platform to address the 
nanoparticle (NP) formulation issue in cancer therapeutics. By designing a trigger-responsive 
camptothecin (CPT) prodrug structure, it was demonstrated for the first time that a small molecule 
prodrug could be encapsulated in PEGylated nanoparticles with quantitative drug loading 
efficiency and more than 50% drug loading. The nanoparticles were shown to have controlled 
release profile in response to cancer-specific trigger. A series of dimeric CPT derivatives were 
designed that are responsive to various in vivo applicable triggers to study the formulation 
mechanism. The prodrug library suggested that the dimeric prodrug structure and the flexible 
trigger-responsive side chain are both critical to the high drug loading formulation. A hypoxia-
responsive CPT dimeric prodrug was further developed and was co-encapsulated with 
photodynamic sensitizer, chlorin e6, in one NP for combination therapy to combat tumor resistance 
to photodynamic therapy (PDT) caused by a hypoxic environment. The ultra-high drug loading 
nanoparticles with controllable release and defined nano-structure mark a milestone in the 
formulation of nanomedicine and will have significant impact on nanomedicine platform design 
as well as their clinical translation. In connection with the dimeric prodrug design, a trigger-
responsive amphiphilic polymeric nano-assembly is also explored for cancer treatment based on 
thiol-responsive chain-shattering polymeric therapeutics. The polymeric therapeutics showed 
controlled self-assembly behavior and good in vivo anti-tumor efficacy. To develop novel 
polymeric biomaterials for biomedical application, I also studied dynamic aromatic hindered urea 
chemistry as degradable polymeric materials. The aromatic hindered ureas have hundred times 
higher dynamic exchange kinetics (k-1) than the reported aliphatic hindered ureas and showed fast 
hydrolytic degradation in polymers with pH-independent kinetics. The room temperature self-
healing property of the aromatic hindered ureas in a cross-linked gel was explored as a proof of 
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Nanomedicine, transformative therapeutics for cancer treatment: Nanomedicines (NMs) have 
been extensively studied as novel therapeutic and diagnostic agents for various applications.1-4 For 
cancer treatment, nanomedicines that have size between 5 to 200 nm have shown to have enhanced 
permeation and retention (EPR) effect, i.e. preferential accumulation in solid tumors due to the 
leaky vasculature and impaired lymphatic drainage of the tumor tissue.5-7 Furthermore, NMs 
generally have a better pharmacokinetic profile than molecular agents because of less recognition 
by the immune system for clearance.1,8-15 While many platforms of NM have been investigated 
including liposomes,16,17 polymeric nanoparticles,18-26 carbon materials,27-31 and inorganic 
particles,32-36 clinical success is limited to the only two FDA approved NMs, Doxil and 
Abraxane.37-39 Although NMs are shown to have much lower toxicology profile than conventional 
chemotherapeutics, most NMs have comparable or less anti-tumor efficacy than chemotherapy, 
which prohibits their regulatory approval for clinical use. 
Formulation challenges prohibit the translation of nanomedicines into clinical applications: 
Direct encapsulation of free drugs by hydrophobic polymers or amphiphilic copolymers is 
extensively used for preparing polymeric nanoparticles (NPs). However, drug loading and loading 
efficiency in NPs are typically very low.40-45 Less than 5% of drug loading and 50% loading 
efficiency (>50% drug self-aggregation or loss during formulation) are frequently reported in 
polymeric NMs.19 The drug loading of a NM is a critical measurement of its applicability in clinic. 
At low drug loading, large amount of NMs are needed at fixed administration volume, which 
would result in highly concentrated formulations that may not be easily administered in vivo. On 
the other hand, low drug loading efficiency results in large, micrometer-size drug aggregates that 
can be very difficult or impractical to be removed from the NMs; administration of these 
heterogeneous mixtures containing both drug-encapsulated nanostructures and un-encapsulated 
drug aggregates may lead to immediate animal death. Furthermore, the batch variation of NMs’ 
size and composition imposes a significant hurdle in manufacturing and quality control of NMs, 
which prevents further translational development. Each of these challenges significantly prohibit 




Scheme 1.1. Schematic illustration of two types of polymeric nanomedicines, micelle (a) and 
polymer-drug conjugate (b). 
Polymeric NMs have attracted much attention in past few decades for cancer therapy.8,46-51 
Micelles and polymer-drug conjugates (Scheme 1.1) are the two major types of polymeric NM 
explored so far. A micelle is a type of nano-assembly formed from amphiphilic polymers driven 
by the hydrophobic interaction of the polymer chains. Hydrophobic drugs can be encapsulated in 
the core of the micelle stabilized by the hydrophobic interaction between the drug and polymer. 
The drug loading capacity of the micelle is limited by the size of the micelle hydrophobic core, 
which generally holds less than 10 wt% of the drug. Furthermore, the formulation of a typical 
micelle-drug encapsulate often gives low drug loading efficiency as the formation of drug-drug 
aggregation kinetically competes with the micelle encapsulation process which could generate 
micron-size precipitates during formulation. A polymer-drug conjugate is prepared by covalent 
conjugation of drug molecules onto a polymer chain that can self-assemble into aqueous-stable 
nanoparticles. The synthesis of polymer-drug conjugates requires highly-efficient conjugation 
chemistry to ensure efficient drug modification and minimal side reaction on the polymer chain. 
Although the drug loading of polymer-drug conjugate can be reasonably high without disturbing 
the nano-assembly behavior of the polymer, the drug distribution variation within one polymer 





conjugate heterogeneous and poorly reproducible if not well controlled. The drug-polymer linker 
needs to be cleavable in biological environment in order to release the authentic drug for 
therapeutic effect. 
Prodrug approach to achieve cancer-specific therapeutic release: The release of free drugs from 
directly drug-encapsulated nanostructures can be very difficult to control52,53 as the release of free 
drugs depends on the kinetics of diffusion.52,53 Undesired drug leakage or uncontrolled burst 
release from NPs is almost inevitable and occurs once these nanostructures are exposed to 
biological media,19 which result in undesired toxicity due to the high accumulation of free drugs 
in major organs. One approach to address the uncontrolled drug leakage and burst release effect 
after administration is to adopt a prodrug design.19 By conjugating a therapeutic drug to the NM 
carrier polymer or a specifically designed linker, the drug activity is diminished due to the blocking 
of the bio-activity site or change of the binding moiety. The prodrug can release the authentic drug 
by cleavage of the drug-linker bond through either non-specific hydrolysis or triggered chemical 
reaction that can be potentially disease-specific. Ester based prodrugs have been extensively 
explored26,54-58 and a few are currently in human clinical trials for cancer treatment.38,47,59  
Trigger-responsive drug release through covalent chemistry: Ester-containing prodrugs are one of 
the most explored prodrugs class so far. Although the synthesis and formulation of drug-ester is 
generally convergent and well-controlled, the drug release from drug-ester is regulated by the 
hydrolysis of the ester bond and the drug diffusion, which are non-specific to disease tissues. To 
further improve the selectivity of drug release in target tissue, my thesis research focuses on the 
design of various trigger-responsive chemistries that may potentially be used for different disease-
specific on-demand release (Scheme 1.2). Various trigger-responsive approaches have been 
reported using both endogenous and exogenous triggers. Cancer, for example, has distinct 
biological fingerprint that is different from normal tissues that can be used to design cancer-
specific drug release trigger mechanism including pH,60-64 hypoxia (low oxygen level),65-68 
reactive oxygen species (ROS),69-71 upregulated protease activity,72-74 etc.18,75-78 Exogenous 
triggers can also be used to direct the drug release in a spatial temporal control if the disease lesion 
is spatially well-identified prior to treatment. Triggering mechanism including UV light,79-81 and 




Scheme 1.2. Trigger-responsive chemistries, release mechanism and degradation products. All of 
the trigger groups can be linked either directly to a prodrug or one/multiple self-immolative 
structures that conjugated to one/multiple prodrug (R group). (a) Reductive thiol responsive 
disulfide. (b) aliphatic and aromatic azide. (c) UV responsive o-nitrobenzyl alcohol derivative. (d) 
UV/NIR light-responsive courmarin derivative. (e) Hydrogen peroxide-responsive boronic ester. 
(f) Reduction-responsive quinone derivative. 
Self-immolative chemistry that ensures efficient drug release through spontaneous covalent bond 
cleavage: The covalent trigger-responsive chemistries can only release specific chemical groups 
due to the thermodynamic and kinetic limitations. In order to adapt trigger-responsive chemistry 
to a specific drug of interest, a linker chemistry is needed for the conversion of the release group 
into the conjugation site of the drug as well as to provide a spacer for more complex prodrug 
structure design with efficient release kinetics. Series of self-immolative linkers have been 
developed92-96 and I adopted those linkers into my prodrug design to form various trigger-
responsive prodrug molecules that can potentially release authentic drugs quantitatively (Scheme 
1.3). All of the trigger-responsive groups (Scheme 1.2) can either directly release an amine or 
alcohol containing drug or release an active terminus including thiol, amine, or hydroxyl group. 
Therefore, I chose a few self-immolative chemistries that can further release functional amines or 
alcohols through self-elimination or self-cyclization to de-cap another self-immolative group or 










Scheme 1.3. Self-immolative chemistry that can convert a thiol, amine or hydroxyl group signal 
into amines or alcohols suitable for prodrug design. (a) 1,4 and 1,6 self-elimination of 
aniline/phenol structure to degrade a urethane or carbonate containing side chain. (b) Self-
cyclization of thiol and amine to form 5 membrane prodrug from a carbonate or urethane bond. 
1.2. Scope and organization 
Scheme 1.4 depicts the organization and flow of my thesis. The aim of my Ph.D. thesis is to 
develop a trigger-responsive prodrug platform to address the nanoparticle (NP) formulation issue 
in cancer therapeutics. By designing a trigger-responsive smaller-molecular camptothecin (CPT) 
prodrug structure, I demonstrated for the first time that a small molecule prodrug can be 
encapsulated in PEGylated nanoparticles with quantitative drug loading efficiency and more than 
50% drug loading and the nanoparticles have controlled release profile in response to cancer-
specific trigger (Chapter 2). To further understand the underlying mechanism for the high loading 
NP formation, I next studied the various formulation factors including the prodrug structure, 
amphiphilic polymer type/molecular weight, solvent choice, temperature, etc. (Chapter 3). The 
formulation study indicated that the dimeric prodrug structure and the flexible trigger-responsive 
side chain are both critical to the high drug loading phenomenon. Based on the formulation 
understanding of the prodrug design and the core-shell nanoparticle structure, I further designed a 
hypoxia-responsive CPT dimeric prodrug for the NP formulation to co-encapsulate photosensitizer 





original dimeric prodrug design, I also developed a trigger-responsive amphiphilic polymeric 
nano-assembly for cancer treatment based on the self-immolative domain (Chapter 5). To further 
expand the existing biomaterial library, I also studied dynamic aromatic hindered urea chemistry 
as degradable polymeric materials. The room temperature self-healing property of the aromatic 
hindered ureas in a cross-linked gel was explored as a proof of concept as a potent self-healable 
biomaterials (Chapter 6). 
 
Scheme 1.4. Organization of the dissertation. 
Trigger-responsive prodrug
Thiol-responsive Prodrug NP (Chapter 2)
Photodynamic Therapy Combination
with Hypoxia-responsive NP (Chapter 4)
NIR light
O2
Polymeric self-assembled NP (Chapter 5)
Formulation Control and Understanding (Chapter 3)
UV control on dynamicity
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FORMULATION OF DIMERIC HIGH-LOADING TRIGGER-RESPONSIVE DRUG 
NANOENCAPSULATES* 
2.1. Introduction 
The major challenge of drug encapsulation into polymer NPs with high efficiency lies in the 
formulation process, during which polymer carriers form nanostructures while drugs either form 
undesired aggregates (Process A as shown in Scheme 2.1a) or diffuse into the carrier to form 
desired polymeric NPs (Process B as shown in Scheme 2.1b). In the case of hydrophobic drugs 
that tend to crystallize to have long-range order, the kinetic process for forming large drug 
aggregates may dominate (Process A). In order to form drug-embedded polymeric NPs with high 
efficiency, the fast kinetics of drug self-aggregation/ crystallization leading toward very large drug 
aggregates (usually several to tens of micrometer size) (Process A) has to be prohibited so that the 
hydrophobic drug molecules can interact with hydrophobic polymers and be embedded (Process 
B). However, even if the Process A is constrained, the drug embedding mechanism (Process B) 
cannot yield high drug loading efficiency since drug self-aggregation/crystallization is both 
kinetically and thermodynamically trapped stable state. Therefore, inhibiting Process A does not 
necessarily promote Process B. We envision a process that can lead to the formation of very small 
drug nano-crystal/nano-aggregates (ideally 20-200 nm) and such small, densely-packed drug 
nano-crystals/nano-aggregates function as the NP core while the polymers act as the surface 
stabilizer to form the NP shell instead of as bulk carrier (Scheme 2.1c). The mechanism should be 
the way to prepare high drug-loading with up to 100% loading efficiency and very stable NM 
without undesired drug leakage during post-formulation processes (NM production, sterilization, 
packing, shipping and storage). 
                                                 
* Part of this chapter is adapted from the publication: Cai, K.; He, X.; Song, Z.; Yin, Q.; Zhang, Y.; Uckun, F.M.; 
Jiang, C.; Cheng, J. "Dimeric Drug Polymeric Nanoparticles with Exceptionally High Drug Loading and Quantitative 




Scheme 2.1. Illustration of encapsulating hydrophobic drugs into nanoparticles. (a) Hydrophobic 
drugs form large precipitates due to fast aggregation/ crystallization. (b) Hydrophobic drugs 
encapsulated in polymeric micelle. (c) Formation of high-loading drug nanoparticles via formation 
of drug nano-aggregates/nano-crystals followed by surface coating/stabilization by polymer.  
2.2. Dimeric camptothecin conjugate quantitatively forms nanoparticles with amphiphilic 
polymer 
CPT forms micron-size precipitate upon addition into water even with 10-fold mPEG-PLA: We 
focused on camptothecin (CPT) (Figure 2.1a), an anticancer drug, to validate our design. CPT is a 
very potent anticancer drug, but not clinically used due to its low water solubility.1 It binds 
topoisomerase I to arrest DNA replication through the hydroxyl group and the lactone ring.2 
Therefore, modification of the CPT hydroxyl group can diminish CPT’s bioactivity and be used 
as a prodrug approach for delivery. Moderate encapsulation efficiency and very low drug loading 
have been reported for CPT polymeric micelles (< 5%) presumably due to the strong π−π 
interaction of its planar pentacyclic aromatic ring structure that leads to micron size large 
aggregates (Scheme 2.1a).3-5 We hypothesize that by introducing a dimeric structure to disrupt the 
CPT intermolecular π-π interaction, the aggregation kinetics of the conjugates would be reduced 









precipitation of CPT from DMF to water without addition of amphiphilic copolymer. CPT 
precipitate (larger than 10 µm) was formed almost instantly (within seconds) upon addition of the 
CPT/DMF solution to water (Figure 2.1b). When CPT was precipitated with mPEG-PLA 
(methoxy-polyethylene glycol-b-D,L-polylactide) at 1:1 (w/w) ratio, multiple distributions were 
observed with significant micron size aggregates (Table 2.1, entry 1). When the amount of CPT 
was reduced by 10 times to CPT/mPEG-PLA ratio of 1:10 (w/w) (Table 2.1, entry 2), there was no 
substantial improvement on the heterogeneity of the formulation and large aggregates were 
observed. Only when the drug:polymer ratio decreases to 1:20 did the mixture form negligible 
micrometer size aggregates (Table 2.1, entry 3) and the drug loading and loading efficiency were 
determined to be 1.6% and 33%, respectively. 
 
Figure 2.1. (a) Chemical structure of camptothecin (CPT), CPT-SS-CPT, and CPT-SS; CPT-SS-
CPT decomposition and release of CPT upon triggering by thiols. (b) Size evolution of CPT and 
CPT-SS-CPT aggregates (without mPEG-PLA) over time. The drug/DMF solution was diluted by 
20-fold water.  
Table 2.1 Formulation results of drugs with mPEG-PLA via nanoprecipitation (DMF-H2O). α, LE: 
drug loading efficiency. β, DL: drug loading. γ, large aggregates were observed. 
 


















d (nm) PDI LE(%)α DL(%)β
1 CPT 1.0 2669γ 0.28 - -
2 CPT 0.1 4588γ 0.36 - -
3 CPT 0.05 35.8 0.23 33 1.6 
4 CPT-SS-CPT 1.0 170.8 0.09 > 99 50.0 
5 CPT-SS-CPT 3.0 172.9 0.15 > 99 75.0 
6 CPT-SS-CPT 6.0 165.0 0.13 > 99 85.7 
7 CPT-SS-CPT 10.0 181.4 0.12 > 99 90.9 
8 CPT-SS 1.0 726γ 0.30 - -
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Precipitation of CPT-SS-CPT in water form smaller aggregates and CPT-SS-CPT/mPEG-PLA 
formed sub 200 nm nanoparticles with quantitative loading efficiency: To validate the dimer design 
strategy for preparing high loading NM, we designed and synthesize CPT-SS-CPT (Figure 2.1a). 
CPT-SS-CPT has two CPT molecules conjugated to 2,6-bis(hydroxymethyl)aniline (BHA) via its 
2,6-benzylic hydroxyl groups with carbonate linkages. The amine group of the aniline is protected 
by a disulfide bond bearing flexible chain with terminal azide group (subject to further 
modification via Click Chemistry). Upon triggering, cleavage of the disulfide bond in CPT-SS-
CPT would result in cascade decomposition of the drug dimer, releasing CPT in its original form 
(Figure 2.1a). We compared CPT-SS-CPT with CPT in the same experiments as described above. 
The CPT-SS-CPT was first precipitated from DMF to water. As expected, CPT-SS-CPT 
aggregation was much slower than that of CPT (Figure 2.1b). When a mixture of CPT-SS-CPT 
and mPEG-PLA (1:1, w/w) was precipitated in water, DLS analysis showed monomodel 
distribution, indicating homogeneous NP formation. This formulation has a calculated CPT-SS-
CPT loading of 50% which was exactly the case after the content of CPT-SS-CPT was analyzed 
by UV-vis absorption (Table 2.1, entry 4). We also attempted using a mixture of CPT-SS-
CPT/mPEG-PLA at a weight ratio of 3:1, 6:1 and 10:1 for making CPT-SS-CPT/mPEG-PLA NP 
(Table 2.1, entry 5-7). All three cases gave single NP size distribution, suggesting homogeneous 
formulation and well-controlled compositions. The determined CPT-SS-CPT loading were 75%, 
89% and 91% (corresponding to 43%, 49% and 52% of CPT contents), respectively, in excellent 
agreement with the calculated drug contents. TEM observation confirmed a spherical morphology 
of the NP with a distinct core-shell structure (Figure 2.2a) ranging 100-200 nm in size. The NP 
remained stable in serum containing medium for more than 3 days (Figure 2.2b). These 
experiments demonstrated that even at a drug dimer/polymer weight ratio of 10, we can still get 
100% drug dimer “encapsulated” into the polymeric NP. As a comparison, a ‘monomeric’ CPT 
derivative, CPT-SS, linking CPT directly to the disulfide side chain without the aniline fragment 
(structure see Figure 2.1a) resulted in uncontrolled large aggregate when being coprecipitated with 
mPEG-PLA at 1:1 drug/polymer ratio (Table 2.1, entry 8). The results further demonstrate the 
necessity of the dimer structure for high loading formation: dimeric structure affords stronger 
intermolecular drug interactions than both CPT and CPT-SS. Clearly, these observations are 
dramatically different from conventional nanoprecipitation typically with low drug loading and 
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low loading efficiency, substantiating the proposed NM formation process (Scheme. 2.1, Process 
C).  
 
Figure 2.2. (a) TEM image of the CPT-SS-CPT/mPEG-PLA NP. Scale bar 200nm. (b) CPT-SS-
CPT/mPEG-PLA NP size in serum. (c) CPT release from DTT triggered CPT-SS-CPT high loading 
NPs. (d) Cytotoxicity of the CPT-SS-CPT NPs in human cervical cancer cells (HeLa).  
2.3. Controlled drug release and anti-cancer evaluation of the thiol-responsive prodrug NP  
Triggered Drug Release: The CPT-SS-CPT NP showed controlled release over 48 hours with 
model thiol trigger, 1,4-Dithiothreitol (DTT) and only the free drug was detected over the course 
of the study. In contrast, negligible CPT release was detected in the absence of DTT (Figure 2.2c) 
and the NP size remained unchanged for more than one week. Thus, this is a very rare example of 
drug-encapsulated NPs (drugs not covalently bound to polymer matrices) with completely 
eliminated burst release/leakage effect presumably due to the drug dimer “crosslinking” as 
illustrated in Scheme 2.1b. 
In vitro and in vivo anticancer efficacy of CPT-SS-CPT/mPEG-PLA nanoparticles: We next 
evaluated the anticancer effect of the trigger-responsive NPs. The in vitro anticancer effect of the 
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SS NPs was evaluated in vitro by MTT assay. By incubating HeLa cells with the SS NPs for 72 
hours, significant cell proliferation inhibition was observed in a drug/NP concentration dependent 
manner (Figure 2.2d). The IC50 of the SS NPs was 114 nM compared to 17 nM of free CPT. 
Irinotecan, a clinically used CPT derivative, has an IC50 value of 2700 nM under the same 
condition. The significant cytotoxicity of the high loading NPs indicated the intracellular thiols 
actively reduced the disulfide bond within the NPs, releasing CPT in a timely manner. 
 
Figure 2.3. (a) Schematic illustration of the timeline of the acute antitumor efficacy study on 4T1 
xenograft model. (b) Apoptotic index of tumor cells analyzed by TUNEL assay. 
To further demonstrate the therapeutic potential of NP, we carried out in vivo acute antitumor 
efficacy study using 4T1 xenograft tumor model (Figure 2.3a). After the subcutaneously implanted 
tumor reached volume of 200 mm3, the high drug loading NPs (CPT-SS-CPT) were injected 
intravenously (i.v.) through tail vein (equivalent 50 mg CPT/kg). Control groups including PBS 
(i.v. injection) and irinotecan (i.p. injection, 50 mg/kg) control were delivered in parallel as well. 
After 72 h post injection, mice were sacrificed and the tumor cell apoptosis was analyzed by 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. As characterized 
by the apoptosis index of the tumor tissue, the high loading CPT-SS-CPT/mPEG-PLA NPs showed 
significantly higher toxicity compared with PBS control. The apoptosis index increased from 4.9 
% for the negative control (PBS) to 35.6 % for the drug NPs (Figure 2.3b) and also outperformed 
irinotecan. Overall, the in vitro and in vivo studies indicated that the high loading NPs can be 
applied to anticancer drug delivery applications and they exhibited superior efficacy compared 
with clinically used CPT derivative, irinotecan. 
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2.4. Materials and methods 
Materials and cell lines. 
Chemicals were purchased and used as received unless otherwise specified. Anhydrous 
dimethylformamide (DMF) was dried with a column packed with 4Å molecular sieves. 
Tetrahydrofuran (THF) was dried with a column packed with alumina. 2,6-
bis(hydroxymethyl)aniline (BHA) was synthesized according to literature report.6 mPEG-PLA 
(Mw 5000-3500) was purchased from Laysan Bio Inc. Camptothecin (CPT), 3-chloro-1-propanol, 
sodium azide, N,N-dimethylamino pyridine (DMAP), dithiothreitol (DTT), triphosgene, and 
human serum (from platelet poor human plasma) were purchased from Sigma-Aldrich. Human 
serum was filtered through 0.22 µm PVDF filter to remove large aggregates prior to the NP 
stability test. Phosphate buffered saline (PBS) was purchased from Mediatech, Inc. A Corning 
Subsidiary. The HeLa cells (ATCC, Manassas, VA, USA) used in the MTT (3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay were cultured in Dulbecco’s 
modified Eagle medium (DMEM) containing 10% fetal bovine serum, 1000 units/mL aqueous 
penicillin G, and 100 μg/mL streptomycin at 37 ℃ under 5% CO2 humidified atmosphere. 
Instrumentation.  
NMR spectra were recorded on a Varian U500 (500 MHz) or VXR-500 (500 MHz) spectrometer. 
All chemical shifts were reported in part per million (ppm). Particle sizes and polydispersities were 
measured with a ZetaPlus dynamic light scattering (DLS) detector (15 mW laser, incident beam = 
676 nm, detecting angle = 90 o, CONTIN algorithm, Brookhaven Instruments, Holtsville, NY, 
USA). CPT release test of CPT-SS-CPT was performed on a System Gold system (Beckman 
Coulter, Fullerton, CA, USA) equipped with a 126P solvent module, a System Gold 128 UV 
detector, and an analytical C18 column (Luna C18, 250 mm × 4.6 mm, 5 µm, Phenomenex). The 
UV wavelength for detecting camptothecin-based compounds was set at 369 nm. All other HPLC 
tests were performed on a Shimadzu HPLC system (LC-20AT) connected with PDA detector 
(SPD-M20A) and fluorescence detector (RF-20A). Shimadzu C18 column (3 µm, 50 mm × 4.6 
mm) was used for analysis. Gradient method was adopted using 0.1 % TFA-H2O and acetonitrile 
as mobile phase. TEM samples were prepared on 200 mesh carbon film supported copper grids. 
One drop of the nanoparticle solution (~ 10 μL) was placed on the grid and allowed to stand for 
10 min. Filter paper was then used to remove the residual solution. The resulting sample was 
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imaged using JEOL 2100 Cryo TEM at 200 kV. MTT absorption was measured on Perkin Elmer 
Victor3 multi-label readers at λabs = 570 nm. 
CPT-SS-CPT water solubility test. 
1 mg CPT-SS-CPT was suspended in 3 mL water and stirred vigorously at room temperature for 
24 hour. The suspension was filtered through 0.45 µm PVDF memberane to remove insoluble 
solid. The solution was diluted 1:1 with 0.1 % TFA-water then subject to HPLC analysis. No CPT-
SS-CPT peak was detected in the solution by fluorescence detector. The fluorescence detector 
could detect CPT-SS-CPT down to 5 ng/mL. Therefore, the saturated CPT-SS-CPT concentration 
in water is lower than 10 ng/mL. 
Nanoparticle Preparation.  
Drug or dimeric prodrug was first dissolved in DMF with mPEG-PLA at designated weight ratio 
and the drug concentration was 10 mg/mL. For CPT/mPEG-PLA encapsulation, mPEG-PLA 
concentration was 10 mg/mL and CPT concentration was adjusted accordingly except that for 1:1 
CPT/mPEG-PLA experiment, concentration was both 3 mg/mL due to the poor solubility of CPT 
in DMF. 100 μL above solution was added dropwise into 2.0 mL DI water with mild stirring (550 
rpm) using a magnetic bar. Nanoparticle size and distribution was analyzed by DLS directly 
without further purification.  
Nanoparticle stability test.  
The freshly prepared nanoparticle solution was diluted with PBS 10, 100 and 1000 fold to test its 
stability in the presence of salt and dilution effect. The size and distribution of the nanoparticle 
was measured by DLS. For serum stability test, 1.0 mL nanoparticle solution (~400 µg/mL) was 
diluted with 1.0 mL 1:1 human serum/PBS and characterized by DLS. No significant size change 
was observed for all groups over 24 hours. 
Drug loading and loading efficiency measurement.  
The freshly prepared nanoparticle solution was centrifuged at 3000 rpm for 10 minutes to remove 
large aggregate. An aliquot of the supernatant was dissolved in DMF and the CPT conjugate 
content was quantified by UV-vis absorption at λmax through standard curve. The detection 
wavelength for CPT, CPT-SS-CPT, were 369, 364 nm respectively. Drug loading was calculated 
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as DL = w(drug)/[ w(drug conjugates)+ w(polymer)] and drug loading efficiency was calculated 
as LE = w(drug in NP)/[ w(initial drug added)]. 
For Dox-SS-Dox nanoparticles, the freshly prepared nanoparticle solution was centrifuged at 3000 
rpm for 10 minutes to remove large aggregate. An aliquot of the supernatant was dissolved in 5 
fold acetonitrile and the Dox-SS-Dox content was quantified by HPLC standard curve at UV 
absorption 234 nm. Drug loading and loading efficiency was calculated accordingly. 
CPT release from CPT-SS-CPT/mPEG-PLA nanoparticle (SS NP).  
The SS NPs were diluted with PBS to 2 µg/mL. Then 10 mM DTT was added and the clear solution 
was incubated at 37 ℃. At specified time point, 1.0 mL solution was collected, centrifuged at 15 
krpm to remove particles and the supernatant was subject to HPLC analysis after 1:1 dilution with 
0.1% TFA-H2O to quantify the drug release content (λabs = 369 nm). Gradient method (0.1% TFA-
H2O/Acetonitrile) was adopted to elute both CPT and CPT-SS-CPT in single run. Blank control 
was carried out without the addition of DTT. 
In vitro cytotoxicity of SS NP. 
Standard MTT protocol was followed to evaluate the cytotoxicity of the high loading 
nanoparticles. Briefly, HeLa cells were seeded in 96-well plate at 1000 cells/well in 100 μL 
DMEM medium and were allowed to attach overnight. Free CPT and irinotecan was first dissolved 
in DMSO and diluted with PBS to the concentration desired. For the highest concentration, the 
DMSO content was 5% for CPT and 1% for irinotecan respectively. SS NPs were formulated in 
PBS from 10/2.5 mg/mL CPT-SS-CPT/mPEG-PLA DMF solution through nanoprecipitation. The 
particles were then washed with PBS via ultrafiltration 5 times (3 krpm, 5 min each) and diluted 
with PBS, filtered through 0.45 µm PVDF filter to sterilize. No significant NP size change was 
observed throughout the process as characterized by DLS. 10 μL drug or nanoparticle solution was 
added into the well to the designated final concentration and incubated at 37 oC for 72 hours. PBS 
and 5% DMSO-PBS was taken as 100 % control. 20 μL 5 mg/mL MTT solution was added to the 
medium and incubated at 37 ℃ for 3 hours. Then the medium was carefully removed and the violet 
crystal was dissolved in 100 μL DMSO and quantified by absorption at λabs = 570 nm. Cytotoxicity 
of N3-SS-BHA was conducted following the same procedure except that N3-SS-BHA was first 
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dissolved in DMSO as 1 mg/mL solution and then diluted with PBS. The cell viability data was 
fitted by dose-response curve as follows, in which parameter c0 is the IC50 value. 





Synthesis of 3-azido-1-propanol (1) 
An aqueous solution (150 mL) of 3-chloro-1-propanol (9.45 g, 100 mmol) was refluxed with 
sodium azide (9.75 g, 150 mmol, 1.5 equiv) for 22 h. The product was extracted with 100 mL 
methylene chloride three times, dried over sodium sulfate and concentrated as colorless oil (9.31 
g, 92 % yield). 1H NMR (500 MHz, CDCl3), δ 3.76 (t, 2H, J = 5.7 Hz), 3.46 (t, 2H, J = 6.5 Hz), 
1.84 (m, 2H).
 13C NMR (126 MHz, CDCl3), δ 59.63, 48.31, 31.30. HRMS-EI (m/z): [M]+ calcd for 
C3H7N3O, 101.0589; observed, 101.0589. 
Synthesis of 3-azidopropyl 2-((2-hydroxyethyl)disulfanyl)ethyl carbonate (2) 
5 mL DCM solution of 1 (1.13 g, 11.2 mmol) was added slowly to a phosgene-toluene solution 
(15 wt%, 30 mL, 45 mmol, 4.0 equiv) at 0 oC. After stirring at room temperature for 17 h, solvent 
and excessive phosgene was removed under vacuum. The as prepared chloroformate was 
redissolved in 10 mL DCM, which was added into a DCM/THF solution (10/40 mL) of 2,2'-
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hydroxylethyl disulfide (8.64 g, 56 mmol, 5.0 equiv) and DMAP (2.8 g, 23 mmol, 2.0 equiv). After 
stirring for 2 h, the mixture was concentrated under vacuum, extracted with 100 mL EtOAc, 
washed excessively with water (100 mL each, 6 times). The organic layer was dried over sodium 
sulfate and solvent was removed under vacuum affording a light yellow oil as the product (2.34 g, 
74 % yield). 1H NMR (500 MHz, CDCl3) δ 4.41 (t, 2 H, J = 6.7 Hz), 4.25 (t, 2 H, J = 6.1 Hz), 3.90 
(m, 2 H), 3.45 (t, 2 H, J = 6.7 Hz), 2.96 (t, 2 H, J = 6.7 Hz), 2.89 (t, 2 H, J = 5.7 Hz), 1.93 (m, 
2H).
 13C NMR (126 MHz, CDCl3), δ 154.87, 65.79, 65.05, 60.23, 47.85, 41.57, 36.75, 28.15. 
HRMS-EI (m/z): [M]+ calcd for C8H15N3O4S2, 281.0504; observed, 281.0513. 
Synthesis of 3 (N3-SS-BHA-OTBS) 
To 2 mL DCM solution of 2,6-bis((tert-butyldimethylsilyloxy)methyl)aniline (110 mg, 0.28 
mmol) and DMAP (88 mg, 0.70 mmol, 2.5 equiv) was added triphosgene (29 mg, 0.090 mmol, 
0.35 equiv). White precipitates formed and dissolved gradually over 20 minutes. After stirred for 
2 h, 2 mL DCM solution of 2 (77 mg, 0.28 mmol, 1.0 equiv) was added. The mixture was subject 
to column after the reaction finished as monitored by TLC. The mixture was subject to 
chromatography directly. (Hexane: EtOAc 10:1) The product was obtained as a colorless oil (110 
mg, 57 % yield). 1H NMR (500 MHz, CDCl3) δ 7.58 (br 1H), 7.34 (d, 2H, J = 7.5 Hz), 7.21 (t, 1H, 
J = 7.5 Hz), 4.70 (s, 4H), 4.40 (m, 2H+2H), 4.21 (t, 2H, J = 6.2 Hz), 3.41 (d, 2H, J = 6.7 Hz), 2.97 
(m, 2H+2H), 1.92 (m, 2H), 0.92 (s, 18H), 0.09 (s, 12H).
 13C NMR (126 MHz, CDCl3) δ 154.71, 
153.86, 136.07, 132.56, 126.94, 125.97, 65.62, 64.87, 62.89, 62.83, 47.75, 37.60, 36.87, 28.08, 
25.84, 18.23, -5.36. HRMS-ESI (m/z): [M+H]+ calcd for C29H53N4O7S2Si2, 689.2894; observed, 
689.2894. 
Synthesis of 4 (N3-SS-BHA) 
110 mg 3 was stirred with 100 mg amberlyst-15 in a mixture of DCM/MeOH (8/6 mL) overnight. 
After the reaction completed, the suspension was subject to flash column (hex:EtOAc 4:1 to 
EtOAc) giving a white solid (70 mg, 95 % yield). 1H NMR (500 MHz, CDCl3) δ 7.60 (br 1H), 7.38 
(d, 2H, J = 7.5 Hz), 7.27 (t, 1H, J = 7.5 Hz), 4.63 (d, 4H, J = 5.0 Hz), 4.44 (m, 2H+2H), 4.21 (t, 
2H, J = 6.2 Hz), 3.41 (d, 2H, J = 6.7 Hz), 3.01 (m, 6H), 1.92 (m, 2H). 13C NMR (126 MHz, CDCl3) 
δ 155.58, 154.53, 136.41, 133.04, 128.82, 126.79, 65.35, 64.77, 63.07, 61.77, 47.47, 37.18, 36.54, 




Synthesis of 5 (CPT-SS-CPT) 
A DCM suspension (3 mL) of camptothecin (63.5 mg, 0.182 mmol, 2.4 equiv), DMAP (49 mg, 
0.40 mmol, 5.3 equiv) and triphosgene(18.9 mg, 0.064 mmol, 0.84 equiv) was stirred at room 
temperature for 15 minutes, during which the camptothecin dissolved gradually. Then 1 mL DCM 
solution of 4 was added once. After completion of the reaction as monitored by TLC, the solution 
was subject to chromatography. DCM:MeOH 50:1, EtOAc:MeOH 20:1 giving an off-white 
powder (65 mg, 71 % yield). 1H NMR (500 MHz, CDCl3) δ 8.39 (s, 2H), 8.23 (d, J = 8.5 Hz, 2H), 
7.93 (d, J = 8.1 Hz, 2H), 7.84 (s, 2H), 7.66 (s, 2H), 7.35 (d, J = 7.5 Hz, 3H), 7.30 (s, 2H), 7.23 (t, 
J = 7.5 Hz, 1H), 5.50 (dd, J = 151 Hz, 17Hz, 4H), 5.25 (s, 4H), 5.11 (s, 4H), 4.26 (s, 2H), 4.14 (s, 
4H), 3.35 (m, 4H), 2.81 (m, 2H), 2.73 (t, J = 6.5 Hz, 2H), 2.18 (dq, J = 53.5 Hz, 6.5 Hz, 4H), 1.85 
(m, 2H), 0.98 (t, J = 6.5 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 167.40, 157.31, 154.81, 154.37, 
153.60, 152.19, 148.73, 146.47, 145.68, 133.15, 132.60, 131.50, 130.95, 129.78, 129.58, 128.59, 
128.34, 128.27, 128.22, 127.96, 120.27, 96.12, 78.14, 77.41, 77.15, 76.90, 67.12, 67.01, 65.69, 
65.00, 63.46, 50.14, 47.88, 37.27, 36.79, 31.90, 28.15, 7.74. HRMS-ESI (m/z): [M+H]+ calcd for 
C59H53N8O17S2, 1209.2970; observed, 1209.2961. 
 
Synthesis of 6 (CPT-SS) 
A DCM suspension (1 mL) of camptothecin (34.8 mg, 0.10 mmol, 1.0 equiv), DMAP (26.8 mg, 
0.22 mmol, 2.2 equiv) and triphosgene(11.0 mg, 0.037 mmol, 0.37 equiv) was stirred at room 
temperature for 10 minutes, during which the camptothecin dissolved gradually. Then 1 mL DCM 
solution of 2 (33.8 mg, 0.12mmol, 1.2 equiv) was added once. After completion of the reaction as 
monitored by TLC, the reaction was quenched by 1 drop of water and subject to chromatography 
(pure EtOAc) giving an off-white powder (43 mg, 66 % yield). 1H NMR (500 MHz, CDCl3) δ 8.41 
(s, 1H), 8.24 (d, J = 8.5 Hz, 1H), 7.95 (d, J = 8.1 Hz, 1H), 7.85 (dd, J = 8.5 Hz, 8.1 Hz, 1H), 7.68 
(dd, J = 8.5 Hz, 8.1 Hz, 1H), 7.35 (s, 1H), 5.55 (dd, J = 155.6, 17.2 Hz, 2H), 5.31 (s, 2H), 4.35 (m, 
4H), 4.20 (t, J = 6.2 Hz, 2H), 3.40 (t, J = 6.6 Hz, 2H), 2.96 (d, J = 6.2 Hz, 2H), 2.92 (d, J = 6.2 Hz, 




13C NMR (126 MHz, CDCl3) δ 167.35, 157.34, 154.79, 153.54, 152.28, 148.79, 146.45, 145.65, 
131.44, 130.92, 129.63, 128.59, 128.31, 128.28, 128.25, 120.41, 96.22, 78.13, 67.17, 66.61, 65.64, 
65.00, 50.11, 47.90, 37.09, 36.62, 31.96, 28.22, 7.75. HRMS-ESI (m/z): [M+H]+ calcd for 
C29H30N5O9S2, 656.1485; observed, 656.1488. 
 






Scheme 2.2. Proposed CPT release mechanism from SS-CPT upon DTT treatment.  





















Figure 2.5. Cytotoxicity of N3-SS-BHA in HeLa cells. No significant toxicity was observed up to 




In summary, we found that using the drug dimer for encapsulation with amphiphilic polymer can 
drastically improve drug loading and NP properties. Drug can be encapsulated in polymer NP with 
over 50% drug loading and close to 100% loading efficiency. Unlike direct encapsulates of free 
drugs in polymeric micelles that have drug burst release and micelle stability issues, this drug 
dimer conjugate encapsulated NP showed excellent NP stability and completely eliminated burst 
release effect. In vitro and in vivo experiment also demonstrated the therapeutic potential of the 
high loading nanoparticles. This NP formulation strategy provides a new and potentially scalable7,8 
method to encapsulate hydrophobic drugs efficiently without complicate carrier polymer design 
and screening.  
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UNDERSTANDING THE HIGH DRUG LOADING FORMULATION MECHANISM  
3.1. Introduction 
Our previous study demonstrated the high-drug loading phenomenon and tested its application 
toward anti-cancer treatment in vitro and in vivo using a model thiol-responsive CPT prodrug NP. 
In this chapter, we aim to further understand the underlying mechanism of the NP formation, 
expand the trigger-responsive prodrug library, explore formulation control to tune the size and 
surface functionality of the high-loading NP for further in vivo applications. 
3.2. Understanding of the high drug loading nanoparticles formulation 
Understanding the NP formation of CPT-SS-CPT/mPEG-PLA NP: We designed series of 
experiments to study the NP formulation mechanism. When a DMF solution of CPT-SS-CPT (in 
the absence of mPEG-PLA) was dropwise added to water (Figure 3.1a), the CPT-SS-CPT 
aggregates grew larger over the time, reaching ~6 μm at t = 60 min (denoted as rectangle, Figure 
3.1a). When CPT-SS-CPT was added to water followed by the addition of mPEG-PLA 10 seconds 
and 30 seconds after the drug-water mixing, the particle was stabilized at 850 nm and 1100 nm, 
respectively (denoted as triangle and circle, Figure 3.1a), suggesting the successful coating of CPT-
SS-CPT aggregates with mPEG-PLA on surface, which inhibited the further growth of the drug 
nano-aggregate. When mPEG-PLA empty micelles (without CPT-SS-CPT) were pre-formed (~ 50 
nm) followed by the addition of a DMF solution of CPT-SS-CPT (1/16 relative to mPEG-PLA, 
w/w) (illustrated in Figure 3.1c), drug loaded NPs with size around 180 nm were formed with 
complete disappearance of the 50 nm distribution (Figure 3.1b). The mixing of the CPT-SS-CPT 
with pre-formed mPEG-PLA micelle clearly modulates the original mPEG-PLA micellar structure 
as the size of the NPs increased dramatically. Further addition of CPT-SS-CPT solutions did not 
change the average size of the NPs (Figure 3.1b). TEM analysis revealed a core-shell nano-
structure (Figure 3.1d), suggesting rapid formation of CPT-SS-CPT nanoaggregate that recruited 
mPEG-PLA on the surface to stabilize it through the hydrophobic interaction of hydrophobic drug 




Figure 3.1. (a) CPT-SS-CPT nano-aggregate size change as a function of time without mPEG-
PLA (rectangle) and with mPEG-PLA 10 s (triangle) and 30 s (circle) after water dilution. (b) Size 
change of mPEG-PLA micelles after the addition of CPT-SS-CPT solution. Data are presented as 
mean value ± standard deviation of 4 independent measurements. (c) Schematic illustration of post 
addition experiment. DMF solution of CPT-SS-CPT was added into aqueous solution of mPEG-
PLA micelle. (d) TEM image of NP prepared in Figure 2c. Scale bar = 400 nm. Inset: enlarged 
view of the NP. Scale bar = 50 nm.  
The high loading NP is stabilized by drug-polymer interaction: We next evaluated the stability of 
the formulated NPs in phosphate buffered saline (PBS). The as-formed NP was stable for more 
than one week when being stored at room temperature. Further formulation with methoxy-
polyethylene glycol-b-L-polylactide (mPEG-PLLA) also gave NPs with similar size; however, 
dramatic size increase and significant aggregates were observed after 24 hours as revealed by DLS 
(Figure 3.2a). It is known that mPEG-PLLA micelle is more stable than mPEG-PLA because the 
inter-chain interaction between isotactic PLLA is stronger. The reversed NP stability observed in 
the high loading NPs thus indicated the NP is not predominantly stabilized by hydrophobic PLA-







































Figure 3.2. (a) NP size evolution of CPT-SS-CPT NP with mPEG-PLA and mPEG-PLLA in PBS. 
(b) Fluorescence spectrum of 2×10-7 mol/L CPT-SS-CPT in organic solvent, water, mPEG-PLA 
micelle, and the high loading NP. The fluorescence of CPT-SS-CPT is strong in free state (organic 
solvent) and is quenched in aggregation state (water). (c) Fluorescence spectra of CPT-SS-CPT 
NPs at different concentration. Note that the CMC of the mPEG-PLA is 69 µg/mL. (d) Linear 
regression of the fluorescence intensity of the CPT-SS-CPT NPs. The linear correlation indicated 
that there was no significant change of the prodrug aggregation state at concentration much lower 
than the CMC of the mPEG-PLA. 
Fluorescence study indicated CPT dimer was in aggregation state in the high loading NP: CPT-
SS-CPT showed strong fluorescence in organic solvent such as DMF and THF (Figure 3.2b, red 
and dark yellow curve) while its fluorescence is quenched in aggregation state when it is dissolved 
in aqueous solution with trace DMSO (Figure 3.2b, black curve). A CPT-SS-CPT/mPEG-PLA 
micelle was prepared by nano-precipitating 400:1 (w/w) mPEG-PLA/CPT-SS-CPT into water and 
sonicated for 2 minutes. The fluorescence of CPT-SS-CPT in the micelle was not significantly 
quenched (Figure 3.2b, brown curve) as compared with the aggregated aqueous state. In contrast, 
the high loading NP prepared with 1:4 (w/w) mPEG-PLA/CPT-SS-CPT ratio showed minimal 
















































































confirmed a non-micellar structure and the prodrug was in a closely packed aggregation state in 
the NP. 
Ultrastability of the high loading NP against dilution and mechanical agitation: We next 
characterized the stability of the high loading NP against dilution (Figure 3.2c&d) and ultra-
sonification by fluorescence spectroscopy (Figure 3.3). The CPT-SS-CPT nanoparticles were 
stable at concentrations well below the critical micelle concentration (CMC) of the mPEG-PLA 
(69 µg/mL). DLS measurement showed that the NPs were stable at 5 µg/mL for more than 24 
hours. Furthermore, the fluorescence of the CPT-SS-CPT showed a linear dependence on 
concentration with no change on the fluorescence spectra (Figure 3.2c&d) indicating minimal 
prodrug aggregation pattern change at such low concentration.. 
The fluorescence of CPT-SS-CPT was quenched in an aqueous nano-aggregate state without 
mPEG-PLA which was prepared by precipitating the DMSO solution into aqueous solution (Figure 
3.3a). An excessive amount of mPEG-PLA micelle was then added to the nano-aggregates with 
gentle mixing and the fluorescence of the solution was partially recovered immediately after the 
mixing. 15-second ultra-sonification resulted in almost complete recovery of the CPT-SS-CPT 
fluorescence (Figure 3.3b) indicating that the nano-aggregates tended to be broken and migrate 
into the hydrophobic segment of the mPEG-PLA micelles. In contrast, the high loading NP’s 
fluorescence didn’t show any significant change under the same condition (Figure 3.2b) suggesting 
that the high loading NP was stable against the ultrasound once the particle was formed 
substantiating a non-dynamic nano-structure of the NP. Considering that the fluorescence of CPT-
SS-CPT is very sensitive to the environment and solid state packing of the molecule, the above 
phenomenon demonstrated the ultra-stability of the nanoparticles at low concentration as well as 




Figure 3.3. (a) Fluorescence spectra of CPT-SS-CPT aggregate in aqueous solution before and 
after ultra-sonification with mPEG-PLA micelles. The fluorescence of CPT recovered indicating 
that the aggregates were encapsulated into the hydrophobic micelle core. (b) Fluorescence spectra 
of CPT-SS-CPT nanoparticles in aqueous solution before and after ultra-sonification with mPEG-
PLA micelles. The fluorescence of CPT remained quenched indicating that the CPT-SS-CPT 
remained in the nanoparticles even after strong mechanical perturbation of ultrasound. 
3.3. Trigger-responsive prodrug library design  
We next explored how the trigger-responsive side chain could impact the NP formation with 
mPEG-PLA. We design several CPT conjugates with distinct side chain structures (Scheme 3.1a). 
Specifically, they are CPT dimers with no side chain (H-CPT2), CPT dimer with small side chain 
(N3-CPT2), and CPT dimer with rigid aromatic side group (coumarin-CPT2). By nanoprecipitating 
with mPEG-PLA, all of the three CPT conjugates precipitated instantly to form micron-sized 
aggregates in aqueous solution even at 1:1 drug:polymer ratio, which is in sharp contrast to the 
CPT-SS-CPT formulation which could form ultra-stable NPs at 90% prodrug loading. The results 
suggested that the dimeric structure was not the only factors facilitating the high loading NP 
formation. We reasoned that the flexible aliphatic side chain in the CPT-SS-CPT dimer was critical 
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to the formation of high loading NPs as the alkyl chain could interact with the amphiphilic polymer 
with the CPT dimer, which stabilize the NPs through hydrophobic interactions with mPEG-PLA 
while the dimers without the flexible chains fail to form sufficiently strong binding with mPEG-
PLA at the interface of the drug aggregating and polymer coating.  
 
Scheme 3.1. Chemical structures of CPT dimers with different side chains. (a) CPT dimer with no 
(H-CPT2), small (N3-CPT2, H2S responsive) and rigid aromatic (coumarin-CPT2, UV and NIR 
responsive) side chains. (b) H2O2 responsive CPT dimer with boronic esters that have various 
linker or terminal groups. 
To confirm the hypothesis, we further prepared a series of H2O2 responsive CPT prodrug 





specifically designed to have a rigid phenyl spacer and small boronic ester tail (BE-CPT2), a rigid 
phenyl spacer and cleavable flexible tail (C8-BE-CPT2), or a flexible N,N'-dimethylethylene-
diamine spacer and small boronic ester tail (BE-L-CPT2). The BE-CPT2 without aliphatic chain 
precipitated into large aggregates similarly as the previous prodrug dimers. The BE-L-CPT2 with 
a stable flexible chain formed stable NPs up to 80% prodrug loading and remained unchanged for 
more than three days. Interestingly, the C8-BE-CPT2 first formed stable NPs during formulation 
and gradually formed micro-sized aggregates over 1 hour which is likely due to the loss of the 
flexible tail over time by hydrolysis of the boronic ester. The study confirmed that the flexible side 
chains were critical to the high loading NP formation.  
 
We next explore whether the N,N'-dimethylethylene-diamine1 linker used in the BE-L-CPT2 
design is a universal linker strategy for high loading NP encapsulation since the self-cyclizable 
group is suitable for linking various trigger-responsive domains to control drug release (Scheme 
3.2b).2,3 We designed UV and reduction-responsive dimeric CPT prodrugs (Scheme 3.2a). The 
UV-responsive nitrobenzyl group directly linked to the CPT dimer structure was not able to form 
high loading NP with mPEG-PLA;4 however, the incorporation of the new linker (nb-L-CPT2) 
UV-responsiveH2O2-responsive Reduction-responsive
Scheme 3.2. (a) Chemical structure of
N,N'-dimethylethylene-diamine linker
containing dimeric prodrug with H2O2,
UV, and reductase responsive groups.







facilitated formation of NPs with 50% prodrug loading in unoptimized nano-precipitation 
condition. The reduction-responsive prodrug hQ-L-CPT2 also formed stable nanoparticles with 
high drug loading, which will be further discussed in Chapter 4. The validation of the N,N'-
dimethylethylene-diamine linker in the NP formation paves the way for incorporation of more 
trigger-responsive groups that don’t have a flexible aliphatic chains into the high loading NP 
system.  
 
Figure 3.4. (a) Chemical structure of Dox-SS-Dox. (b) Chemical structure of CPT3-SS-N3. (c) 
hydrodynamic size of CPT3-SS-N3 NP formulated with 1/4 (w/w) mPEG5k-PLA3k. 
We next tested whether this strategy can be used for nano-formulation of other drugs with strong 
crystallization tendency, such as doxorubicin (Dox). Dox-SS-Dox (Figure 3.4a) was synthesized 
sharing the same trigger responsive linker with CPT-SS-CPT. When Dox-SS-Dox/mPEG-PLA at 
a ratio of 4/1 (w/w) was precipitated, NP with size of 221 nm and monomodal DLS distribution 
was obtained. The loading efficiency was determined to be 88% and the equivalent doxorubicin 
loading was calculated to be 53 %. Compared with conventional micelle5,6 and liposome 
















encapsulation7 method, this dimeric drug strategy greatly improved the drug loading and loading 
efficiency of Dox in NPs. 
To further increase the drug loading capacity of CPT in the prodrug NP, we prepared a trimeric 
CPT prodrug conjugate (CPT3-SS-N3, Figure 3.4b). The CPT trimer could also form stable sub-
200 nm nanoparticles through from DMF solution with 1/4 (w/w) mPEG5k-PLA3k (Figure 3.4c) 
suggesting that the strategy to interrupt the intermolecular drug interactions holds true for a more 
complex prodrug structure. 
3.4. Formulation control on nanoparticle size and surface functionality 
The NP formation is kinetically controlled: Our above study indicates that the NP is a stable nano-
structure once it is formed, therefore, the NP formation process uniquely determines the size and 
size distribution of the NP. We next explore if the mechanical agitation during the formulation 
would affect the formulation (Figure 3.5a). Decreased the stirring rate of the aqueous solution 
resulted in larger NP size while dialysis, which had minimal agitation gave stable NPs with size 
more than 300 nm. Further increasing the stirring rate to 900 rpm couldn’t further decrease the NP 
size likely due to the limited improvement in the solvent mixing process. The study clearly showed 
that the NP formulation is a kinetic-controlled process that give smaller NP with faster 
homogenization of the system. 
 
Figure 3.5. (a) The impact of mixing rate on NPs. The prodrug/polymer ratio was fixed at 1:2. (b) 
Solvent and temperature effect on the NPs size.  
Solvent and temperature effect on NP size: Size of NPs have been reported to be a crucial factor 
for tumor penetration and retention,8-10 and the formulation on size controlled NP would 
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potentially afford better nanomedicine for cancer treatment. We tested formulation conditions that 
may affect the NP size of the high loading NPs. The organic solvent used to dissolve the prodrug 
and polymer was first screened with water miscible solvent including DMF, DMSO, THF, and 
acetone.11 As shown in Figure 3.5b, increased water miscibility of the organic solvent increased 
the nanoparticle size by up to 120 nm under the same prodrug-polymer ratio, which is opposite to 
what is reported in conventional PEG-PLGA nanoformulation system.12 It can be reasoned that 
better water miscible solvent (e.g. DMSO) can mix with water faster during the nanoprecipitation 
and resulted in faster prodrug aggregation kinetics giving larger NP size before the amphiphilic 
polymer could coating the growing nano-aggregate surface to prohibit further NP growth. Notably, 
precipitating the organic solution into DI H2O, 1×PBS, or 10×PBS gave similar NPs with 
negligible difference suggesting that the aqueous ionic strength has minimal impact on the 
formulation. Nanoprecipitation at 60 oC resulted in smaller nanoparticles than that at room 
temperature except for the acetone which has a boiling point of 56 oC. The increased temperature 
would accelerate the diffusion and enhance the mixing of different components which likely cause 
the decrease of NP size through the formulation. Further increasing the temperature to 90 oC gave 
NP size slightly larger than that at 60 oC (data not shown) likely because the aqueous solution was 
close to the boiling point and nano-bubbles were generating to interfere with the formulation. 
 
Figure 3.6. (a) PLA length and temperature impact on NPs size with mPEG5k-PLAx and 1:2 
prodrug/polymer ratio using DMF as the dissolution solvent for the nanoprecipitation. (b) PEG 
length and temperature impact on NPs size with PEG:PLA length about 2:1 and 1:2 




























































Amphiphilic polymer’s impact on the NP formulation: We continue to use mPEG-PDLLA to study 
formulation as we previously discussed in Section 3.2 that mPEG-PLLA could form NPs but with 
much lower stability. mPEG5k-PLAx (Figure 3.6a) with different PLA block length were 
synthesized by mPEG5k-OH initiated ring-opening polymerization of lactide with Sn(Oct)2 as the 
catalyst in toluene (110 oC). The mPEG5k-PLAx was characterized by both gel permeation 
chromatography (GPC) and 1H NMR to confirm the molecular weight of the PLA block. 
Nanoprecipitation of the prodrug-polymer at 1:2 weight ratio from DMF all gave stable NPs with 
size smaller than 120 nm and longer hydrophobic PLA chain resulted in smaller NP size (Figure 
3.6a). Further increase of the PLA chain to 20k and 30 kDa rendered the mPEG-PLA assembly 
(without prodrug) unstable and precipitated to interfere with the formulation test. mPEG-PLA with 
similar hydrophobic-hydrophilic block ratio was also used to evaluate the polymer length effect 
on the formulation (Figure 3.6b). Shorter polymer chains potentially have less entanglement and 
interaction with prodrug aggregate and the formulation resulted in much larger NP size (60 nm to 
130 nm) with lower stability (Figure 3.6b). Based on the above formulation of prodrug-mPEG-
PLA, our follow-up studies (Chapter 4) use mPEG5k-PLA8k as the polymer coating with THF-PBS 
as the dissolution-precipitation solvent to prepare stable NPs with smaller size.  
 
Scheme 3.3. Chemical structures of amphiphilic polymers used in the formulation study.  
We next test amphiphilic polymers with larger hydrophobic side groups in the formulation using 
mPEG-poly(phenyl-lactide) (Scheme 3.3).13 The polymer was prepared by mPEG-OH initiated 
ring-opening polymerization of D,L-phenyl O-carboxyanhydrides (Phe-OCA) with N,N-dimethyl 
pyridine (DMAP) as the catalyst. We prepared three mPEG5k-PheLAx with different PheLA length 
(Table 3.1). Formulation of mPEG5k-PheLAx with CPT-SS-CPT all gave sub-100 nm 
nanoparticles stable for more than 2 days as revealed by DLS. The length of the hydrophobic 
domain didn’t have significant impact on the NP size as opposite to the mPEG-PLA result. It is 
possible that the PheLA has a stronger hydrophobic interaction with the prodrug molecules due to 
the phenyl ring structure such that it doesn’t require too long hydrophobic chain length to achieve 
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the maximal polymer-prodrug interaction to form smaller NPs during the NP formation process. 
It is worth noting that a preliminary test of mPEG-PheLA with coumarin-CPT2 (Scheme 3.1) first 
gave a stable sub-200 nm NPs after the formulation and gradually formed micron-sized precipitates 
within 60 minutes. The phenomenon indicated that 1) PheLA chains have sufficiently strong 
interaction with a CPT dimer (e.g. coumarin-CPT2) without a flexible aliphatic chain to form 
nanoparticles during the kinetically controlled nanoprecipitation process; 2) The coumarin-CPT2 
has a higher tendency in thermodynamics to form self-aggregates rather than form a prodrug-
amphiphilic polymer complex, which made the as-formed NP unstable over time. 
Table 3.1. Formulation of mPEG5k-PheLAx with CPT-SS-CPT from DMF. α. mPEG-
PheLA/CPT-SS-CPT concentration (mg/mL) in DMF solution in DI H2O or PBS at room 
temperature (or specified). 
Amphiphilic polymer Formulation Conditionα 
NP Size/nm (PDI) 
t = 0 t = 48 h 
mPEG5k-PheLA5k 
10/10 90 (0.05) 98 (0.02) 
10/10, PBS 87 (0.11) 92 (0.08) 
10/10, 60 oC 142 (0.20) 176 (0.16) 
5/10 74 (0.08) 79 (0.04) 
mPEG5k-PheLA10k 10/10 104 (0.09) 97 (0.09) 
mPEG5k-PheLA20k 10/10 98 (0.08) 107 (0.12) 
Amphiphilic polyacrylate can also form high loading NP with the dimeric prodrug: We next 
explored whether amphiphilic polymers that has negative charges can form high loading NP with 
the dimeric prodrug through similar mechanism. Poly(methylacrylate)-b-poly(acrylic acid) 
(Scheme 3.3, PMA-PAA) was prepared through reversible addition−fragmentation chain-transfer 
(RAFT) polymerization with a negatively charged polyacrylic acid block about 4300 Da and a 
hydrophobic poly(methylacrylate) block about 8600 Da. Formulation of the PMA-PAA with CPT-
SS-CPT showed that stable 110 nm nanoparticle could be formed at 1:1 prodrug/polymer weight 




Table 3.2. Formulation of PMA-PAA with CPT-SS-CPT from DMF. * mPEG-PheLA/CPT-SS-
CPT concentration (mg/mL) in DMF solution in DI H2O or PBS at room temperature (or specified). 
Prodrug/polymer concentration 
in DMF (mg/mL) 
NP Size/nm (PDI) 
t = 0 t = 24 h 
10/2.5 147 (0.11) 103 (0.37) 
10/10 94 (0.08) 111 (0.08) 
5/10 96 (0.09) 115 (0.05) 
0/10 72 (0.10) 73 (0.07) 
3.5. Materials and methods 
Materials. 
Chemicals were purchased and used as received unless otherwise specified. Anhydrous 
dimethylformamide (DMF) was dried with a column packed with 4Å molecular sieves. 
Tetrahydrofuran (THF) were dried with a column packed with alumina. BE-CPT2,4 PheOCA,13 
BHA-OTBS314 was prepared according to previous report. 
Instrumentation.  
NMR spectra were recorded on a Varian U500 (500 MHz) or VXR-500 (500 MHz) spectrometer. 
All chemical shifts were reported in part per million (ppm). Particle sizes and polydispersities were 
measured with a ZetaPlus dynamic light scattering (DLS) detector (15 mW laser, incident beam = 
676 nm, detecting angle = 90 o, CONTIN algorithm, Brookhaven Instruments, Holtsville, NY, 
USA). HPLC tests were performed on a Shimadzu HPLC system (LC-20AT) connected with PDA 
detector (SPD-M20A) and fluorescence detector (RF-20A). Shimadzu C18 column (3 µm, 50 mm 
× 4.6 mm) was used for analysis. Gradient method was adopted using 0.1 % TFA-H2O and 
acetonitrile as mobile phase. TEM samples were prepared on 200 mesh carbon film supported 
copper grids. One drop of the nanoparticle solution (~ 10 μL) was placed on the grid and allowed 
to stand for 10 min. Filter paper was then used to remove the residual solution. The resulting 
sample was imaged using JEOL 2100 Cryo TEM at 200 kV. Fluorescence was measured on 
Perkin-Elmer LS55 fluorescence spectrometer. MTT absorption was measured on Perkin Elmer 
Victor3 multi-label readers at λabs = 570 nm. Tandem gel permeation chromatography (GPC) was 
performed on a system equipped with an isocratic pump (Model 1200, Agilent Technologies, Santa 
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Clara, CA, USA), a DAWN HELEOS multi-angle laser light scattering detector (MALLS); (Wyatt 
Technology, Santa Barbara, CA, USA), and an Optilab rEX refractive index detector (Wyatt 
Technology). The detection wavelength of the HELEOS was set at 658 nm. Separations were 
performed on serially connected size exclusion columns (100 Å, 1000 Å, 104 Å, 105Å and 106 Å 
Phenogel columns, 5 μm, 300 × 7.8 mm, Phenomenex, Torrance, CA, USA) at 60 °C with DMF 
containing 0.1 M LiBr as the mobile phase. The HELEOS detector was calibrated with pure 
toluene without using external polymer standards and was used for the determination of the 
absolute molecular weights. The molecular weight of polymer was determined from the dn/dc value 
calculated assuming 100% mass recovery, and was processed by ASTRA software (Version 6.1.1, 
Wyatt Technology). 
Nanoparticle Formulation Study. 
Nanoparticle Preparation.  
Drug or dimeric prodrug and the amphiphilic polymer was first dissolved in DMF (or other water 
miscible solvent as specified) with mPEG-PLA at specified concentration. For CPT/mPEG-PLA 
encapsulation, mPEG-PLA concentration was 10 mg/mL and CPT concentration was adjusted 
accordingly except that for 1:1 CPT/mPEG-PLA experiment, concentration was both 3 mg/mL 
due to the poor solubility of CPT in DMF. 20 or 100 μL above solution was added dropwise into 
2.0 mL DI water or PBS at room temperature or 60 oC with mild stirring (550 rpm) using a 
magnetic bar. Nanoparticle size and distribution was analyzed by DLS directly without further 
purification.  
Drug aggregation test by post mPEG-PLA coating (described in Figure 3.1a). 
mPEG5k-PLA3k solution was first prepared by mixing 25 µL mPEG5k-PLA3k solution (20 mg/mL 
in DMF) with 2.0 mL DI H2O. 25 µL DMF solution of CPT-SS-CPT (10 mg/mL) was added into 
2.0 mL PBS at 550 rpm mixing at once (denoted as solution A). 500 µL solution A was mixed 
with 1.0 mL as-prepared mPEG-PLA solution 10 seconds or 30 seconds after the drug dimer 
addition. The leftover solution A (without mPEG-PLA) was diluted with 1.0 mL H2O. The particle 
sizes of all the solutions were monitored by DLS. The experiment was done in triplicate and the 




The post addition experiment described in Figure 3.1b. 
50 μL DMF solution of mPEG5k-PLA3k (20 mg/mL) was added dropwise into 2.0 mL DI water 
with mild stirring (550 rpm) using a magnetic bar. The micelle size was then measured by DLS. 
To the micelle solution was then added 12.5 μL DMF solution of CPT-SS-CPT (5 mg/mL) under 
stirring. Extra 37.5 μLCPT-SS-CPT solution was added in 3 three portions and the size was 
monitored by DLS right after the mixing. 4 independent entries were done and the results were 
presented as mean value ± standard deviation. 
Nanoparticle stability test.  
The freshly prepared nanoparticle solution was diluted with PBS 10, 100 and 1000 fold to test its 
stability in the presence of salt and dilution effect. The size and distribution of the nanoparticle 
was measured by DLS. For serum stability test, 1.0 mL nanoparticle solution (~400 µg/mL) was 
diluted with 1.0 mL 1:1 human serum/PBS and characterized by DLS. No significant size change 
was observed for all groups over 24 hours. 
Drug loading and loading efficiency measurement.  
The freshly prepared nanoparticle solution was centrifuged at 3000 rpm for 10 minutes to remove 
large aggregate. An aliquot of the supernatant was dissolved in DMF and the CPT conjugate 
content was quantified by UV-vis absorption at λmax through standard curve. The detection 
wavelength for CPT, CPT-SS-CPT, were 369, 364 nm respectively. Drug loading was calculated 
as DL = w(drug)/[ w(drug conjugates)+ w(polymer)] and drug loading efficiency was calculated 
as LE = w(drug in NP)/[ w(initial drug added)]. 
For Dox-SS-Dox nanoparticles, the freshly prepared nanoparticle solution was centrifuged at 3000 
rpm for 10 minutes to remove large aggregate. An aliquot of the supernatant was dissolved in 5 
fold acetonitrile and the Dox-SS-Dox content was quantified by HPLC standard curve at UV 
absorption 234 nm. Drug loading and loading efficiency was calculated accordingly. 
Critical micelle concentration (CMC) determination of mPEG5k-PLA3k. 
mPEG-PLA was first dissolved in PBS to designated concentration. Then 1.0 mg/mL DMSO 
solution of Nile Red was added to a final concentration of 2×10-4 mg/mL (6×10-7 M). The 
fluorescence of the solution was then measured by fluorescence spectrometer. (λex=557 nm, λem = 
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601 nm) The CMC was determined by extending the linear FL intensity of both the high and low 
concentration region. 
Fluorescence measurement of the CPT-SS-CPT and CPT-SS-CPT NP. 
CPT-SS-CPT NPs were prepared according to the above method using CPT-SS-
CPT/mPEG5kPLA3k 4:1 weight ratio from DMF. The CPT-SS-CPT micelle was prepared by the 
same nanoprecipitation method except that CPT-SS-CPT/mPEG5kPLA3k weight ratio was 1:400. 
CPT-SS-CPT solution was prepared by dissolving the prodrug directly in DMF or THF. All of the 
samples were adjusted to a final CPT-SS-CPT concentration of 2×10-7 mol/L and the fluorescence 
was measured by fluorescence spectrometer (λex = 369nm). For the sonification study, the NP or 
micelle solution was sonicated in a water bath sonicator for 15 seconds and then subject t 
fluorescence measurement directly. 
 
Synthesis of (2-azido-1,3-phenylene)dimethanol (N3-BHA) 
2,5-bis-hydroxylmethyl aniline ( 153 mg, 1.0 mmol, 1.0 equiv) was dissolved in 3 mL 12% H2SO4 
aqueous solution, to which was added NaNO2 solution (76 mg in 1.0 mL H2O, 1.1 mmol, 1.1 
equiv) at 0 oC slowly. The yellow solution was stirred at for additional 30 minutes. An aqueous 
solution of NaN3 (78 mg in 2.0 mL H2O, 1.2 mmol, 1.2 equiv) was added slowly and yellow foam 
was generated. The product was extracted with 20 mL EtOAc and washed with 20 mL brine. The 
organic layer was dried over Na2SO4, concentrated and subject to chromatography (hex/EtOAc 
1:1) giving off-white powder as product 154 mg (86 % yield). 1H NMR (500 MHz, CDCl3) δ 7.36 
(d, J = 7.6 Hz, 2H), 7.20 (t, J = 7.6 Hz, 1H), 4.81 (s, 4H). 13C NMR (126 MHz, DMSO) δ 135.78, 
134.22, 127.44, 125.47, 59.64. ESI-MS (low resolution, positive mode): calculated for 




Synthesis of N3-CPT2 
A DCM suspension (1 mL) of camptothecin (167.2 mg, 0.48 mmol, 2.4 equiv), DMAP (122 mg, 
0.10 mmol, 5 equiv) and triphosgene(47 mg, 0.016 mmol, 0.80 equiv) was stirred at room 
temperature for 10 minutes, during which the camptothecin dissolved gradually. Then 2 mL THF 
solution of BHA-N3 (36 mg, 0.20 mmol, 1.0 equiv) was added once. After completion of the 
reaction as monitored by TLC (25 minutes), the reaction was subject to chromatography 
(DCM:MeOH 50:1, EtOAc:MeOH 20:1) giving an off-white powder (170 mg, 90 % yield).1H 
NMR (500 MHz, CDCl3) δ 8.36 (s, 2H), 8.22 (d, J = 8.5 Hz, 2H), 7.98 – 7.89 (d, J = 7.4 Hz, 2H), 
7.84 (dd, J = 8.5 Hz, 7.4 Hz, 2H), 7.66 (dd, J = 8.5 Hz, 7.4 Hz, 2H), 7.33 (d+s, 2H+2H), 7.10 (t, J 
= 7.6 Hz, 1H), 5.53 (dd, J = 154.1, 17.1 Hz, 4H), 5.33 – 5.12 (m, 8H), 2.20 (dq, J = 56.3 Hz, 7.5Hz, 
4H), 0.99 (t, J = 7.5 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 167.35, 157.34, 154.79, 153.54, 
152.28, 148.79, 146.45, 145.65, 131.44, 130.92, 129.63, 128.59, 128.31, 128.28, 128.25, 120.41, 
96.22, 78.13, 67.17, 66.61, 65.64, 65.00, 50.11, 47.90, 37.09, 36.62, 31.96, 28.22, 7.75. ESI-MS 
(low resolution, positive mode): calculated for C50H38N7O12, m/z, 928.26 [M + H]+; found 928.4 
[M + H]+. 
 
Synthesis of coumarin-BHA 
To a 15 mL CH2Cl2 solution of 2,6-bis(hydroxymethyl)aniline (494 mg, 2.0 mmol) with NaHCO3 
(504 mg, 6.0 mmol, 3.0 equiv) was added 3.8 mL 15% w/w phosgene toluene solution (5.4 mmol, 
2.7 equiv) and the suspension was stirred at room temperature overnight. Solvent and phosgene 
was removed under vacuum to obtain a mixture of the carbonyl chloride and inorganic salt. THF 
was added to dissolve the carbonyl chloride, which was added slowly to a 20 mL THF solution of 
BHA (306 mg, 2.0 mmol, 1.0 equiv) containing 0.5 mL saturated NaHCO3 (aq). The suspension 
was stirred at room temperature for 4 h until all the chloride was consumed as monitored by TLC. 
Then the solution was dried over Na2SO4 and concentrated under vacuum. The solid was collected 
and washed with THF (15 mL*3), EtOAc (15 mL *3), 1:1DCM/EtOAc (15 mL*3) to afford the 
product (0.48 g yellow powder, 56% yield). 1H NMR (500 MHz, DMSO-d6) δ 8.97 (s, 1H), 7.49 
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(d, J = 9.0 Hz, 1H), 7.39 (d, J = 7.6 Hz, 2H), 7.31 (t, J = 7.6 Hz, 1H), 6.71 (dd, J = 9.0, 2.8 Hz, 
1H), 6.56 (d, J = 2.8 Hz, 1H), 6.09 (s, 1H), 5.33 (s, 2H), 5.12 (brs, 2H), 4.49 (s, 4H), 3.44 (q, J = 
7.1 Hz, 4H), 1.13 (t, J = 7.1 Hz, 6H). 13C NMR (126 MHz, DMSO) δ 160.81, 155.84, 153.81, 
151.86, 150.52, 139.50, 130.49, 126.62, 125.35, 125.08, 108.79, 105.25, 104.42, 96.88, 61.42, 
59.21, 44.08, 12.35. ESI-MS (low resolution, positive mode): calculated for C23H27N2O6, m/z, 
427.18 [M + H]+; found 427.0 [M + H]+. 
 
 
Synthesis of coumarin-CPT2 
A DCM suspension (1 mL) of camptothecin (125 mg, 0.36 mmol, 2.4 equiv), DMAP (92 mg, 0.75 
mmol, 5 equiv) and triphosgene(35.6 mg, 0.012 mmol, 0.80 equiv) was stirred at room temperature 
for 15 minutes, during which the camptothecin dissolved gradually. Then DCM/THF (4 mL/5 mL) 
solution of coumarin-BHA (64.0 mg, 0.15 mmol, 1.0 equiv) was added once. After completion of 
the reaction as monitored by TLC (within 1 hour), the reaction was subject to chromatography 
(DCM:MeOH 50:1, EtOAc:MeOH 10:1) giving an off-white powder (130 mg, 74 % yield).1H 
NMR (500 MHz, CDCl3) δ 8.35 (s, 2H), 8.23 (d, J = 8.0 Hz, 2H), 7.92 (d, J = 8.1 Hz, 3H), 7.81 
(dd, J = 8.0 Hz, 8.1 Hz, 2H), 7.64 (dd, J = 8.0 Hz, 8.1 Hz, 2H H), 7.43 (d, J = 7.5 Hz, 2H), 7.40-
7.34 (m, 3H), 7.32 (t, J = 7.5 Hz, 1H), 6.95 (d, J = 8.5 Hz, 1H), 6.38 (d, J = 36.4 Hz, 2H), 5.63 
(dd, J = 160 Hz, 17Hz, 4H), 5.29-5.11 (m, 12H), 3.38 (q, J = 7.2 Hz, 4H), 2.16 (dq, J = 48.7 
Hz,7.5Hz, 4H), 1.19 (t, J = 7.2 Hz, 6H), 0.99 (t, J = 7.5Hz, 6H).13C NMR (126 MHz, CDCl3) δ 
167.30, 157.30, 153.41, 152.19, 148.86, 146.56, 145.72, 137.40, 131.19, 130.81, 129.73, 128.92, 
128.44, 128.21, 128.16, 128.12, 126.35, 120.14, 95.99, 78.22, 67.08, 66.55, 50.06, 31.86, 7.73. 
ESI-MS (low resolution, positive mode): calculated for C65H55N6O16, m/z, 1175.36 [M + H]+; 




Synthesis of Boc-BE 
To a DCM solution (10 mL) of 4-(Hydroxymethyl)phenylboronic acid pinacol ester (400 mg, 1.7 
mmol) was added phosgene (15 wt% in toluene, 6 mL, 8.4 mmol) at room temperature. After the 
clear solution was stirred for 36 h, solvent and excessive phosgene was removed under vacuum. 
A DCM solution (5 mL) of tert-Butyl N-methyl-N-[2-(methylamino)ethyl]carbamate1 (320 mg, 
1.7 mmol) was added quickly. Extra 10 mL DCM and triethylamine (517 µL, 3.7 mmol) was added 
subsequently and the clear solution was stirred for 10 minutes, then quenched with 1 mL methanol. 
The solution was concentrated and then subject to chromatography. Hexane: Ethyl acetate 4:1 to 
2:1 giving colorless oil as pure product (391 mg, 50 % yield). 1H NMR (500 MHz, CDCl3), δ 7.75 
(d, 2H, J = 8.0 Hz), 7.30 (d, 2H, J = 8.0 Hz), 5.08 (s, 2H), 3.27-3.33 (m, 4H), 2.70-2.90 (m, 6H), 
1.38 (s, 9H), 1.28 (s, 12H). 13C NMR (126 MHz, CDCl3), δ 156.0, 139.7, 134.9, 127.1, 126.9, 
125.9, 83.7, 79.5, 66.9, 47.1, 46.7, 35.4, 34.4, 28.3, 24.8. HRMS-ESI (m/z): [M+Na]+ calcd for 
C23H37BN2O6Na, 471.2642; observed, 471.2633.  
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Synthesis of BE-OTBS2 
Boc-BE (60 mg, 0.13 mmol) was stirred in trifluoroacetic acid/DCM (5/5 mL) at room temperature 
for 4 h to deprotect the Boc group and then concentrated under vacuum to remove the solvent 
completely. A DCM solution (5 mL) of 2,6-bis((tert-butyldimethylsilyloxy)- methyl)phenol (106 
mg, 0.27 mmol) and N, N-dimethylaminopyridine (71 mg, 0.59 mmol) was mixed with triphosgene 
(27 mg, 0.09 mmol) and stirred at room temperature for 5 min. The suspension was then mixed 
with the above BE-amine and stirred for 40 minutes until the reaction completed. The mixture was 
directly subject to chromatography. Hexane: Ethyl acetate 8:1-6:1-4:1 giving white solid as pure 
product (70 mg, 67 % yield). 1H NMR (500 MHz, CDCl3), δ 7.83 (d, 2H, J = 8.0 Hz), 7.39 (d, 2H, 
J = 8.0 Hz), 7.22 (s, 2H), 5.18 (s, 2H), 4.64 (s, 4H), 3.47-3.63 (m, 4H), 2.95-3.17 (m, 6H), 2.37 (s, 
3H), 1.37 (s, 12H), 0.95 (s, 18H), 0.09 (s, 12H). 13C NMR (126 MHz, CDCl3), δ 156.4, 154.1, 
143.1, 139.9, 135.3, 135.1, 133.4, 133.3, 127.3, 127.1, 83.9, 67.1, 60.5, 47.2, 46.4, 35.4, 34.9, 26.0 
25.0, 21.4, 18.5, -5.2. HRMS-ESI (m/z): [M+H]+ calcd for C40H68BN2O8Si2, 771.4607; observed, 
771.4603.  
Synthesis of BE-OH2 
BE-OTBS2 (70 mg, 0.091 mmol) was stirred with amberlyst-15 (~10 mg) in a mixture of 
DCM/MeOH (5/5 mL) overnight. After the reaction was completed, the suspension was filtered 
and concentrated giving a white solid as pure product (40 mg, 81 % yield). 1H NMR (500 MHz, 
CDCl3), δ 7.79 (d, 2H, J = 8.0 Hz), 7.36 (d, 2H, J = 8.0 Hz), 7.18 (s, 2H), 5.15 (s, 2H), 4.48 (s, 
4H), 3.47-3.65 (m, 4H), 2.92-3.15 (m, 6H), 2.32 (s, 3H), 1.33 (s, 12H). 13C NMR (126 MHz, 
CDCl3), δ 139.5, 136.4, 135.1, 133.4, 130.8, 130.4, 130.1, 127.5, 127.2, 127.1, 84.0, 67.3, 60.8, 
47.2, 46.8, 35.5, 34.4, 25.0, 21.0 HRMS-ESI (m/z): [M+H]+ calcd for C28H40BN2O8, 543.2878; 
observed, 543.2874.  
Synthesis of BE-L-CPT2 
A DCM suspension (2 mL) of camptothecin (77 mg, 0.22 mmol), DMAP (54 mg, 0.44 mmol) and 
triphosgene (22 mg, 0.074 mmol) was stirred at room temperature for 10 minutes, during which 
the camptothecin dissolved gradually. Then 10 mL DCM solution of BE-OH2 (40 mg, 0.074 mmol) 
was added once. After completion of the reaction as monitored by TLC, the solution was subject 
to chromatography. DCM:MeOH 50:1, EtOAc:MeOH 20:1 giving an off-white powder (48 mg, 
50 % yield). 1H NMR (500 MHz, CDCl3), δ 8.34 (s, 2H), 8.18 (d, J = 8.5 Hz, 2H), 7.90 (d, J = 8.0 
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Hz, 2H), 7.82 (dd, J1 = J2 = 8.0 Hz, 2H), 7.68 (d, 2H, J = 7.5 Hz), 7.64 (dd, J1 = J2 = 8.0 Hz, 2H), 
7.28 (s, 2H), 7.21 (d, 2H, J = 7.5 Hz), 7.11 (s, 2H), 5.51 (dd, J = 148 Hz, 17Hz, 4H), 5.23 (m, 4H), 
4.99 (m, 6H), 3.30-3.58 (m, 4H), 2.82-3.06 (m, 6H), 2.21 (dq, J = 51.5 Hz, 6.5 Hz, 4H), 2.15 (s, 
3H), 1.32 (s, 12H). 0.97 (t, J = 6.5 Hz, 6H). 13C NMR (126 MHz, CDCl3), 167.3, 157.3, 153.8, 
153.6, 152.3, 148.9, 146.6, 145.6, 145.5, 136.2, 135.0, 134.9, 131.2, 130.8, 130.2, 129.8, 128.5, 
128.3, 128.2, 128.1, 127.9, 127.2, 127.1, 127.0, 120.4, 96.0, 83.9, 78.1, 67.2, 66.9, 65.7, 50.1, 47.7, 
46.3, 35.8, 34.6, 32.1, 25.0, 20.9, 7.7. HRMS-ESI (m/z): [M+H]+ calcd for C70H68BN6O18, 
1291.4683; observed, 1291.4675.  
 
Synthesis of C8-BE-OH 
4-hydroxylphenyl boronic acid (3.2 g, 21 mmol) and 1,2-octanediol was mixed in THF (20 mL) 
and refluxed for 1.5 h. The solvent was then evaporated and the crude oil was subject to flash 
chromatography giving a color less oil as the product (5.04 g, 96 yield). 1H NMR (500 MHz, 
CDCl3), δ 7.81 (d, 2H, J = 8.0 Hz), 7.37 (d, 2H, J = 8.0 Hz), 4.71 (s, 2H), 4.56 (tt, 1H, J1 = J2 = 
7.0 Hz), 4.42 (dd, 1H, J1 = 7.0 Hz, J2 = 8.0 Hz), 3.94 (dd, 1H, J1 = 7.0 Hz, J2 = 8.0 Hz), 1.24-1.73 
(m, 10H), 0.89 (t, 3H, J = 7.0 Hz)  
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Synthesis of C8-BE-BHA-OTBS2 
A DCM solution (5 mL) of 2,6-bis((tert-butyldimethylsilyloxy)- methyl)phenol (382 mg, 1.0 
mmol) and N, N-dimethylaminopyridine (305 mg, 2.5 mmol) was mixed with triphosgene (112 
mg, 0.40 mmol) and stirred at room temperature for 15 min. The suspension was then mixed with 
C8-BE-OH (393 mg, 1.5 mmol) and stirred for 1.5 h until the reaction completed. The mixture was 
directly subject to chromatography. Hexane: Ethyl acetate 20:1 to 8:1 giving colorless oil as pure 
product (379 mg, 57 % yield). 1H NMR (500 MHz, CDCl3), δ 7.81 (d, 2H, J = 6.5 Hz), 7.64 (br, 
1H), 7.40 (d, 2H, J = 6.5 Hz), 7.33 (d, 2H, J = 7.5 Hz), 7.21 (t, 1H, J = 7.5 Hz), 5.21 (s, 2H), 4.68 
(s, 4H), ), 4.58 (tt, 1H, J1 = J2 = 7.0 Hz), 4.50 (dd, 1H, J1 = 7.0 Hz, J2 = 8.5 Hz), 3.96 (dd, 1H, J1 
= 7.0 Hz, J2 = 8.5 Hz), 1.27-1.81 (m, 10H), 0.89 (s and t, 3+18H), 0.06 (s, 12H). 13C NMR (126 
MHz, CDCl3) δ 154.2, 139.8, 136.2, 135.1, 132.9, 127.7, 127.1, 127.0, 126.1, 77.7, 71.3, 66.9, 
63.0, 36.3, 31.8, 29.3, 26.0, 22.7, 18.4, 14.19, -5.3. 
Synthesis of C8-BE-BHA-OH2 
C8-BE-BHA-OTBS2 (189 mg, 0.28 mmol) was stirred with amberlyst-15 (~20 mg) in a mixture of 
DCM/MeOH (10/10 mL) overnight. After the reaction was completed, the suspension was filtered, 
concentrated, subject to chromatography Hexane: Ethyl acetate 2:1 to pure ethyl acetate giving a 
mixture of the product and 1,2-octanediol. The colorless oil was then precipitated in DCM: Hexane 
2/12 mL 3 times and the white solid was collected by centrifugation as the pure product (28 mg, 
22 % yield). 1H NMR (500 MHz, CDCl3), δ 7.83 (d, 2H, J = 7.5 Hz), 7.59 (br, 1H), 7.41 (d, 2H, J 
= 6.5 Hz), 7.36 (d, 2H, J = 7.5 Hz), 7.25 (t, 1H, J = 7.5 Hz), 5.23 (s, 2H), 4.61 (s, 4H), ), 4.57 (tt, 
1H, J1 = J2 = 7.0 Hz), 4.43 (dd, 1H, J1 = 7.0 Hz, J2 = 8.5 Hz), 3.95 (dd, 1H, J1 = 7.0 Hz, J2 = 8.5 
Hz), 2.86 (br, 2H), 1.22-1.79 (m, 10H), 0.89 (t, 3H, J = 6.5 Hz) 
Synthesis of C8-BE-CPT2 
A DCM suspension (3 mL) of camptothecin (84 mg, 0.24 mmol), DMAP (61 mg, 0.5 mmol) and 
triphosgene (24 mg, 0.08 mmol) was stirred at room temperature for 15 minutes, during which the 
camptothecin dissolved gradually. The above solution was then transferred to a 7 mL vial charged 
with C8-BE-BHA-OH2 (45 mg, 0.1 mmol). After completion of the reaction in 2h as monitored by 
TLC, the solution was subject to chromatography. DCM:MeOH 15:1, EtOAc:MeOH 50:1-30:1-




Synthesis of Boc-BE 
To a DCM solution (10 mL) of 4-(Hydroxymethyl)phenylboronic acid pinacol ester (400 mg, 1.7 
mmol) was added phosgene (15 wt% in toluene, 6 mL, 8.4 mmol) at room temperature. After the 
clear solution was stirred for 36 h, solvent and excessive phosgene was removed under vacuum. 
A DCM solution (5 mL) of tert-Butyl N-methyl-N-[2-(methylamino)ethyl]carbamate1 (320 mg, 
1.7 mmol) was added quickly. Extra 10 mL DCM and triethylamine (517 µL, 3.7 mmol) was added 
subsequently and the clear solution was stirred for 10 minutes, then quenched with 1 mL methanol. 
The solution was concentrated and then subject to chromatography. Hexane: Ethyl acetate 4:1 to 
2:1 giving colorless oil as pure product (391 mg, 50 % yield). 1H NMR (500 MHz, CDCl3), δ 7.75 
(d, 2H, J = 8.0 Hz), 7.30 (d, 2H, J = 8.0 Hz), 5.08 (s, 2H), 3.27-3.33 (m, 4H), 2.70-2.90 (m, 6H), 
1.38 (s, 9H), 1.28 (s, 12H). 13C NMR (126 MHz, CDCl3), δ 156.0, 139.7, 134.9, 127.1, 126.9, 
125.9, 83.7, 79.5, 66.9, 47.1, 46.7, 35.4, 34.4, 28.3, 24.8. HRMS-ESI (m/z): [M+Na]+ calcd for 
C23H37BN2O6Na, 471.2642; observed, 471.2633.  
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Synthesis of BE-BHP-OTBS2 
Boc-BE (60 mg, 0.13 mmol) was stirred in trifluoroacetic acid/DCM (5/5 mL) at room temperature 
for 4 h to deprotect the Boc group and then concentrated under vacuum to remove the solvent 
completely. A DCM solution (5 mL) of 2,6-bis((tert-butyldimethylsilyloxy)- methyl)phenol (106 
mg, 0.27 mmol) and N, N-dimethylaminopyridine (71 mg, 0.59 mmol) was mixed with triphosgene 
(27 mg, 0.09 mmol) and stirred at room temperature for 5 min. The suspension was then mixed 
with the above BE-amine and stirred for 40 minutes until the reaction completed. The mixture was 
directly subject to chromatography. Hexane: Ethyl acetate 8:1-6:1-4:1 giving white solid as pure 
product (70 mg, 67 % yield). 1H NMR (500 MHz, CDCl3), δ 7.83 (d, 2H, J = 8.0 Hz), 7.39 (d, 2H, 
J = 8.0 Hz), 7.22 (s, 2H), 5.18 (s, 2H), 4.64 (s, 4H), 3.47-3.63 (m, 4H), 2.95-3.17 (m, 6H), 2.37 (s, 
3H), 1.37 (s, 12H), 0.95 (s, 18H), 0.09 (s, 12H). 13C NMR (126 MHz, CDCl3), δ 156.4, 154.1, 
143.1, 139.9, 135.3, 135.1, 133.4, 133.3, 127.3, 127.1, 83.9, 67.1, 60.5, 47.2, 46.4, 35.4, 34.9, 26.0 
25.0, 21.4, 18.5, -5.2. HRMS-ESI (m/z): [M+H]+ calcd for C40H68BN2O8Si2, 771.4607; observed, 
771.4603.  
Synthesis of BE-BHP-OH2 
BE-BHP-OTBS2 (70 mg, 0.091 mmol) was stirred with amberlyst-15 (~10 mg) in a mixture of 
DCM/MeOH (5/5 mL) overnight. After the reaction was completed, the suspension was filtered 
and concentrated giving a white solid as pure product (40 mg, 81 % yield). 1H NMR (500 MHz, 
CDCl3), δ 7.79 (d, 2H, J = 8.0 Hz), 7.36 (d, 2H, J = 8.0 Hz), 7.18 (s, 2H), 5.15 (s, 2H), 4.48 (s, 
4H), 3.47-3.65 (m, 4H), 2.92-3.15 (m, 6H), 2.32 (s, 3H), 1.33 (s, 12H). 13C NMR (126 MHz, 
CDCl3), δ 139.5, 136.4, 135.1, 133.4, 130.8, 130.4, 130.1, 127.5, 127.2, 127.1, 84.0, 67.3, 60.8, 
47.2, 46.8, 35.5, 34.4, 25.0, 21.0 HRMS-ESI (m/z): [M+H]+ calcd for C28H40BN2O8, 543.2878; 
observed, 543.2874.  
Synthesis of BE-CPT2  
A DCM suspension (2 mL) of camptothecin (77 mg, 0.22 mmol), DMAP (54 mg, 0.44 mmol) and 
triphosgene (22 mg, 0.074 mmol) was stirred at room temperature for 10 minutes, during which 
the camptothecin dissolved gradually. Then 10 mL DCM solution of BE-OH2 (40 mg, 0.074 mmol) 
was added once. After completion of the reaction as monitored by TLC, the solution was subject 
to chromatography. DCM:MeOH 50:1, EtOAc:MeOH 20:1 giving an off-white powder (48 mg, 
50 % yield). 1H NMR (500 MHz, CDCl3), δ 8.34 (s, 2H), 8.18 (d, J = 8.5 Hz, 2H), 7.90 (d, J = 8.0 
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Hz, 2H), 7.82 (dd, J1 = J2 = 8.0 Hz, 2H), 7.68 (d, 2H, J = 7.5 Hz), 7.64 (dd, J1 = J2 = 8.0 Hz, 2H), 
7.28 (s, 2H), 7.21 (d, 2H, J = 7.5 Hz), 7.11 (s, 2H), 5.51 (dd, J = 148 Hz, 17Hz, 4H), 5.23 (m, 4H), 
4.99 (m, 6H), 3.30-3.58 (m, 4H), 2.82-3.06 (m, 6H), 2.21 (dq, J = 51.5 Hz, 6.5 Hz, 4H), 2.15 (s, 
3H), 1.32 (s, 12H). 0.97 (t, J = 6.5 Hz, 6H). 13C NMR (126 MHz, CDCl3), 167.3, 157.3, 153.8, 
153.6, 152.3, 148.9, 146.6, 145.6, 145.5, 136.2, 135.0, 134.9, 131.2, 130.8, 130.2, 129.8, 128.5, 
128.3, 128.2, 128.1, 127.9, 127.2, 127.1, 127.0, 120.4, 96.0, 83.9, 78.1, 67.2, 66.9, 65.7, 50.1, 47.7, 
46.3, 35.8, 34.6, 32.1, 25.0, 20.9, 7.7. HRMS-ESI (m/z): [M+H]+ calcd for C70H68BN6O18, 
1291.4683; observed, 1291.4675.  
 
Synthesis of 7 (nP-SS-BHA) 
To a stirred DCM solution of p-nitrophenyl chloroformate (101 mg, 0.50 mmol, 5.0 equiv in 1mL 
DCM) was added a mixture of 4(N3-SS-BHA) (46 mg, 0.10 mmol, 1.0 equiv), triethylamine (84 
uL, 0.60 mmol, 6.0 equiv) in 1 mL DCM. The solution was stirred at room temperature overnight 
and then subject to silica chromatography. Hexane: EtOAc 3:1 to 2:1. The product was obtained 
as a white powder after being crystallized in DCM/hexane (32 mg, 41 % yield). 1H NMR (500 
MHz, CDCl3) δ 8.26 (d, 4H, J = 14 Hz), 7.58 (d, 2H, J = 7.5 Hz), 7.44 (t, 1H, J = 7.5 Hz), 7.37 (d, 
4H, J = 14 Hz), 7.2 (br 1H), 5.36 (s, 4H), 4.44-4.39 (m, 2H+2H), 4.20 (t, 2H, J = 6.0 Hz), 3.38 (d, 
2H, J = 6.5 Hz), 2.99 (m, 6H), 1.90 (m, 2H).13C NMR (126 MHz, CDCl3) δ 155.43, 154.93, 154.58, 
152.63, 145.62, 134.06, 132.44, 131.13, 128.15, 125.44, 121.86, 67.46, 65.80, 65.14, 63.56, 47.91, 




Synthesis of 8 (Dox-SS-Dox) 
Dox-HCl salt (24.9mg, 0.043 mmol, 2.2 equiv) was dissolved in 1.2 mL DMF with triethylamine 
(24 µL, 0.18 mmol, 9.0 equiv). 600 µL DMF solution of 7 was dropwise added into the above 
solution. After the clear solution was stirred at room temperature overnight, 10 mL DCM was 
added and washed with 0.1 M HCl (aq) 20 mL, dried over Na2SO4, concentrated, subject to 
chromatography. (DCM:MeOH 25:1 to 15:1) The product was obtained as a red powder (17 mg, 
54 % yield). 1H NMR (500 MHz, CDCl3) δ 7.99-7.77 (m, 4H), 7.37 (d, J = 7.5 Hz, 2H), 7.28 (m, 
2H), 7.17 (t, J = 7.5 Hz, 1H), 5.47 (s, 2H), 5.29-5.23 (m, 4H), 5.06 (m, 2H), 4.95 (m, 2H), 4.75 (s, 
4H), 4.52 (s, 1H), 4.30 (m, 2H), 4.17 (m, 2H+4H), 4.06 (s, 6H), 3.76 (m, 2H), 3.65 (m, 2H), 3.38 
(t, J = 6.0 Hz, 2H), 3.12 (m, 2H), 2.88 (m, 4H+2H+2H), 2.34 (d, J = 12.5 Hz, 2H), 2.16 (d, J = 
12.5 Hz, 2H), 1.89 (m, 4H+2H), 1.32 (d, 6H). HRMS-ESI (m/z): [M-H]- calcd for C73H77N6O31S2, 
1597.4075; observed, 1597.4070. 
 
Synthesis of SS-BHA-OTBS3 
Triphosgene (31.3 mg, 0.106 mmol), DMAP (82 mg, 0.67 mmol) was mixed in DCM (4 mL) and 
stirred for 5 minutes, A DCM (10 mL) solution of BHA-OTBS3 (111 mg, 0.31 mmol) was added 
to the white suspension at room temperature slowly and stirred for 15 minutes. 3 mL DCM solution 
of 3-azidopropyl 2-((2-hydroxyethyl)disulfanyl)ethyl carbonate (118 mg, 0.42 mmol) was added 
to the white suspension which gradually dissolved in 3 minutes. The clear solution was stirred 
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overnight and was subject to chromatography (Hexane: EtOAc 20:1 to 10:1 to 6:1) giving a 
colorless oil as the product (62 mg, 35% yield). 1H NMR (500 MHz, CDCl3) δ 7.30 (s, 2H), 4.72 
(s, 2H), 4.69 (s, 4H), 4.22 (t, J = 6.0 Hz, 2H), 3.42 (t, J = 7.0 Hz, 2H), 2.97 (m, 4H), 1.93 (tt, J1 = 
J2 = 6.5 Hz, 2H), 0.94 (s, 9H), 0.92 (s, 18H), 0.10 (s, 6H), 0.09 (s, 12H).   
Synthesis of SS-BHA-OH3 
SS-BHA-OTBS3 (62 mg, 0.074 mmol) was stirred with 10 mg amberlyst-15 in a mixture of 
DCM/MeOH (15/10 mL) overnight. After the reaction completed, the suspension was filtered, 
concentrated and was subject to flash column (hex:EtOAc 1:2 to EtOAc to EtOAcLMeOH 20:1) 
giving a colorless oil (25 mg, 68 % yield).  
Synthesis of CPT3-SS-N3 
A DCM suspension (3 mL) of camptothecin (41 mg, 0.117 mmol), DMAP (30 mg, 0.24 mmol) 
and triphosgene(11.6 mg, 0.039 mmol) was stirred at room temperature for 2 minutes, during 
which the camptothecin dissolved gradually. The pink solution was then added into a DCM/THF 
(5/5 mL) solution of SS-BHA-OH3 (16 mg, 0.033). The reaction was monitored by HPLC and 
stirred overnight. It was noted that the reaction didn’t change after 2h. The mixture was subject to 
chromatography. DCM:MeOH 15:1, EtOAc:MeOH 50:1 to 30:1 to 10:1 giving an off-white 
powder (17 mg, 32 % yield). 1H NMR (500 MHz, CDCl3) δ 8.38 (s, 3H), 8.14 (d, J = 8.5 Hz, 3H), 
7.93 (d, J = 8.1 Hz, 3H), 7.83 (m, 3H), 7.65 (m, 3H), 7.10 (m, 5H), 5.99 (d, J = 17 Hz, 1H), 5.78 
(d, J = 17 Hz, 2H), 5.42-5.21 (m, 9H), 4.81 (s, 4H), 4.30 (m, 4H), 4.17 (m, 4H), 3.34 (t, J = 6.5 
Hz, 2H), 2.86 (m, 2H), 2.76 (t, J = 7.0 Hz), 2.14 (m, 6H), 1.88 (tt, J1 = J2 = 6.5 Hz, 2H), 0.96 (t, J 
= 7.5 Hz, 9H). MS-ESI (m/z): [M+H]+ calcd for C81H69N10O23S2+, 1613.4; observed, 1612.9. 
Synthesis of mPEG-PLA 
D,L-Lactide or L-lactide was recrystallized in ethyl acetate three times and stored in glovebox 
prior to the polymerization. For a typical polymerization, mPEG-OH, lactide and Sn(Oct)2 (5% 
mol of mPEG-OH) was mixed in a sealed vial with toluene (total concentration of monomer ~ 0.5 
g/mL) and heated to 110 oC for 24-48 hours. The polymer was then precipitated in ethyl ether, 
washed with DCM-ether three times, dried as white powder. All polymers were characterized by 




Synthesis of mPEG5k-PheLAx  
To a DCM solution of PheOCA,13 and mPEG-OH was added DCM solution of DMAP ( 1.0 equiv 
to mPEG-OH) quickly in glovebox. Gas was generated upon stirring and the solution was stirred 
at room temperature overnight. The polymer was precipitated in 40 mL ethyl ether, washed with 
15 mL ether 3 times and collected by centrifuge. The polymer was dried under vacuum as white 
powder. 
Table 3.3. Summary of mPEG-PhePLA molecular weight, and polydispersity. 
 dn/dc Mn Mw PDI 
mPEG5k-PheLA5k 0.0637 9.7 k 9.9 k 1.02 
mPEG5k-PheLA10k 0.0832 11.8 k 12.3 k 1.04 
mPEG5k-PheLA20k 0.0897 23.1 k 23.9 k 1.03 
 
Synthesis of PMA-PAA 
PAA-CTA (DP =61, 215 mg, 0.050 mmol), methacrylate (473 mg, 498 μL, 5.5 mmol) and AIBN 
(4 mg, 0.024 mmol) was mixed in 2.0 mL THF in Schlenk tube and freeze-pump-thawed 3 times 
to remove oxygen. The clear solution was heated at 70 oC overnight. The reaction was quenched 
in liquid N2 and the polymer was precipitated in 12 mL hexane. The polymer was collected by 
centrifuge, redissolved in 2 mL DCM, precipitated in 12 mL hexane 3 times and dried under 




Figure 3.7. HPLC trace of synthesized CPT conjugate  
 
 
Figure 3.8. Nile Red Fluorescence intensity change versus concentrations of mPEG5k−PLA3k. The 
Nile Red concentration was fixed at 6×10-7 M. The CMC in PBS was determined to be 69 µg/mL.  
 








































Figure 3.9.The hydrodynamic diameter and PDI of CPT-SS-CPT nanoparticles with different 
CPT-SS-CPT/PEG feed ratio. 100 uL DMF solution of CPT-SS-CPT (10 mg/mL) with 
corresponding mPEG-PLA (weight ratio shown in figure) was added dropwise into 2.0 mL DI 
water. Particle size was measured by DLS without purification.  
 
Figure 3.10. a) CPT-SS-CPT nanoparticle size change in the presence of serum; b-c) CPT-SS-
CPT nanoparticle size distribution before (b) and after (c) ultrafiltration; d-e) CPT-SS-CPT 
nanoparticle size distribution before (d) and after being diluted 100 fold with PBS for 14 h (e) and 




Figure 3.11. 1H NMR of SS-BHA and CPT-SS-CPT. All of the side chain hydrogens are up-field 
shifted after conjugation of CPT indicating that the side chain are within the projected planes of 
the two CPT aromatic region. It is likely that the CPT-SS-CPT adopts a sandwich structure with 




Based on our extensive studies on various formulation factors including the prodrug, amphiphilic 
polymer, solvent choice, temperature, etc, we obtained further understanding of the high loading 
nanoparticle formation mechanism. It is believed that during the nanoprecipitation process, the 
water diffuses into the organic solution droplet forcing the nucleation of the prodrug and further 
prodrug nano-aggregates growth on the nuclei (Scheme 3.4). The hydrophobic domains of the 
amphiphilic polymers such as the PLA block bind with the surface of the nano-aggregates and coat 
the surface with hydrophilic chains. The coating of the hydrophilic surface slows down the further 
growth of the hydrophobic prodrug aggregates as the coating density increase and a stable NP is 
formed after the surface of the nano-aggregates is covered by sufficient amount of amphiphilic 
polymers. Due to the unique structure of the dimeric prodrug, the prodrug aggregation growth step 
is sufficiently slow such that amphiphilic polymer coating could achieve high density to prohibit 
further nano-aggregation before the prodrug aggregates’ size reaches more than 200 nm. Since the 
drug molecules constitute the bulk structure of the NP, the prodrug loading can thus be much higher 
than 50%. The TEM observation of a core-shell NP structure also substantiates the above 
mechanism considering that the core of NP is a closely packed prodrug aggregates and the shell is 
an entangled complex of prodrug and PLA chains. (The NP surface PEG is not observable in TEM 
because the PEG is not densely packed around the NP and PEG are only composed of low atomic 
weight light element.) 
 
Scheme 3.4. Proposed NP formation mechanism for the high loading nanoparticles.  
The design of the trigger-responsive prodrug library clearly demonstrated that flexible side chain 
in the dimer molecule is critical in the formation of high loading NPs while the incorporation of 
N,N'-dimethylethylene-diamine linker renders design of trigger groups that don’t have flexible 
chain feasible for the high loading NP system. The large hydrophobic core of the NP also makes 
it possible to encapsulate a secondary reagent in the NP system with high loading to achieve 
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combination therapy. There will be further in-depth study for a combination cancer treatment with 
photodynamic therapy in the next chapter. 
We also screened amphiphilic polymers with different molecular weight and tunable surface 
functionalities in the formulation studies. Although it is not extensively explored, the preliminary 
results clearly show that surface functionality tuning of the NP is feasible by simply changing the 
hydrophilic chain of the polymer linking to a sufficiently long hydrophobic block. Due to the 
simplicity of the surface functionality tuning, it is possible to use this organic NP system in future 
research to study the NP surface groups’ impact on NP-biological interactions. 
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HYPOXIA-RESPONSIVE CPT PRODRUG NANOPARTICLES AND COMBINATION 
WITH PHOTODYNAMIC THERAPY* 
4.1. Introduction 
Photodynamic therapy (PDT) has been recognized as an effective approach for cancer treatment.1,2 
In PDT, a photo-sensitizer (PS) is first delivered and the lesion area is irradiated with light of 
adequate wavelength to excite the PS, which will transfer the energy to oxygen to generate various 
reactive oxygen species (ROS) including hydrogen peroxide, superoxide, hydroxyl radical etc. The 
ROS will damage various intracellular organelles to induce cancer cell necrosis or apoptosis as 
well as disrupt blood vessels to restrain nutrient supply in tumor tissue to achieve maximum killing 
efficacy. Although PDT is very efficient in cancer cell killing in normoxic (of normal oxygen 
level) region, the efficacy in in hypoxic (low oxygen level) regions is limited due to the lack of 
oxygen to generate cell-killing ROS.3 Moreover, PDT consumes oxygen in tumor and restrains 
blood (oxygen) supply through blood vessel disruption, which could induce a hypoxic stress in 
tumor that further limits PDT efficacy for recurring treatment. Under hypoxic stress, tumor cells 
upregulate hypoxia-inducible factor 1α (HIF-1α) and its downstream pathways to grow more 
aggressively and have higher metastasis tendency in order to survive through the environment.4-6 
All of the abovementioned facts undermine the efficacy of PDT. Based on the understanding of 
PDT and biological activity of camptothecin (CPT), We design to combined a hypoxia-responsive 
CPT dimer (hQ-CPT2) nanoparticles with PDT via co-encapsulation of photosensitizer in NPs. 
Since PDT consumes oxygen upon light irradiation and further generates a hypoxic stress 
intracellularly, we hypothesize that PDT can facilitate the drug (CPT) release from hypoxia-
responsive hQ-CPT2 NPs and the release of CPT can inhibit HIF-1α activity, which helps to 
enhance the therapeutic effect of PDT (Scheme 4.1a). The combination treatment will maximize 
the therapeutic efficacy of the PDT and the chemodrug toward cancer growth inhibition. 
4.2. Hypoxia-responsive CPT prodrug, hQ-CPT2 and reduction-triggered drug release  
A hypoxia-responsive dimeric CPT prodrug, hQ-CPT2 (Scheme 4.1b) was designed with a flexible 
N,N'-dimethylethylene-diamine spacer in order to form stable high loading nanoparticles based on 
                                                 
* Collaboration and contribution statement: The photodynamic treatment studies were performed in collaboration 
with Hua He, and Prof. Lichen Yin in Soochow University, China (including Figure 4.2, 4.3 and Table 4.2) 
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our previous understanding about the high drug loading encapsulation mechanism (Chapter 3). 
The quinone moiety in the hQ-CPT2 can be reduced to hydroquinone (Figure 4.1a) by intracellular 
reductase and the reaction is further accelerated in hypoxic environment.7-10 A control CPT dimer, 
Boc-CPT2, was also prepared with a stable urethane termini that cannot release CPT in biological 
environment (Scheme 4.1b).  
 
Scheme 4.1. (a) Schematic illustration of photodynamic therapy combination with the hypoxia-
responsive prodrug. Reactive oxygen species (ROS) are generated from intracellular oxygen upon 
photosensitizer excitation by near infrared light. The ROS can effectively kill cells through series 
of biochemical reactions. The consumption of the intracellular oxygen resulted in a local hypoxia 
stress that induces the release of CPT from the prodrug and the released CPT sensitizes cells to 
PDT killing. (b) Chemical structure of hypoxia-responsive dimeric CPT prodrug hQ-CPT2, control 
CPT dimer Boc-CPT2, and photosensitizer chlorin e6 (Ce6). 
We first characterized the reductive drug release kinetics of small molecular hQ-CPT2 by a model 
reductant, sodium dithionite (Na2S2O4). In the presence of 10 mM sodium dithionite in phosphate 
buffered saline-DMF solution, the release was distinctly stepwise as revealed by HPLC (Figure 
4.1b) and hQ-CPT2 showed a fast CPT release profile with more than 80% CPT released within 








Cell sensitization to PDT
 
68 
structures were confirmed by LC-MS (Figure 4.1c, d). The release intermediates are in accordance 
with our original chemical design of the hQ-CPT2 based on the quinone cyclization,9,11 N,N'-
dimethylethylene-diamine self-cyclization,12,13 and self-immolative elimination of the phenol.13-16 
 
Figure 4.1. CPT release from hQ-CPT2 in reductive environment. (a) Release mechanism of hQ-
CPT2 and key intermediates. (b) HPLC trace of hQ-CPT2 after reductive treatment. (c-e) mass 
spectra of HPLC peaks assigned in (b) and corresponding chemical structures in (a) analyzed by 
LC-MS. (f) CPT release kinetics from hQ-CPT2 at 37 oC with/without reductive reagent.  
We next tested the formulation of hQ-CPT2 with mPEG-PLA as we did previously. The hQ-CPT2 
can form stable nanoparticles smaller than 200 nm at prodrug/polymer ratio less than 8:1 (Table 
4.1) and the prodrug loading efficiency were mostly more than 80% while free CPT could only 
load into the mPEG-PLA micelle with less than 3% drug loading and 55% drug loading efficiency. 
The prodrug nanoparticles were stable for more than three days in both PBS and serum containing 





















































Table 4.1. Formulation of hQ-CPT2 with mPEG5k-PLA3k. 








CPT loading (%) 
1 0.1a 44 0.24 27 2.6 1.5 
2 0.2a 97 0.20 82 14 8 
3 0.5a 136 0.15 85 30 16 
4 1.0a 173 0.13 92 48 27 
5 2.0b 163 0.11 54 52 29 
6 3.0b 164 0.12 78 70 39 
7 4.0b 169 0.11 78 76 42 
8 6.0b 186 0.12 87 84 46 
9 8.0b 196 0.15 42 77 43 
10 10.0b 305 0.28 42 81 45 
11 4.0c 147 0.08 - -  
12 4.0d 246 0.31 - -  
13 4.0e 358 0.30 - -  
14 CPTa, f 36 0.23 55 2.9 2.9 
a, cmPEG-PLA = 10 mg/mL. b, chQ-CPT2 = 10 mg/mL. c, chQ-CPT2 = 5 mg/mL. d, chQ-CPT2 = 2.0 mg/mL. 
e, chQ-CPT2 = 1.0 mg/mL. f, CPT equivalent to 1.0:10 w/w hQ-CPT2/mPEG-PLA. 
4.3. Combination of hypoxia-responsive CPT prodrug nanoparticles with photodynamic 
therapy 
We formulated chlorin e6 (Ce6) 17-19 into the hQ-CPT2 NPs following the previous 
nanoprecipitation method by co-dissolving the hQ-CPT2, Ce6, and mPEG-PLA in the organic 
phase (THF). The hQ-CPT2 loading efficiency remained quantitative while the Ce6 could be 
encapsulated in the NPs in good efficiency (Table 4.2). The control CPT dimer, Boc-CPT2, 
generated comparable NP size and Ce6 loading in the formulation.  




Loading efficiency (%) Loading (%) 
CPT prodrug Ce6 CPT prodrug Ce6 
hQ-CPT2+Ce6 93±2 100.0 44.2 50.0 12.1 
Boc-CPT2+Ce6 101±2 65.3 18.8 39.5 5.5 
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Light irradiation enhanced the intracellularly release of free CPT from hQ-CPT2–Ce6 NP in vitro: 
Since CPT fluorescence is quenched when it is conjugated in hQ-CPT2 (as well as in Boc-CPT2) 
inside NPs, we were able to directly track the CPT release intracellularly through fluorescence 
microscopy. Incubation of the NPs with 4T1 breast cancer cells and irradiation of 660 nm light for 
30 minutes increased free CPT release from the hQ-CPT2 NP with Ce6 remarkably in cytosol as 
revealed by confocal fluorescence imaging (Figure 4.2a) while the hQ-CPT2 NP alone without 
NIR light irradiation (Figure 4.2b) didn’t give rise to reactive oxygen species (ROS) or CPT release. 
Irradiation of the Boc-CPT2 control NP with NIR light (Figure 4.2c) generated significant 
intracellular ROS while no CPT release was observed suggesting that the light induced CPT 
release from the hQ-CPT2 came along with the generation of ROS which was likely due to the 
consumption of oxygen that induced a temporal hypoxic milieu upon light treatment. When an 
ROS quencher, ascorbic acid (Vc), was co-incubated with the hQ-CPT2 NPs with NIR light 
irradiation, intracellular ROS generation was suppressed and negligible CPT release was observed 
(Figure 4.2d). The in vitro study clearly showed that PDT could enhance the intracellular release 
of CPT from hQ-CPT2 NPs. 
hQ-CPT2–Ce6 NP combination inhibit MCF-7 breast tumor growth in vivo: The in vivo anti-tumor 
efficacy of the hypoxia-responsive NP with PDT was then evaluated in orthotopic MCF-7 breast 
tumor model. MCF-7 cells were injected into the mammary fat pad of female nude mice to 
establish the orthotopic tumor model. The nanoparticles were injected three times every four days 
(q3d4) followed by NIR light irradiation each time (Figure 4.3a). Clinically used CPT derivative, 
irinotecan had minimal tumor inhibition effect compared with PBS group and the control Boc-
CPT2 NP with PDT or the hQ-CPT2 NP without light irradiation exhibited moderate anti-cancer 
efficacy (Figure 4.3b). The hQ-CPT2-PDT combination effectively inhibited the tumor growth and 
significantly prolonged the mice survival than all other treatments (Figure 4.3c). Terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was used to analyze the 
apoptotic index of tumor cells in tissue sections. Quantitative analysis showed that the hQ-CPT2-
PDT combination induced largest portion of cancer cells undergoing apoptosis among all treatment 




Figure 4.2. In vitro CPT release induced by PDT treatment. Cells were incubated with hQ-CPT2 
or Boc-CPT2 nanoparticles coencapsulated with Ce6 for 4 h and then irradiated with 660 nm NIR 
laser for 30 minutes. Ascorbic acid (Vc) was used as a quencher to inhibit the ROS generation. 
hQ-CPT2–Ce6 NP combination relieved PDT-induced hypoxia stress in tumor and inhibit HIF-1α 
generation: The in vivo anti-cancer mechanism was further studied. The intratumoral hypoxia was 
semi-quantified in tumors by an established in vivo hypoxia probe, pimonidazole, and 
immunohistology staining. After treatment of nanoparticles with/without NIR light irradiation, the 
mice was injected with the hypoxyprobe, euthanized, and the tissue sections were stained with 
pimonidazole antibody. The fluorescence signal of the secondary antibody that binds with the 
reduced pimonidazole was visualized and quantified with confocal fluorescence microscopy 
(Figure 4.3e). The control Boc-CPT2 NP with light irradiation showed significantly increased 
hypoxia strength induced by PDT while the hQ-CPT2 NP showed much lower hypoxia signal 
either with or without PDT. Hypoxic condition is known to induce upregulation of HIF-1α and 
angiogenesis which could facilitate tumor growth and PDT resistance. Endothelia cell staining by 
CD-31 antibody showed that the PDT treatment with the control Boc-CPT2 significantly enhanced 
vessel generation upon treatment (Figure 4.3e) while both the hQ-CPT2 NP with and without PDT 
suppressed vascularization as the hypoxia stress is minimally introduced by the hQ-CPT2 NP 











treatment. Immunohistological staining also confirmed that PDT upregulated the HIF-1α 
production by the Boc-CPT2-PDT treatment. hQ-CPT2 alone significantly downregulated HIF-1α 
likely due to the fact that the quinone moiety in hQ-CPT2 can act as an oxidant to accelerate the 
HIF-1α degradation and release of CPT from reductive enzyme in normoxic condition further 
inhibited HIF-1α activity. hQ-CPT2-PDT combination showed HIF-1α concentration between the 
mock and hQ-CPT2 alone (Figure 4.3d) as a result of hQ-CPT2 induced HIF-1α downregulation 
and PDT induced HIF-1α upregulation. 
 
Figure 4.3. In vivo evaluation of the hypoxia-responsive prodrug nanoparticles in combination 
with photodynamic therapy. (a) Timeline of in vivo efficacy study against orthotopic MCF-7 breast 
tumor model. (b) MCF-7 tumor growth curve of different treatment. (c) survival curve for different 
treatment groups. (d) Apoptotic index of tumor tissues for different treatments. (e) Quantification 
of the hypoxia stress, vessel density, and HIF-1α level in tumors after the treatment. 
b) c)
d)




































































































































4.4. Materials and methods 
Materials, cell lines and animal models.  
Chemicals were purchased and used as received unless otherwise specified. Anhydrous 
dimethylformamide (DMF) was dried with a column packed with 4Å molecular sieves. 
Tetrahydrofuran (THF) were dried with a column packed with alumina. Succinimidyl β,β, 2,4,5-
Pentamethyl-3,6-dioxo-1,4-cyclohexadiene-1-propanoate (hQ-NHS),20 2,6-bis((tert-
butyldimethylsilyloxy)methyl)-4-methylphenol (BHP)15 2,6-bis(hydroxymethyl)aniline (BHA),21 
was synthesized according to literature report. mPEG-PLA (Mw 5000-3000) was synthesized by 
Sn(Oct)2 catalyzed mPEG-OH (Mw 5000) initiated ring opening polymerization of D,L-lactide.22 
Camptothecin, N,N-dimethylamino pyridine, 2,6-Bis(hydroxymethyl)-p-cresol, triphosgene and 
sodium dithionite were purchased from Sigma-Aldrich. Chlorin e6 was purchased from Frontier 
Scientific. MCF-7 (human mammary carcinoma), and 4T1 (mouse mammary carcinoma) cells 
were purchased from the American Type Culture Collection (Rockville, MD, USA). MCF-7 cells 
was cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Grand Island, NY, USA) 
containing 10% fetal bovine serum. 4T1 cells were cultured in RPMI-1640 (Gibco, Grand Island, 
NY, USA) containing 10% fetal bovine serum. Female nude mice and BALB/c mice (6-8 wk, 18-
20 g) were purchased from Shanghai Slaccas Experimental Animal Co. Ltd. (Shanghai, China) 
and housed in a clean room, five to a cage, with access to water ad libitum, a 12:12 h light-dark 
cycle (7:00-19:00), and a temperature of 25 ± 1 oC. All animal study protocols were reviewed and 
approved by the Institutional Animal Care and Use Committee, Soochow University. 
Instrumentation.  
NMR spectra were recorded on a Varian U500 (500 MHz) or VXR-500 (500 MHz) spectrometer. 
All chemical shifts were reported in part per million (ppm). Particle sizes and polydispersities were 
measured with a ZetaPlus dynamic light scattering (DLS) detector (15 mW laser, incident beam = 
676 nm, Brookhaven Instruments, Holtsville, NY, USA). HPLC was performed on a System Gold 
system (Beckman Coulter, Fullerton, CA, USA) equipped with a 126P solvent module, a System 
Gold 128 UV detector, and an analytical C18 column (Luna C18, 250 mm × 4.6 mm, 5 µm, 
Phenomenex). Part of the HPLC tests were performed on a Shimadzu HPLC system (LC-20AT) 
connected with PDA detector (SPD-M20A) and fluorescence detector (RF-20A). Shimadzu C18 
column (3 µm, 50 mm × 4.6 mm) was used for analysis. Gradient method was adopted using 0.1% 
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TFA-H2O and acetonitrile as mobile phase. The UV wavelength for detecting camptothecin-based 
compounds was set at 369 nm. 
Nanoparticle Preparation.  
Camptothecin (CPT) conjugate was dissolved in DMF with mPEG-PLA at designated ratio and 
the conjugate concentration was 10 mg/mL if not specified. Then 100 μL above solution was added 
dropwise into 2.0 mL DI water with mild stirring using a magnetic bar. Nanoparticle size and 
distribution was analyzed by DLS directly without further purification.  
Serum stability test. 
1.0 mL nanoparticle solution (500 µg/mL) was diluted with 1.0 mL 1:1 human serum/PBS and 
characterized by DLS. 
Drug loading measurement.  
The freshly prepared nanoparticle solution was centrifuged at 3000 rpm for 10 minutes to remove 
large aggregate and an aliquot of the suspension was dissolved in DMF and the CPT conjugate 
content was quantified as the summation of nanoparticle and free conjugate by UV-vis absorption 
at λmax through standard curve. The remaining suspension was centrifuged at 15000 rpm for 10 
minutes to precipitate all the nanoparticles. The clear solution was diluted with DMF and the CPT 
conjugate was quantified by UV-vis absorption. The detection wavelength for CPT, hQ-CPT2 were 
369, 362 nm respectively. 
CPT release from hQ-CPT2 in DMF/PBS solution. 
hQ-CPT2 was dissolved in DMF/10×PBS (1:1, v/v) to 50 μg/mL. The solution was purged with N2 
for 5 minutes to remove oxygen. Then sodium dithionite (Na2S2O4) was added in one portion to a 
concentration of 10 mM. At designated time, an aliquot of 100 µL was taken, diluted with 400 µL 
0.1% TFA-H2O, and subject to HPLC analysis. The composition of each peak was analyzed by 
LC-MS using the same elution method. 
In vitro CPT release. 
 For the observation of ROS generation and CPT release in cells, 4T1 cells before and after light 
irradiation was visualized by confocal laser scanning microscopy (CLSM). Briefly, 4T1 cells were 
seeded on 24-well plates at 1.5  104 cells/well and cultured for 24 h. The hQ NPs, Boc-Ce6 NPs 
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and hQ-Ce6 NPs were added at CPT dimer final concentration of 20 μg/mL. After incubation at 
37 oC for 4 h, cells were washed three times with PBS, incubated with DCFH-DA (10 μM), 
irradiated by 660 nm light at the power density of 2 mW/cm2 for 30 min and fixed with 
paraformaldehyde (4%) before confocal laser scanning microscopy (CLSM) observation.  
In vivo anticancer efficacy. 
 In vivo anticancer efficacy was performed in orthotopic breast tumor model. Female nude mice 
were anesthetized by isoflurane, and injected with 1  107 MCF-7 cells in the mammary fat pads. 
When the tumor volume reached 50 mm3, mice were divided into five groups (n = 8). Mice in each 
group were i.v. injected with PBS or NPs (10 mg CPT/kg, 2.3 mg Ce6/kg) on day 1, 4 and 7. Group 
1 received i.v. injection of PBS. Group 2 received i.v. injection of irinotecan. Group 3 received i.v. 
injection of hQ NPs. Group 4 was i.v. injected with Boc-Ce6 NPs and light irradiated (660 nm, 10 
mW/cm2) for 30 min at 6 h post injection. Group 5 was i.v. injected with hQ-Ce6 NPs and light 
irradiated (660 nm, 10 mW/cm2) for 30 min at 6 h post injection. The antitumor efficacy was 
assessed by measuring the tumor volume, body weight, and survival rate of mice in each group 
every other day. Tumor volume (V) was calculated as length  (width)2  0.5. Relative tumor 
volume were calculated as V/V0 (V0 represents the tumor volume before treatment). Mice were 
considered to be dead either when the tumor volume reached 1000 mm3 or when the mice died 
during the treatment. 
Molecular mechanism.  
Female BABL/c mice were anesthetized by isoflurane, and subcutaneously injected with 4  106 
4T1 cells in the right flank. When the tumor volume reached 70 mm3, the mice were divided into 
four groups (n = 4). The mice in each group were intratumorally injected with PBS or NPs (3.6 
mg CPT/kg, 0.8 mg Ce6/kg). Group 1 received injection of PBS. Group 2 received injection of hQ 
NPs. Group 3 was injected with Boc-Ce6 NPs and light irradiated (660 nm, 10 mW/cm2) for 30 
min at 1 h post injection. Group 4 was injected with hQ-Ce6 NPs and light irradiated (660 nm, 10 
mW/cm2) for 30 min at 1 h post injection. Pimonidazole (60 mg/kg) (Hypoxyprobe™ RedAPC 
Kit, Hypoxyprobe Inc) was intraperitoneally administrated mice 1 h before tumors were collected 
at 4 h post-irradiation. The tumors were embedded in OCT and the frozen tissues were 
sectionalized. Frozen sections were fixed with acetone at 4 oC before confocal laser scanning 
microscopy (CLSM) observation. Alternatively, tumors were harvested from mice at 4 h post-
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irradiation, embedded in OCT and the frozen tissues were sectionalized. HIF-1α was stained using 
anti- HIF-1α mouse monoclonal antibody (dilution 1:200, Abcam) and Alexa Fluor 488-labeled 
goat anti-mouse IgG (dilution 1:500, Beyotime). 
Expression of HIF-1α protein was evaluated by immunoblot analyses. Briefly, Mice with 4T1 
subcutaneous tumors received the same treatment as described above in the immunochemical 
staining study. After 4 h post-irradiation, tumor tissues were collected, washed and homogenized 
for 30 min on ice in lysis buffer supplemented with a mixture of proteinase inhibitors (Invitrogen). 
The samples were cleared by microcentrifugation (10000 rpm, 30 min, 4 °C) and assessed for 
protein concentration. One hundred micrograms of protein per sample was electrophoresed in a 10 
% sodium dodecyl sulfate–polyacrylamide gel and electroblotted onto nitrocellulose membranes. 
After incubation in 5 % BSA buffer, the membranes were exposed to anti-HIF-1α mouse 
monoclonal antibody (dilution 1:1000, Abcam). After washing, the HRP-labeled goat anti-mouse 
IgG (dilution 1:1000, Beyotime) was applied for 1 h at room temperature. The bound antibodies 
were visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech). Beta-actin 
labeling was used for control of loading conditions. 
 
Synthesis of hQ-NH 
To a DCM solution of hQ-NHS ester (1.39 g, 4.0 mmol) and DIPEA (2.0 mL) was added N, N'-
dimethyl-ethylene diamine (4.30 mL, 40 mmol, 10 equiv) at room temperature. After the solution 
was stirred for 30 min, solvent was removed under vacuum and product was extracted with ethyl 
acetate, washed with water (60 mL*4), saturated Na2SO4, dried over Na2SO4, concentrated under 
vacuum giving a yellow powder as a mixture of mono-substituted and disubstituted amide, which 
was used for the next step reaction without further purification. ESI-MS (m/z): [M + H]+ calculated 




Synthesis of hQ-BHP-OTBS 
A mixture of 2,6-bis((tert-butyldimethylsilyloxy)methyl)-4-methylphenol (793 mg, 2.0 mmol), 
triphosgene (208 mg, 0.70 mmol, 0.35 equiv) and N, N-dimethylaminopyridine (732 mg, 6.0 
mmol, 3.0 equiv) in DCM (60 mL) was stirred at room temperature for 15 min. Then a DCM 
solution (10 mL) of hQ-NH (640 mg, 2.0 mmol, 1.0 equiv) was added in one portion to the white 
suspension. The precipitate gradually dissolved with the addition. Solvent was removed after 1 h 
stirring and the mixture was purified with chromatography, hexane: ethyl acetate 8:1 giving a 
yellow powder (1.20 g, yield: 81 %).1H NMR (500 MHz, CDCl3) δ 7.18 (s, 2H), 4.60 (s, 4H), 3.43 
(m, 4H), 3.23 – 2.85 (m, 8H), 2.34 (s, 3H), 2.14 (s, 3H), 1.92 (m, 6H), 1.43 (s, 6H), 0.92 (s, 18H), 
0.06 (s, 12H). 13C NMR (126 MHz, CDCl3)* δ 191.1, 187.5, 172.3, 154.5, 153.9, 153.6, 143.2 
138.0, 136.3, 135.3, 133.3, 128.2, 60.5, 53.4, 47.8, 45.6, 37.7, 36.4, 35.7, 28.7, 25.9, 21.3, 14.1, 
12.6, 12.0, -5.2, -5.3. HRMS-ESI (m/z): [M+H]+ calcd for C40H67N2O7Si2, 743.4487; observed, 
743.4474. 
 
Synthesis of hQ-BHP-OH 
930 mg hQ-BHP-OTBS was stirred with 110 mg amberlyst-15 in a mixture of DCM/MeOH (40/10 
mL) overnight. After the reaction completed as revealed by TLC, the resin was filtered and the 
filtrate was concentrated and subject to flash column (hex:EtOAc 1:2 to EtOAc:MeOH 15:1) 
giving a yellow solid (610 mg, 95 % yield).1H NMR (500 MHz, CDCl3) δ 7.19 (s, 2H), 4.50 (s, 
4H), 3.75 – 3.40 (m, 4H), 3.25 – 2.96 (m, 8H), 2.80 (s, 2H), 2.33 (s, 3H), 2.11 (s, 3H), 1.96 – 1.78 
(m, 6H), 1.41 (s, J = 8.0 Hz, 5H).† 13C NMR (126 MHz, CDCl3) δ 191.5, 187.6, 172.8, 156.0, 
155.4, 154.5, 144.9, 143.1, 138.2, 136.4, 133.4, 129.9, 60.5, 47.7, 46.9, 44.9, 37.8, 36.3, 31.5, 28.7, 
                                                 
* NMR revealed a mixture of the stereoisomer of the amide, only one set of the NMR peaks are reported here. 
† NMR revealed a mixture of the stereoisomer of the amide, only one set of the NMR peaks are reported here. 
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20.9, 14.2, 12.6, 11.9. HRMS-ESI (m/z): [M+H]+ calcd for C28H39N2O7, 515.2752; observed, 
515.2755. 
Synthesis of hQ-CPT2 
A suspension of camptothecin (83.6 mg, 0.24 mmol, 2.4 equiv), DMAP (65 mg, 0.53 mmol, 5.3 
equiv) and triphosgene (24.9 mg, 0.084 mmol, 0.84 equiv) in methylene chloride (10 mL) was 
stirred at room temperature for 15 minutes, in which the camptothecin dissolved gradually. Then 
the solution was added into 3 mL DCM solution of hQ-BHP-OH (51.5 mg, 0.10 mmol). After 
completion of the reaction as monitored by TLC, the solution was concentrated and subject to 
chromatography. DCM:MeOH 15:1, EtOAc:MeOH 25:1 giving a yellow powder (80 mg, 64 % 
yield). 1H NMR (500 MHz, CDCl3) δ 8.38 (s, 2H), 8.18 (d, J = 8.3 Hz, 2H), 7.93 (d, J = 7.9 Hz, 
2H), 7.83 (dd, J = 8.3, 7.9 Hz, 2H), 7.66 (dd, J = 8.3, 7.9 Hz, 2H), 7.29 (s, 2H), 7.16 (s, 2H), 5.52 
(dd, J = 146.0, 17.2 Hz, 2H), 5.26 (s, 4H), 5.23 – 4.87 (m, 4H), 3.69 – 3.27 (m, 4H), 3.20 – 2.74 
(m, 8H), 2.32 – 2.08 (m, 10H), 2.08 – 1.97 (s, 2H), 1.96 – 1.75 (s, 6H), 1.41 – 1.27 (s, 6H), 0.98 
(t, J = 7.5 Hz, 6H). 13C NMR (126 MHz, CDCl3)* δ 190.8, 187.4, 172.3, 167.2, 157.0, 154.7, 153.5, 
152.0, 148.5, 146.3, 145.4, 145.3, 144.9, 143.2, 137.5, 136.0, 131.1, 130.6, 130.5, 130.1, 129.4, 
128.2, 128.2, 128.0, 127.7, 127.6, 120.0, 95.8, 77.9, 66.9, 60.2, 49.8, 47.3, 47.1, 45.8, 37.5, 36.3, 
31.7, 28.3, 20.9, 14.1, 13.9, 12.5, 11.9, 7.5. HRMS-ESI (m/z): [M+H]+ calcd for C70H67N6O17, 
1263.4557; observed, 1263.4551. 
                                                 




Synthesis of Boc-OTBS2 
A DCM solution (8 mL) of 2,6-bis((tert-butyldimethylsilyloxy)-methyl)phenol (110 mg, 0.28 
mmol) and N, N-dimethylaminopyridine (85 mg, 0.69 mmol) was mixed with triphosgene (27 mg, 
0.092 mmol) and stirred at room temperature for 15 min. The clear solution was then mixed with 
tert-Butyl N-methyl-N-[2-(methylamino)ethyl]carbamate (44 mg, 0.23 mmol) and stirred at rrom 
temperature for 1 h. The mixture was directly subject to chromatography. Hexane: Ethyl acetate 
10:1-8:1 giving colorless oil as pure product (85 mg, 60 % yield). 1H NMR (500 MHz, CDCl3), δ 
7.19 (s, 2H), 4.61 (s, 4H), 3.31-3.68 (m, 4H), 2.86-3.22 (m, 6H), 2.34 (s, 3H), 1.46 (s, 9H), 0.92 
(s, 18H), 0.07 (s, 12H).* 13C NMR (126 MHz, CDCl3), 154.0, 153.8, 142.9, 135.3, 133.4, 133.3, 
127.1, 60.5, 60.3, 47.6, 47.4, 35.5, 35.3, 28.5, 26.0, 21.4, 18.5, -5.1. HRMS-ESI (m/z): [M+H]+ 
calcd for C31H59N2O6Si2, 611.3912; observed, 611.3915. 
Synthesis of Boc-OH2 
Boc-OTBS2 (387 mg, 0.63 mmol) was stirred with amberlyst-15 (~10 mg) in MeOH (10 mL) 
overnight. After the reaction was completed, the suspension was filtered, concentrated and subject 
to chromatography. Ethyl acetate to ethyl acetate: MeOH 10:1 giving colorless oil as pure product 
(161 mg, 67 % yield). 1H NMR (500 MHz, CDCl3), δ 7.14 (s, 2H), 4.46 (s, 4H), 2.78-3.65 (m, 
                                                 
* NMR revealed a mixture of the stereoisomer of the amide, only one set of the NMR peaks are reported here. 
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14H), 2.28 (s, 3H), 1.40 (s, 9H).* 13C NMR (126 MHz, CDCl3), δ 155.8, 155.6, 136.1, 133.4, 130.4, 
130.0, 80.3, 60.3, 50.4, 47.0, 35.6, 35.0, 28.5, 20.9. HRMS-ESI (m/z): [M+Na]+ calcd for 
C19H30N2NaO6, 405.1996; observed, 405.1995. 
Synthesis of Boc-CPT2  
A DCM suspension (2 mL) of camptothecin (67 mg, 0.19 mmol), DMAP (49 mg, 0.40 mmol) and 
triphosgene (19 mg, 0.064 mmol) was stirred at room temperature for 5 minutes, during which the 
camptothecin dissolved gradually. Then 1 mL DCM solution of Boc-OH2 (31 mg, 0.081 mmol) 
was added once. After completion of the reaction as monitored by TLC, the solution was subject 
to chromatography. DCM:MeOH 50:1, EtOAc:MeOH 20:1 giving an light yellow powder (74 mg, 
81 % yield). 1H NMR (500 MHz, CDCl3), δ 8.34 (s, 2H), 8.16 (d, J = 8.5 Hz, 2H), 7.89 (d, J = 8.5 
Hz, 2H), 7.81 (dd, J1 = J2 = 8.5 Hz, 2H), 7.63 (dd, J1 = J2 = 8.5 Hz, 2H), 7.27 (s, 2H), 7.10 (s, 2H), 
5.50 (dd, J = 144 Hz, 17Hz, 4H), 5.22 (m, 4H), 5.06 (m, 2H), 4.96 (m, 2H), 3.24-3.65 (m, 4H), 
2.73-3.15 (m, 6H), 2.06-2.33 (m, 7H), 1.36 (s, 9H). 0.96 (t, J = 7.5 Hz, 6H).† 13C NMR (126 MHz, 
CDCl3) δ 167.2, 157.2, 155.4, 153.6, 152.2, 148.8, 146.49, 145.6, 145.5, 136.1, 131.2, 130.7, 
130.5, 130.0, 129.6, 128.4, 128.2, 128.1, 128.1, 127.7, 120.3, 95.9, 78.0, 67.1, 65.8, 60.4, 50.0, 
47.4, 46.5, 35.4, 32.0, 28.4, 20.8, 14.2, 7.7. HRMS-ESI (m/z): [M+H]+ calcd for C61H59N6O16, 
1131.3988; observed, 1131.3975.  
4.5. Conclusion 
In summary, we demonstrated that the high drug loading nanoparticles can co-encapsulate 
photosensitizer in the hydrophobic core of the high loading NP to achieve combination treatment 
using the chemodrug with photodynamic therapy. A hypoxia-responsive dimeric CPT prodrug, hQ-
CPT2, was designed and was shown to release CPT efficiently in response to reductive 
environment. In vitro and in vivo studies confirmed that the photodynamic treatment induced an 
intracellular hypoxia stress that accelerated the CPT release from the prodrug NP and the 
combination of PDT with the prodrug effectively inhibited breast cancer proliferation. The all-in-
one NP delivery marked a novel approach to enhance the therapeutic efficacy of individual 
treatment through one simple nanoformulation with controlled size and composition. 
                                                 
* NMR revealed a mixture of the stereoisomer of the amide, only one set of the NMR peaks are reported here. 
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REDOX-RESPONSIVE SELF-ASSEMBLED CHAIN-SHATTERING POLYMERIC 
THERAPEUTICS* 
5.1. Introduction 
Polymeric nanomedicine has attracted much attention as a new modality for potentially improved 
cancer treatment that may change the landscape of oncology.1-6 Efforts in the area of therapeutic 
polymeric nanomedicine have been largely devoted to the development of polymer-drug 
conjugates and polymer/drug encapsulates.7-11 For polymer-drug conjugates, drug molecules are 
usually grafted to the pendant functional groups of a hydrophilic polymer via cleavable linkages. 
Controlled drug loading and sustained drug release can be achievable, but their structure and 
composition control are very difficult.12,13 Moreover, the polymer-drug conjugates may have 
uncontrolled batch-to-batch variations for their physicochemical and pharmacological properties. 
For polymer/drug encapsulates, on the other hand, drug molecules are embedded in hydrophobic 
polymer matrices in which formation of pro-drug is avoided, but such approach may result in 
poorly controlled drug loading and release.14,15 Although both approaches have resulted in a 
handful of systems in clinical development, alternative design of polymeric nanomedicines that 
can address drawbacks above mentioned are clearly of great interest.  
We have been interested in developing new polymeric nanomedicine platform based on the 
assembly of hydrophobic polymer-drug conjugates. Through drug initiated controlled ring-
opening polymerization of lactide and O-carboxyanhydrides,16-19 we developed a series of 
structurally well-defined drug-polyester conjugates that can be prepared with high drug loadings, 
quantitative loading efficiency and sustained drug release profiles with negligible burst release 
effect. They can further self-assembled to form NPs for drug delivery applications. The technique 
provides a highly efficient way to generate controlled polymeric drug NPs, and the drug release is 
dependent on ester linker hydrolysis.  
An ideal polymeric drug conjugate would allow drug being released in an on-demand manner, i.e. 
drugs being released in response to triggers, especially those disease specific.14 A variety of trigger-
                                                 
* Part of this chapter is adapted from the publication: Cai, K.; Yen, J.; Yin, Q.; Yang, L.; Song, Z.; Lezmi, S.; Zhang, 
Y.; Yang, X.; Helferich, G.; Cheng, J.*, "Redox-Responsive Self-Assembled Chain-Shattering Polymeric 
Therapeutics", Biomater. Sci., 2015, 3, 1061-1065. 
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responsive systems have been developed to maximize systemic efficacy in response to various 
triggers, such as pH,20-23 elevated temperature,24 redox,25-28 enzyme,29,30 external stimuli31 and 
combination of multiple triggers.32-37 Among these triggers, intracellular redox environment offers 
an ideal trigger condition for pro-drug design, which possesses 3 orders of magnitude higher 
glutathione level (~10 mM)38 as compared to extracellular environment (~10 μM). Simple 
disulfide bond or thioester can be cleaved efficiently by intracellular thiols39,40 and reductase41 
while they are inert to many other reactions and chemical functional groups, facilitating the easy 
synthesis and chemical modification of disulfide containing materials. 
 
Scheme. 5.1 Chemical structure of thiol responsive SS-CSPT (a) and model small molecule CPT-
SS-CPT (b). (c) Click PEGylation, self-assembly and triggered release of SS-CSPT. 
We recently developed a polymeric delivery system termed as chain-shattering polymeric 
therapeutics (CSPTs) as an effective on-demand delivery system.42 Unlike post modified 
polymeric drug-conjugate, CSPTs have excellent control over both composition and structure, and 






would self-aggregate in aqueous solution and require the assistance of amphiphilic polymers to 
form nano-sized particles for intracellular and in vivo delivery. The two-component nanoparticle 
(NP) formulation is inherently difficult to control since the particle size and drug loading are 
affected by both the polymer ratio and formulation condition. In this contribution, we report a 
thiol-responsive, PEGylated SS-CSPT prepared by 'graft to' strategy. The PEGylated SS-CSPT has 
a high drug loading (up to 18 %) and the particle size can be controlled simply by tuning the 
polymer concentration in organic solvent through nanoprecipitation. Drugs are released only in the 
presence of thiol trigger and the NPs show remarkable efficacy against cancer cells. 
5.2. Self-assembled CSPT therapeutic and in vivo applications 
We designed a terminal azide group in the SS-CSPT side chain as a functional site for “Click” 
modification of PEG (Scheme 1a). The trigger-responsive domain was linked with a hydroxylethyl 
sulfide group, which underwent cyclization spontaneously to release an aniline structure. The 
unstable aniline can self-eliminate to release the conjugated drug molecules in a timely manner.42-
44 SN-38, a camptothecin (CPT) derivative, was used as a model drug in our CSPT design while 
the mono-functional camptothecin was used to prepare a dimeric small molecule conjugate (CPT-
SS-CPT) to study the release mechanism (Scheme 5.1b). SN-38 has been shown to be the active 
metabolite of clinically used irinotecan,45 but is limitedly used due to its poor water solubility and 
difficulty of encapsulation.  
Both CPT-SS-CPT and SS-CSPT can be prepared from the trigger responsive domain in one step. 
Since the backbone of the SS-CSPT polymer is inherently hydrophobic, we envisioned that 
incorporation of hydrophilic PEG chain into the polymer covalently would convert the polymer to 
be amphiphilic and assist the self-assembly thereafter. An arbitrary SS-CSPT/PEG weight ratio 
2.5:1 was used in the copper-catalyzed azide-alkyne cycloaddition (CuAAC) to facilitate the 
further assembly as well as to maintain the high drug loading capacity. After the copper catalyst 
was removed by extensive dialysis in water, the obtained polymer showed bimodal distribution on 
GPC (Figure 5.4), which indicated the successful modification of the mPEG chain onto the 
polymer as the new peak had a short elution time compared with both unmodified SS-CSPT and 
PEG.  
The self-assembly behavior of the SS-CSPT-PEG was studied by nanoprecipitation method. 
Briefly, the SS-CSPT-PEG was first dissolved in DMF, slowly added into 40-fold water and the 
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size of the CSPT-PEG NPs was characterized by dynamic light scattering (DLS) without further 
purification. As a result, the SS-CSPT-PEG readily formed NPs without any precipitation observed 
and was stable over 24 hours in water (Figure 5.5). Interestingly, the NP size depended linearly on 
the original CSPT concentration in DMF (Figure 5.1a), which was similar to a drug-polylactide 
conjugate system reported previously.18,46 The NP size increased from 44 to 89 nm as the SS-
CSPT-PEG concentration in DMF increased from 1.25 to 20 mg/mL while the polydispersity (PDI) 
ranged from 0.22 to 0.13. TEM image of the NPs (Figure 5.1b) showed spherical morphology and 
slightly smaller size compared to the hydrodynamic volume measured by DLS. Drug loading of 
the CSPT NPs were determined to be 18% by HPLC after complete NaOH hydrolysis. For all the 
entries, the encapsulation efficiency ranged from 78 to 89 % (Table 5.1). Salt effect on the particle 
formulation was also investigated using phosphate buffered saline (PBS) to replace water. 
Although the CSPT NPs formulated in water was stable after PBS dilution without significant size 
change, the particles formed in PBS directly had a larger size than that that in water at the same 
SS-CSPT-PEG concentration in DMF solution (112 nm compared to 65 nm). Similar observations 
have been reported in other polymeric NP formulations.18 
 
Figure 5.1 (a) Nanoparticle size (hollow square) and size distribution (solid square) change as a 
function of SS-CSPT-PEG concentration in original DMF solution. (b) TEM image of CSPT 
nanoparticles formulated from 10 mg/mL DMF solution .  
The release mechanism of the SS-CSPT was first studied using the dimeric model conjugate (CPT-
SS-CPT) because the model dimeric conjugate and SS-CSPT share the same trigger-responsive 
domain and similar chemical structure (Scheme 5.1a-b). In the absence of thiol triggers, there was 
no drug release observed (Figure 5.2a) while the disulfide bond was cleaved within 5 minutes in 
the presence of excessive dithiothreitol (DTT) (Figure 5.2b). The intermediate gradually 
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underwent thiol-cyclization over several hours and presumably yielded an unstable aniline 
structure, which was undetectable by HPLC and instantaneously release the carbonate bonded CPT 
through 1,4-self elimination (Figure 5.2c). Overall, the original CPT was released quantitatively 
from the CPT-SS-CPT conjugate over 4 h without byproduct production (Figure 5.2a). 
 
Figure 5.2 (a) CPT release of CPT-SS-CPT in DMF/PBS triggered by 20 mM DTT. Data are 
presented as mean value±standard deviation of 3 measurements. (b) HPLC trace of DTT treated 
CPT-SS-CPT, λabs = 369 nm. (c) Proposed release mechanism of DTT triggered drug release.  
We next studied the drug release profile of the CSPT NPs upon thiol triggering. Considering the 
steric hindrance of the NPs, the thiol exchange step was limited by the diffusion of the thiol trigger, 
hence the first thiol cleavage would be much slower than that of CPT-SS-CPT, the model 
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conjugate. Although free SN-38 drug release from the NPs was slower (Figure 5.3a), the majority 
of the conjugated SN-38 could be released from CSPT NPs over 48 h indicating that the interior 
space of the NPs was accessible and sensitive to external environments. Notably, negligible SN-
38 release was observed in the absence of trigger, while the release kinetics of the trigger-
responsive CSPT NPs was much faster than the polymer-drug conjugates based on ester 
hydrolysis.47-51 
 
Figure 5.3 (a) SN-38 release from CSPT NPs in the presence of DTT treatment. (b) Cytotoxicity 
of CSPT NPs in HeLa cells. Standard MTT protocol was followed by incubating drug solutions 
with cells for 72 hours. Data are presented as mean value±standard deviation of 3 measurements. 
(c) Representative images of (TUNEL) assay for apoptotic index analysis. Apoptotic cells were 
stained as red and cell nuclei were stained as blue. Scale bar: 100 µm. 
The in vitro anticancer effect of the CSPT NPs was next evaluated by the standard MTT (3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay to demonstrate the therapeutic 
potential of the delivery system. By incubating HeLa cells with the CSPT NPs for 72 h, significant 
cancer cell proliferation inhibition was observed (Figure 5.3b). The IC50 value of the CSPT NPs 
was 19 nM, while free SN-38 and irinotecan, a clinically used CPT derivative, showed IC50 values 
of 14 nM and 2800 nM, respectively. The significant cytotoxicity of CSPT NPs indicated that the 
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intracellular thiols and thiol reductase actively reduced the disulfide bond within the NPs, releasing 
SN-38 in a timely manner. We also did preliminary evaluation of the in vivo anticancer efficacy of 
the CSPT NPs against MCF-7 human breast cancer xenografts in athymic nude mice. MCF-7 cells 
were subcutaneously injected and three injections of PBS, irinotecan (50 mg/kg) and CSPT NPs 
(equivalent 20 mg/kg SN-38) were administered every four days after the tumor volume reached 
100 mm3. Mice were sacrificed 3 days after the last injection (time course of the in vivo study see 
Figure 5.6a) and tumors were collected to assess the antitumor efficacy of NPs. The apoptotic 
index of the tumors was analyzed by terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) assay. CSPT NPs showed equivalent efficacy (8.6% vs. 5.3% of irinotecan) as compared 
to higher dose of irinotecan (Figure 5.3c and Figure 5.6c).  
5.3. Materials and methods 
Materials, cell lines and animal models. 
Chemicals were used as received unless otherwise specified. Anhydrous dimethylformamide 
(DMF) was dried with a column packed with 4Å molecular sieves. Tetrahydrofuran (THF) and 
methylene chloride (DCM) were dried with a column packed with alumina. SN-38, sodium azide, 
N,N-dimethylamino pyridine, dithiothreitol (DTT), triphosgene, mPEG2k-OH, CuBr, PMDETA 
(N,N,N′,N′′,N′′-Pentamethyldiethylenetriamine) were purchased from Sigma-Aldrich (St. Louis, 
MO,USA). Irinotecan hydrochloride trihydrate was purchased from LC Laboratory (Woburn, MA, 
USA). In situ cell death detection kit (TMR red) was purchased from Roche Diagnostics 
(Indianapolis, IN, USA). The HeLa cells (ATCC, Manassas, VA, USA) used in the MTT (3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay were cultured in Dulbecco’s 
modified Eagle medium (DMEM) containing 10% fetal bovine serum, 1000 units/mL aqueous 
penicillin G, and 100 μg/mL streptomycin at 37 ℃ under 5% CO2 humidified atmosphere. Female 
athymic nude mice were purchased from the National Cancer Institute (NCI, Frederick, MD, USA) 
and ovariectomized at the age of 21 days by the vendor. After arrival, mice were single-cage 
housed and had free access to food and water. The study protocol was reviewed and approved by 
the Illinois Institutional Animal Care and Use Committee (IACUC) of the University of Illinois at 
Urbana Champaign. 
Instrumentation. NMR spectra were recorded on Varian U500 (500 MHz) or VXR-500 (500 
MHz) spectrometer. All chemical shifts were reported in part per million (ppm). Tandem gel 
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permeation chromatography (GPC) was performed on a system equipped with an isocratic pump 
(Model 1200, Agilent Technologies, Santa Clara, CA, USA), a DAWN HELEOS multi-angle laser 
light scattering detector (MALLS); (Wyatt Technology, Santa Barbara, CA, USA), and an Optilab 
rEX refractive index detector (Wyatt Technology). The detection wavelength of the HELEOS was 
set at 658 nm. Separations were performed on serially connected size exclusion columns (100 Å, 
1000 Å, 104 Å, 105Å and 106 Å Phenogel columns, 5 μm, 300 × 7.8 mm, Phenomenex, Torrance, 
CA, USA) at 60 °C with DMF containing 0.1 M LiBr as the mobile phase. The HELEOS detector 
was calibrated with pure toluene without using external polymer standards and was used for the 
determination of the absolute molecular weights. The molecular weight of polymer was 
determined from the dn/dc value calculated assuming 100% mass recovery, and was processed by 
ASTRA software (Version 6.1.1, Wyatt Technology). Nanoparticle sizes and polydispersities were 
measured with a ZetaPlus dynamic light scattering (DLS) detector (15 mW laser, incident beam = 
676 nm, Brookhaven Instruments, Holtsville, NY, USA). HPLC was performed on a Shimadzu 
HPLC system (LC-20AT, C18, 50 mm × 4.6 mm, 3 µm, Shimadzu) or Gold system (Beckman 
Coulter, Fullerton, CA, USA) equipped with a 126P solvent module, a System Gold 128 UV 
detector, and an analytical C18 column (Luna C18, 250 mm × 4.6 mm, 5 µm, Phenomenex). The 
UV wavelength for detecting camptothecin and SN-38 was set at 369 nm and 380 nm, respectively. 
TEM samples were prepared on 200 mesh carbon film supported copper grids. One drop of the 
nanoparticle solution (~ 10 μL, 100 µg/mL) was placed on the grid and allowed to stand for 10 
min. Filter paper was then used to remove the residual solution. The resulting sample was imaged 
using JEOL 2100 Cryo TEM at 200 kV. Lyophilization was conducted on a Labconco FreeZone 
lyophilizer (Kansas City, MO, USA). MTT absorption was measured on Perkin Elmer Victor3 
multi-label readers at λabs = 570 nm. Fluorescent images of tumor sections were collected by 
Nanozoomer Digital Pathology System (Hamamatsu). Infrared spectra were recorded on a Perkin 






A DCM suspension (3 mL) of SN-38 (39.2 mg, 0.10 mmol), triphosgene (20.8 mg, 0.070 mmol, 
0.70 equiv) and DMAP (61 mg, 0.50 mmol, 5.0 equiv) was stirred at room temperature for 15 
minutes, during which the SN-38 dissolved gradually. Then 3 mL DCM solution of 4 (46.1 mg, 
0.10 mmol, 1.0 equiv) was added once. The solution was stirred at room temperature for 48 hours. 
The solution was then poured into 10 mL ethyl ether. The light yellow precipitate was collected 
by centrifuge and washed with 1% HCl contaning methanol (10 mL) and methanol (5 mL × 3), 
dried under vacuum giving a light yellow powder (47 mg, yield 52 %). dn/dc = 0.1430, Mn = 3.0 
kDa, PDI = 1.53. 
 
Synthesis of mPEG2k-alkyne  
To a THF solution of mPEG2k-OH (2.0 g in 50 mL) was added 48 mg NaH (2.0 mmol, 2.0 equiv) 
in one portion and the suspension was stirred at room temperature for 45 minutes. Then propargyl 
bromide (238 mg, 172 μL, 2.0. mmol, 2.0 equiv) was added and the solution was stirred at room 
temperature overnight. MeOH was added to quench the reaction and the clear solution was subject 
to flash column (neutral alumina, EtOAc:MeOH 3:1) giving a colorless oil. The crude product was 
dissolved in 10 mL DCM and precipitated in 40 mL Et2O, collected by centrifugation, 
reprecipitated in DCM/MeOH twice giving a white powder (1.05 g, yield 50 %) after being dried 
under vacuum. dn/dc = 0.0352, Mn = 1.96 kDa, PDI = 1.06. 
PEGylation of CSPT by click reaction 
20.6 mg SS-CSPT was mixed with 8.2 mg mPEG2k-alkyne, 3.0 mg CuBr and 3.0 μL PMDETA in 
1.0 mL DMF in a glovebox and stirred at room temperature for 72 hours. The solution was then 
burbled with air for 10 minutes to fully oxidized the Cu(I) to Cu(II) salt. 4.0 mL H2O was added 
to dilute the solution and dialyzed against 2 L dilute EDTA (aq). The solution was changed to 2L 
H2O every 6-12 hours (3 times altogether). The final solution was lyophilized to obtain a yellow 
powder as the product (28 mg, yield 97 %). Due to distinct dn/dc difference between the two GPC 
peaks, the absolute Mw calculation is not accurate by combining light scattering (LS) and reflective 
index (dRI) results. Considering the high yield and quantitative modification efficiency shown by 
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GPC, we calculated the Mw from the fed CSPT-PEG ratio and the starting CSPT: Mn = 
(2.5+1.0)/2.5*3.0 kDa = 4.2 kDa. 
Nanoparticle Preparation. 
SS-CSPT-PEG polymer was first dissolved in DMF and 50 μL solution was added dropwise into 
2.0 mL DI water (or phosphate buffered saline) with mild stirring using a magnetic bar. 
Nanoparticle size and distribution was analyzed by DLS directly without further purification.  
Nanoparticle stability test. 
The freshly prepared CSPT NP solution was diluted with H2O or PBS 10 fold to test its stability 
upon dilution and salt effect. The size and distribution of the NPs was measured by DLS. No 
significant size change was observed over 24 hours. 
Drug loading measurement. 
The freshly prepared NP solution was centrifuged at 1000 rpm for 10 minutes to remove large 
aggregates. Then 300 μL supernatant was mixed with 300 μL 2 M NaOH (aq) and incubated at 37 
℃ overnight. Then 300 μL 2 M HCl (aq) was added to neutralize the solution and the clear solution 
was subject to HPLC analysis after being diluted to around 5 μg/mL. Calibration curve was 
obtained by area integration of standard samples (λabs = 380 nm). Drug loading of the PEGylated 
CSPT polymer was determined to be 18 % by the same method. Drug loading efficiency was 
calculated as apparent drug loading of nanoparticle divided by 18%. 
Camptothecin (CPT) release from free CPT-SS-CPT in DMF/PBS. 
8.0 mL 50 μg/mL CPT-SS-CPT in 1:1 DMF/PBS solution was added 22 mg DTT at room 
temperature and the CPT release was monitored by HPLC. CPT release was quantified by 
integration of the peak at the same elution time as free CPT. The experiments were carried out in 
triplicates and the release profile was presented as mean value ± standard deviation. 
SN-38 release from SS-CSPT NP. 
The SS-CSPT NPs prepared from 10 mg/mL DMF solution was diluted with PBS to 50 μg/mL 
(6.9 μg/mL equiv SN-38 according to drug loading and encapsulation efficiency calculation). Then 
specified concentration of DTT was added and the solution was separated into 1 mL volume in 
separate tubes at 37 ℃. At designated time, one tube was centrifuged at 15000 rpm for 5 minutes 
 
94 
to remove particles and the supernatant was analyzed by HPLC and quantified by area integration 
(λabs = 380 nm). 
Cytotoxicity evaluation of SS-CSPT NP. 
Standard MTT protocol was followed to evaluate the cytotoxicity of the CSPT NPs. Briefly, HeLa 
cells were seeded in 96-well plate at 1000 cell/well in 100 μL medium and were allowed to attach 
overnight. Free SN-38 and irinotecan was first dissolved in DMSO and diluted with PBS to the 
concentration desired. For the highest drug concentration tested, the DMSO content was 5% for 
SN-38 and 1% for irinotecan. CSPT NPs were formulated in PBS from 10 mg/mL PEGylated 
CSPT DMF solution through nanoprecipitation, diluted with PBS and sterilized by filtration 
through 0.45 µm PVDF membrane. 10 μL drug/nanoparticle solution was added into the well to 
the designated final concentration and incubated at 37 ℃ for 72 hours. PBS and 5% DMSO-PBS 
were taken as 100% control. 20 μL 5 mg/mL MTT solution was added to the medium and 
incubated at 37 ℃ for 3 hours. Then the medium was carefully removed and the violet crystal was 
dissolved in 100 μL DMSO and quantified by absorption at λabs = 570 nm. 
In vivo efficacy study in xenograft tumor model. 
Acute antitumor efficacy study in athymic nude mice bearing subcutaneously implanted MCF-7 
human breast tumors. Female athymic nude mice, 8-week old, were prepared for implantation of 
the tumor cells. MCF-7 cells were collected from culture, and 1 × 106 cells suspended in a 100 µL 
1:1 mixture of Hank's Balanced Salt Solution (HBSS) buffer and matrigel were injected 
subcutaneously into the flanks of a mouse (four injection sites per mouse). After about 4 weeks 
when tumors had reached ~100 mm3, mice were randomly divided into three groups that each had 
2-3 mice, minimizing weight and tumor size difference among the groups. Tumor-bearing mice of 
the corresponding group were treated three times (every four days) by PBS (200 μL, i.v. injection), 
CSPT NPs (in 200 μL PBS, i.v. injection), irinotecan (in 200 μL PBS, i.p. injection), respectively. 
The experimental time line and injection protocol are summarized in Figure 5.6. All the mice were 
sacrificed on Day 11. All the tumors were collected and embedded in OCT except that one piece 
of tumor in each mouse was excised and subject to H&E staining. Cell apoptosis was analyzed 
using in situ cell death detection kit (Roche Diagnostics GmbH, Mennheim, Germany) and 
TUNEL staining was performed following the manufacture’s procedure. The cell nuclei of the 
sections were stained with Hoechst (blue fluorescence) and the positive apoptotic cell nuclei DNA 
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fragments were stained by TUNEL (red fluorescence). The tissue sections were imaged with 
Nanozoomer Virtual Microscopy (Hamamatsu). The collected images were then created into stack 
using the InCell Translator software. The stacks were then analyzed using the GE InCell Analyzer 
workstation. The nuclei were identified using top-hat segmentation in the DAPI channel and the 
numbers of cells were then calculated. The identified nuclei were further segmented by multiscale 
top-hat in the red signal to determine the number of cells with positive red signals (apoptotic cells). 
The cell death number was then determined by dividing the number of apoptotic positive cells by 
the total number of cells. Data are represented as average ± SEM (standard error of the mean) and 













Figure 5.5. (a) CSPT nanoparticles size change over time as measured by DLS. (b) Size 
distribution of CSPT NP formulated at different concentrations. Particle size was monitored by 
DLS without further purification.  
 
 































 1.3 g/L  2.5 g/L  5 g/L 
 10 g/L  20 g/L












 1.3 g/L  2.5 g/L  5.0 g/L 





c (mg/mL) d (nm) PDI EE (%)a 
1.25 44 0.22 87 
2.5 47 0.23 89 
5.0 54 0.15 79 
10 65 0.16 78 
20 89 0.13 86 
Table 5.1. DLS characterization of CSPT NPs formulated from different DMF solution. aEE 
stands for encapsulation efficiency. 
 
Figure 5.7. (a) Schematic illustration of the timeline of the acute antitumor efficacy study. (b) 
Body weight change of mice after administration of PBS (i.v.), Irinotecan (i.p. 50 mg/kg) and 
CSPT NPs (i.v. 20 mg/kg equiv SN-38). (c) Apoptosis index of subcutaneously implanted MCF-
7 tumors after administration of PBS, irinotecan and CSPT NPs. * p < 0.05 
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Figure 5.8. IR spectrum of SS-CSPT and SS-CSPT-PEG. Note the azide peak (2100 cm-1) is 
present in both polymers while the characteristic peaks of triazole of SS-CSPT-PEG (~1600 cm-1, 
1470 cm-1) overlap with the SS-CSPT peaks. 
5.4. Conclusion 
In summary, we report a novel redox trigger-responsive CSPT. By copper catalyzed “Click” 
reaction post polymerization, we were able to introduce hydrophilic PEG chain onto the 
hydrophobic CSPT. The amphiphilic polymer could self-assemble into NPs. The size of CSPT NPs 
can be precisely controlled by the concentration of the CSPT in DMF prior to nanoprecipitation 
over a range of 40 to 90 nm; NPs are also very stable under physiological conditions. The 
formulated NPs can efficiently release the conjugated drugs through self-elimination and chain 
shattering mechanism in the presence of thiol trigger. As revealed by MTT and TUNEL assay, the 
NPs showed cytotoxicity in vitro comparable to SN38 and anticancer efficacy in vivo over 
clinically used irinotecan. As the azide attached polymer side chain can be used via “Click” 
chemistry, targeting group can be readily introduced to the CSPT NPs. Our previous studies using 
silica NPs showed that ~50 nm could be most optimal size of nanomedicine;52,53 it is subject to 
further studies to demonstrate whether such size is optimal in other nanomedicine system, such as 
polymeric nanomedicine. Therefore, CSPT NP not only is a trigger-responsive nanomedicine for 
translational applications, but could also be an excellent system for fundamental studies, such as 
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AROMATIC HINDERED UREA CHEMISTRY AND APPLICATION TOWARD SELF-
HEALING AND DEGRADABLE MATERIALS 
6.1. Introduction 
There has been growing interest in developing novel dynamic covalent chemistry (DCC) and 
applications toward molecular assembly, smart polymers, and self-healing materials.1,2 We 
recently demonstrated that N-substituted urea bond can be tuned to be dynamic if bulky group is 
incorporated to inhibit the urea bond conjugation (Scheme 6.1).3 Aliphatic ureas were primarily 
explored with a bond dissociation constant (k-1) around 0.2 h-1 at 37 oC for stable N-t-butyl-N-ethyl 
urea that has a bond equilibrium constant higher than 105 M-1. Self-healing,3 water degradation,4 
and malleable thermoset polymer5 have been explored based on the aliphatic hindered urea bond 
(HUB). In this chapter, we explored the dynamic property of aromatic HUB and demonstrated that 
the aromatic HUB has a bond dissociation constant (k-1) two order of magnitude higher than its 
aliphatic counterpart with comparable bond strength. The polymeric aromatic HUB material can 
have room-temperature self-healing performance due to the fast bond exchange kinetics.  
 
Scheme 6.1. Chemical structure of dynamic hindered urea bond. Due to the steric hindrance of the 
bulky substituent on the nitrogen atom, the conjugation of the urea bond is less favored which 
make the bond less stable and dynamic. 
6.2. Aromatic dynamic ureas with fast and ph-independent hydrolytic kinetics 
Water degradable materials have been widely used in a variety of fields including biomedical 
applications6,7 and environmental science.8 Engineered materials that release encapsulated cargo 
consistently independent of surrounding environment, especially pH, have found tremendous 
significance in industries of encapsulation and drug delivery.9 Orally delivered drugs, for example, 
often have varied in vivo bioavailability and thus uncontrolled therapeutic efficacy due to the 
variation of drug release kinetic in response to the change of gastrointesitnal pH. The hydrolysis 
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of conventional degradable polymers including esters,10-18 anhydrides,19,20 orthoesters,21,22 
carbonate,23-28 acetal,29-31 phosphoesters,32-34 are generally logarithmically pH dependent. So far, 
only complex formulations can achieve pH independent cargo release35-38 due to the lack of simple 
chemistries that can degrade consistently irrespective of pH change over a wide range.39-42 In this 
contribution, we report a fast and pH-independent hydrolysable materials based on hindered 
aromatic ureas (HAU) – one of the dynamic covalent chemistry. Degradation profiles of the HAU 
were shown to be correlated with urea bond dissociation irrespective of the solution pH. Polymeric 
HAU was demonstrated to degrade to half the molecular weight within ten minutes at room 
temperature while ambient storage of the solid powder showed negligible hydrolysis over two 
months. The transient feature of the HAU and its facile preparation will have remarkable 
implications in materials design and applications such as sacrificial coatings and biomaterials. 
Our previous studies have shown that by incorporating a secondary hindered substituent onto the 
nitrogen atom, the resulting hindered urea bond (HUB) turns to be dynamic and can reversibly 
dissociate into secondary amine and isocyanate.3 The isocyanate can be hydrolyzed to a primary 
amine, which leads to the breakdown of HUB by water.4 Although isocyanates hydrolysis is highly 
pH dependent,43,44 we hypothesized that by incorporating an environmental insensitive urea 
dissociation as the rate-limiting step, the hydrolysis of this type of “pro-isocyanate” bond can be 
pH independent (Scheme 6.2). To further achieve a faster hydrolytic kinetics, we designed to 
replace the previous aliphatic isocyanate with aryl isocyanate. Aryl amines, as the degradation 
product of aromatic hindered ureas, have much lowered nucleophilicity than aliphatic amines and 
potentially generate much less undesired non-dynamic urea side product4 that is not well soluble 
in common solvents. 
 
Scheme 6.2. Fast and pH-independent hydrolysis of hindered aromatic ureas (HAU). The 




We designed a set of aryl ureas with distinguished electronic effect on the conjugated phenyl ring 
(Table 6.1) and the corresponding Keq were studied by 1H NMR through exchanging of the urea 
with a set of bulky amines in d-chloroform (Appendix Figure A34-45). Similar to our previous 
findings,3 the equilibrium constant of the aryl urea bond increases as the bulkiness of the 
substitution on amine decreases (Table 6.3). All of the three t-butyl-ethylureas (tBEU) showed 
high Keq (> 2×104) and the Keq increases as the phenyl ring becomes more electron deficient (Table 
6.1). The dissociation constant k-1 was measured by exchange study of the ureas with another 




Remarkably, the amine exchange of the tBEU could reach equilibrium within 20 minutes at room 
temperature in d-chloroform (Appendix Figure A46-A48). The k-1 of tBEU with aryl substitution 
is two orders of magnitudes larger than the reported aliphatic urea (Table 6.1) and among the fastest 
dynamic chemistries reported so far.45-48 In addition, the calculated k1 is larger than 105 M-1·h-1 
indicating that the urea formation can complete within seconds upon mixing. The substituent on 
the arene can remotely affect the HUB through electronic effect, thus offering an extra tunability 
on the Keq and k-1 of the bond, which is unprecedented in hindered urea chemistry. The large value 
of Keq also makes it possible to prepare large molecular weight aromatic hindered urea materials 
with quantitative conversion. 
Table 6.1. Equilibrium constants and dissociation rates of different N-t-butyl-N-ethyl ureas (tBEU) 
in d-chloroform at room temperature. k1 is calculated as Keq×k-1. The constant of aliphatic HUB 
(4) was adapted from reference.3  
 
We next studied the water degradation product of the aryl tBEU in water containing solvent. The 
degradation of the aryl tBEU in d6-DMSO were analyzed by 1H NMR. All of the three ureas 
showed fast degradation kinetics with hydrolysis half-life less than 1.5 hours at 37 oC in 5 % water 
 
107 
(v/v) containing d6-DMSO (Figure 6.15), which is 10 times faster than aliphatic HUB under the 
same condition.4 Furthermore, the lowered reactivity of the aryl amines greatly suppresses the 
formation of stable urea (Appendix Figure A49-A51) as the arylamine and secondary amine were 
the exclusive degradation products observed when the conjugated arene structure is electron 
deficient (Appendix Figure A51). 
 
Figure 6.1. Hydrolysis of phenyl-tBEU in 1:1 DMSO-aqueous buffer with various pH at room 
temperature analyzed by HPLC. (a) Chemical structure of Ph-tBEU and hydrolysis product. (b) 
Selected plot of ln ([urea]/[urea]0)-t in buffer solution at different pH and linear fittings. (c) Pseudo 
first order hydrolytic constant (kobs) of Ph-tBEU. The dotted line marked the measured k-1 of the 
Ph-tBEU under the same condition through exchange with 20 equivalent t-butyl amine.  
The hydrolysis of aryl tBEU at different pH was then studied in 1:1 DMSO-aqueous buffer solution 
at room temperature (23 oC). As being analyzed by HPLC, the degradation of phenyl-tBEU showed 
remarkably fast degradation throughout all the pH tested (Figure 6.1c) and the observed hydrolysis 
constant kobs was independent of pH ranging from 3-11 (Figure 6.1c). Fitting of the 
ln([urea]/[urea]0)-t revealed a linear relationship (R2>0.99), which indicated a first-order reaction 
kinetics (Figure 6.1b). More importantly, the apparent hydrolysis constant (kobs = 0.17 h-1) turned 
out to be equal to the k-1 of the urea in the same solvent condition (Figure 6.16), which clearly 
suggested that the hydrolysis rate of the urea is exclusively determined by the dissociation of HUB 
instead of the isocynate hydrolysis. Kinetic analysis of the hydrolytic kinetics confirmed that the 
overall urea degradation rate is determined by the urea dissociation and can be expressed as  
 𝑟(ℎ𝑦𝑑𝑟𝑜𝑙𝑦𝑠𝑖𝑠) = −
𝑑[𝑨]
𝑑𝑡
= 𝑘−1 [𝑨] 
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The above equation indicates that the hydrolysis is a first order reaction and the apparent hydrolysis 
rate kobs equals to the HAU bond dissociation constant k-1, which well matched the experimental 
results. 
We next measured the k-1 of different aromatic ureas by measuring the urea hydrolysis in water 
containing solvent (Table 6.2). It was found that k-1 of the aromatic urea was much smaller in 
DMSO-H2O mixed solvent (~0.5-2 h-1 at 37 oC) than that in d-chloroform (~5-11 h-1 at 25 oC, 
measured by aminolysis). Higer water content in the mixed solvent resulted in much slower urea 
hydrolysis and the calculated k-1 of the aromatic urea was tens of times smaller than that in d-
chloroform. The results indicated that the HUB dissociation is highly solvent dependent and 
polar/hydrophilic environment can significantly slow down the bond dissociation which may have 
negative impact in application of hydrophobic hydrolyzable HUB materials. 
Table 6.2. bond dissociation constant of aromatic ureas in different solvent as measured by 
aminolysis (d-chloroform) or hydrolysis (DMSO-water). 
 
Polymeric HAU (pHAU) were then prepared to characterize the hydrolytic feature of HAU in 
polymeric materials. Considering the wide availability of aryl isocyanates and bulky amines, a 
gigantic library of pHAU structures can be potentially generated by combination of the two 
components. As a proof of concept, we chose to adopt a simple alternating polymer structure by 
addition polymerization of methylene diphenyl diisocyanate (MDI) and N,N'-di-t-butyl-
R- T Solvent k-1(h
-1) t1/2 (h)
MeO
37 oC 50:50 d6-DMSO-D2O 2.3 0.30
25 oC CDCl3 11.2 0.062
H
37 oC 50:50 d6-DMSO-D2O 2.3 0.30
37 oC 50:50 DMSO-H2O 1.2 0.58
37 oC 10:90 DMSO-H2O 0.26 2.7
25 oC CDCl3 8.9 0.078
NO2
37 oC 50:50 d6-DMSO-D2O 0.58 1.19
25 oC CDCl3 5.7 0.12
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ethylenediamine at 1:1 molar ratio (Figure 6.2a). The polymer was then analyzed by gel 
permeation chromatography (GPC). Based on the calibration of polystyrene standards, the Mw of 
the MDI-tBEU polymer was calculated to be 4.5 kDa. In the presence of 5 % water (v/v) in THF 
at room temperature (23 oC), the polymer degraded into less than 50 % of the original Mw within 
10 minutes (Figure 6.2c) while the less bulky N,N-diethyl urea showed negligible Mw change under 
the same condition (Figure 6.17). The hydrolytic degradation of the MDI-tBEU polymer was also 
analyzed by 1H NMR in d7-DMF with 5 % (v/v) 0.1 M aqueous buffer solution of different pH 
(Figure 6.2d). The degradation product was confirmed to be mainly 4,4’methylenedianiline and 
N,N'-di-t-butyl-ethylenediamine at all pH tested (Appendix Figure A52-A55). Increased pH of the 
aqueous buffer (from pH 1 to 10) resulted in slightly faster hydrolysis kinetics while remarkable 
degradation was observed even at neutral pH. On the other hand, MDI-tBEU polymer was 
extremely stable under ambient storage condition. We stored the MDI-tBEU powder in capped 
scintillation vial at room temperature. No hydrolytic arylamine product was detected according to 
1H NMR analysis over 2 months. (Appendix Figure A56). 
 
Figure 6.2. Water degradation of aromatic HUB polymer. (a) Chemical structure of degradable 
linear HUB and degradation product. (b) Representative GPC trace of MDI-tBEU before and after 
water degradation in THF (5% v/v water content) at room temperature. (c) Relative molecular 
weight change of MDI-tBEU in 5% buffer-THF solution at room temperature. (d) Polyurea 
hydrolysis of MDI-tBEU in d7-DMF/H2O (95/5 v/v) at 37 oC analyzed by 1H NMR. 
To further explore the potential of the HUB materials for biomedical application, we tested HUB 
hydrolysis and cargo release in a gel system. A methacrylate based cross-linked gel was prepared 
with a fluorescent cargo, 2-(4-Aminophenyl)benzo-thiazole (BT-amine), covalently conjugated to 
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the polyacrylate backbone through HUB bond. The HUB bond can be easily incorporated into 
methacrylate monomer by reacting t-butyl-aminoethyl methacrylate with isocyanate and the 
resulting methacrylate can be UV cross-linked with other methacrylate and diacrylate monomers 
in the presence of 2,2-Dimethoxy-2-phenyl-acetophenone (DMPA) as the photoiniator (Figure 
6.3a). A control gel based on fluorescein methacrylate was also prepared to compare the hydrolytic 
cargo release of ester bond at different pH. The gels were immersed in aqueous buffers of pH 5.0, 
7.4 and 11.0 to test the release of conjugated BT-amine and fluorescein at 37 oC. The release 
kinetics of BT-amine was similar over pH 5 to 11 (Figure 6.3b). The release of BT-amine was 
slightly faster in acid medium likely due to the faster diffusion of the protonated BT-amine in 
acidic environment. In comparison, the control gel with fluorescein methacrylate showed distinctly 
different release kinetics of fluorescein at different pH – at acid pH, the release of fluorescein was 
minimal after 2 days while the release was 10 times faster at pH 11 (Figure 6.3c).  
 
Figure 6.3. Preparation of degradable organogel by UV cross-linking and release of fluorescent 
probe, 2-(4-Aminophenyl)-benzothiazole (BT-amine) and fluorescein via HUB, ester bond 
hydrolysis, respectively. (a) Schematic illustration of the BT-amine containing gel synthesis and 
release of BT-amine via HUB bond hydrolysis in aqueous buffer. (b) Release profile of BT-amine 
from the HUB gel in buffer of various pH at 37 oC analyzed by HPLC. (c) Release profile of 
fluorescein from the ester gel in buffer of various pH at 37 oC analyzed by HPLC. Data represent 
averages ± standard deviation (n = 3). 
Since the HUB can degrade fast at neutral pH, we next explore the potential of using aromatic 
HUB as a water degradable sacrificial coating materials. We prepared a degradable linear HUB 
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polymer (PDI-tBEU) from m-phenylene diisocyanate and N, N’-di-tert-butylethylene-diamine and 
a control polymer (PDI-DEU) that is not hydrolysable (Figure 6.4a).The polymer was dissolved 
in chloroform and then dip-coated onto a glass slide to form a transparent film. Water vapor was 
generated from boiling water and introduced to the surface of the glass slide. After 1 hour 
treatment, the remaining polymer coatings was weighed and the weight loss was used as a 
measurement of the degradation. The HUB polymer, PDI-tBEU showed significant degradation 
over the treatment while the control polymer had minimal loss (Figure 6.4b). The PDI-tBEU film 
turned from a transparent smooth film into an amorphous irregular shape due to the hydrolytic 
degradation. 
 
Figure 6.4. Water vapor treatment of an HAU coating on glass slides. (a) Chemical structure of 
PDI (1,3-phenylene diisocyanate)-tBEU, PDI-DEU, and corresponding degradation product under 
water vapor treatment. (b) weight loss of the pHAU coating on glass slides after 1 hour treatment. 
(c) photograph of the PDI-tBEU coating on glass slide before and after the treatment. The 
transparent film was etched into amorphous state after the treatment.  
In summary, we report a class of dynamic hindered aromatic ureas (HAU) with pH independent 
degradation profiles and fast hydrolytic kinetics. The urea bond dissociation of HAU is two order 
of magnitudes faster (k-1 >1 h-1) than the reported aliphatic hindered ureas3 and among the fastest 























commercial available aryl isocyanate with bulky secondary amine and remain stable in powder 
form under ambient condition for months while they can be quickly degraded within tens of 
minutes in solution even at neutral pH. The combined features of good stability in solid state and 
consistently fast hydrolysis at various pH is unprecedented in a simple material, which will have 
remarkable implications in materials design and applications such as sacrificial coatings, 
biomaterials, and surface erosion materials. 
6.3. Self-healing application of aromatic dynamic ureas 
After demonstrating the dynamic property and bond exchange features of HUBs, we next 
attempted to use HUBs in the design of catalyst-free, low-temperature self-healing materials. 
Specifically, we designed cross-linked poly(urethanurea)s containing HUBs and tested their self-
healing properties (Figure. 6.5). Trihydroxylmethyl propane (THMP) was used as the cross-linker 
and poly(propylene oxide) (Mw = 425) was used as the chain extender. Hindered diamines DEA 
(N,N'-diethyl-ethylenediamine) and TBEDA were used to form the corresponding HUB motifs 
(DEU and TBEU) in the desired network polymers. THMP, PPO and diamine were allowed to 
react with MDI in DMF with dibutyltin diacetate (DBTDA) as the catalyst to yield cross-linked 
poly(urethane-urea). The molar ratio of MDI:diamine:PPO:THMP was set at 10:3:5:1.5 for the 
synthesis of the self-healing material. The gels behaved as elastomers with good mechanical 
stiffness (Young’s modulus around 1 MPa). The self-healing property of the gels was then tested. 
We prepared the gel in a dog-bone-shaped mold and cut the gel in the middle by razor blade. After 
curing at room temperature under ambient condition, the TBEU gel showed fast self-healing due 
to the fast urea bond exchange (Figure 6.5c). In comparison, the non-dynamic DEU gel showed 
negligible healing property under the same condition depicting the importance of the dynamic 




Figure 6.5. (a) Chemical structures and ratios of components used for the synthesis of HUB-based 
cross-linked poly(urethane-urea). (b) & (c) Strain-stress curve of HUB gels before and after cut. 
The breaking strain of the cut and healed TBEU gel was efficiently and largely restored after 1 day 
of self-healing (100%) at room temperature. 
A key concern for the application of the HUB materials is the water stability over storage and in 
aqueous solutions. We used a model linear aromatic HUB, PDI-iPEU (Figure 6.6) to study its 
powder stability in ethanol-H2O solution. The fine polymer powder was suspended in 8:2 ethanol-
H2O solution and heated to 60 oC with vigorous mixing. Surprisingly, the polymer powder didn’t 
degrade with minimal weight loss over 2 days and the molecular weight of the polymer even 
increased more than 80% as analyzed by GPC (Figure 6.6c). 1H NMR analysis of the polymer 
powder suggested polymer structure was unchanged and no degradation of the urea bond was 
observed (Figure 6.7).  
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Figure 6.6. Stability test of a linear aromatic N-ethyl-N-isopropyl aromatic urea in ethanol/H2O 
mixture at 60 oC. (a) Chemical structure of the linear aromatic HUB. (b) Normalized GPC trace of 
the polymer over ethanol/H2O treatment. Polymers were collected by centrifugation and 
lyophilized before being subject to GPC analysis. (c) Molecular weight change of the polymer 



































Figure 6.7. 1H NMR of the PDI-iPEU polymer over ethanol/H2O treatment. No significant change 
was observed for polymers after the treatment and no new peaks between 6-7 ppm arose indicating 
no degradation of the urea into aromatic amine was present during the study. 
6.4. Conversion of dynamic hindered ureas to non-dynamic ureas by UV irradiation 
Turning a dynamic bond into permanent covalent bond can fix the dynamic molecule into non-
dynamic structure without the concern of molecular disassembly, and/or degradation due to the 
dynamic bond exchange. Various applications have been explored based on the bond-fixing 
chemistry including supramolecular assembly,2 macrocage and organic framework synthesis,1,49 
and malleable thermoset synthesis.5,50-52 Temperature,52,53 pH,50,54 and removal of catalyst55,56 are 
three major methods to tune the dynamicity of DCC such that the chemistry can have minimal 
exchange kinetics and be stable under ambient condition while the dynamic property can be 













above methods, however, can only reduce the exchange of the DCC to a relative low magnitude 
and the bond exchanging still occurs slowly which brings about material degradation over long-
term. Therefore, approach to permanently convert the dynamic bonding to non-dynamic structure 
represents an ideal strategy to fix the DCC into a permanently non-exchangeable structure. 
Reductive hydrogenation of imine, for example, is a widely used reaction to fix the dynamic 
exchange of amine-aldehyde with imine to form various covalent assembly network.46 
As is known that the N,N-disubstituted urea with a bulky group is dynamic while the mono-
substituted urea is non-dynamic,3 we hypothesized that by linking a cleavable group to the nitrogen 
atom in the HUB, we would be able to permanently convert the dynamic urea into non-dynamic 
(Scheme 6.3a). As a proof of concept, we designed a UV-cleavable o-nitrobenzyl substituted HUB, 
N-t-butyl-N-(2-nitrobenzyl)-N’-butylurea (tBNBU), which, upon UV treatment, can generate 
primary urea at high efficiency (Scheme 6.3b). tBNBU has a t-butyl and benzyl substitute on one 
of the nitrogen atom which has similar bulkiness as t-butyl and ethyl. The measure bonding 
dissociation constant k-1 of tBNBU, based on amine exchange, is 0.04 h-1 at 37oC and it has similar 
equilibrium constant Keq as its N-t-butyl-N-ethyl counterpart (Keq ~8.1×105).  
 
Scheme 6.3. (a) Design of trigger-responsive dynamic urea. The reversible bulky urea becomes 
irreversible after the removal of the bulky group generating mono-substituted urea. (b) 
Representative chemical structure for UV responsive HUB. The nitrobenzyl group can be cleaved 
under UV treatment. 
The UV degradation kinetics of tBNBU under UV treatment was first studied by NMR. 1H NMR 
showed that N-t-butyl-N’-butylurea was the exclusive degradation product of the urea (Figure 6.8) 
and the degradation reached more than 80% completion in d-acetonitrile within 2-minute UV 
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irradiation (Figure 6.9). The UV-vis absorption of the N-o-nitrobenzylurea also increased over UV 
irradiation and reached a plateau at 2 min (Figure 6.10). Further UV irradiation resulted in 
decreased absorption at 235 nm and increased absorption at 305 nm indicating the occurrence of 
side reactions of the UV-absorbing aromatic cleaving product. 
 
Figure 6.8. 1H NMR of o-nitrobenzyl-urea in CD3CN after UV treatment. N-t-butyl-N’-butylurea 
was the only product in the aliphatic region as compared with the standard compound. 
 
Figure 6.9. Reaction kinetics of the cleavable urea into N-t-butyl-N’-butylurea after UV treatment 








































Figure 6.10. (a) UV-vis absorption of UV treated nitrobenzyl-urea in acetonitrile. (b) Normalized 
absorption of the urea solution at 305 nm over UV treatment (UV intensity 50 mW/cm2). 
An aromatic UV-cleavable urea, N-t-butyl-N-(2-nitrobenzyl)-N’-phenylurea, was also prepared 
and its UV degradability was tested (Figure 6.11a). The aromatic urea has a comparable 
equilibrium constant as the t-butyl-ethyl urea (Keq~1.5×104). The UV cleavage kinetics of the 
aromatic urea is 4 times slower than that of the aliphatic one and the half-life is about 180 seconds 
in d-acetonitrile.  
 
Figure 6.11. (a) UV degradation of N-t-butyl-N-(2-nitrobenzyl)-N’-phenylurea. (b) Reaction 
kinetics of aromatic o-nitrobenzyl-urea under UV treatment (UV intensity 50 mW/cm2).  
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The above preliminary studies clearly demonstrated that UV treatment can be a method to control 
the dynamicity of hindered urea bond if the hinder urea is properly designed. UV cleavage of the 
o-nitrobenzyl group can be cleaved within a few minutes generating a primary urea that is not 
reversible. 1H NMR analysis confirmed the primary urea as the only urea product generated in the 
process although series of colored aromatic byproducts were identified over extensive UV 
irradiation. We also tested the linear polyurea with the nitro-benzyl group substituent on the main 
chain urea bond (data not shown), however, the linear polymer still degraded significantly upon 
aminolysis after 15-minute UV (50 mW/cm2) irradiation. Although the o-nitrobenzyl can be 
removed upon UV treatment, the polymer study indicated that the o-nitrobenzyl chemistry is not 
efficient to achieve a quantitative urea conversion within a complicated macromolecular structure 
and is highly sensitive to the environment of the bondings. Further development of the N-
substituent chemistry is desired to improve the dynamicity control of the hindered urea bond. 
6.5. Materials and methods 
Materials. 
Chemicals were purchased and used as received unless otherwise specified. Anhydrous 
dimethylformamide (DMF) was dried with a column packed with 4Å molecular sieves. 
Tetrahydrofuran (THF) were dried with a column packed with alumina. Phosphate buffered saline 
(PBS) was purchased from Mediatech, Inc. HPLC grade 0.1% TFA-H2O and acetonitrile were 
purchased from Fisher Scientific Company LLC (Hanover Park, IL, USA). All other chemicals 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Instrumentation.  
NMR spectra were recorded on a Varian U500 (500 MHz) or VXR-500 (500 MHz) spectrometer. 
All chemical shifts were reported in part per million (ppm). HPLC tests were performed on a 
Shimadzu HPLC system (LC-20AT) connected with PDA detector (SPD-M20A) and fluorescence 
detector (RF-20A). Shimadzu C18 column (3 µm, 50 mm × 4.6 mm) was used for analysis. 
Gradient method was adopted using 0.1 % TFA-H2O and acetonitrile as mobile phase. Tandem 
gel permeation chromatography (GPC) was performed on a system equipped with an isocratic 
pump (Model 1200, Agilent Technologies, Santa Clara, CA, USA), a DAWN HELEOS multi-
angle laser light scattering detector (MALLS); (Wyatt Technology, Santa Barbara, CA, USA), and 
an Optilab rEX refractive index detector (Wyatt Technology). The detection wavelength of the 
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HELEOS was set at 658 nm. Separations were performed on serially connected size exclusion 
columns (100 Å, 1000 Å, 104 Å, 105Å and 106 Å Phenogel columns, 5 μm, 300 × 7.8 mm, 
Phenomenex, Torrance, CA, USA) at 60 °C with DMF containing 0.1 M LiBr as the mobile phase. 
The HELEOS detector was calibrated with pure toluene without using external polymer standards 
and was used for the determination of the absolute molecular weights. The molecular weight of 
polymer was determined from the dn/dc value calculated assuming 100% mass recovery, and was 
processed by ASTRA software (Version 6.1.1, Wyatt Technology). 365 nm UV light was generated 
from an OmiCure S1000 UV lamp (EXFO, Mississauga, Canada) and the light intensity was calibrated 
by General® UVAB digital light meter (UV513AB). 
Synthesis of N-t-butyl-N-ethyl-N’-aryl urea. 
Aryl isocyanate (0.20 mmol) was mixed with N-t-butyl- ethylamine (26 mg, 36 µL, 0.26 mmol) in 
methylene chloride (0.5 mL). The precipitates (hydrolyzed urea/aryl amine from the isocyanate if 
present) were discarded through centrifugation. Then solvent was removed completely under 
vacuum giving white (4-methoxyphenyl and phenyl tBEU)/ yellow (4-nitrophenyl tBEU) powder 
as pure product as confirmed by 1H NMR.  
MeO-Ph-tBEU: 1H NMR (500 MHz, CDCl3), δ 7.23 (d, 2H, J = 9.0 Hz), 6.83 (d, 2H, J = 9.0 Hz), 
6.18 (br, 1H), 3.77 (s, 3H), 3.38 (q, 2H, J = 7.5Hz), 1.47 (s, 9H), 1.28 (t, 3H, J = 7.5Hz). 13C NMR 
(126 MHz, CDCl3) δ 156.6, 155.7, 132.6, 122.5, 114.2, 56.5, 55.7, 39.6, 29.6, 17.0. HRMS-ESI 
(m/z): [M+H]+ calcd for C14H23N2O2+, 251.1754; observed, 251.1759. 
Ph-tBEU: 1H NMR (500 MHz, CDCl3), δ 7.33 (dd, 2H, J1 = 8.5 Hz, J2 = 1.5 Hz), 7.27 (dd, 2H, J1 
= 7.0 Hz, J2 = 8.5 Hz), 7.00 (dt, 1H, J1 = 7.0 Hz, J2 = 1.5 Hz), 6.31 (br, 1H), 3.77 (s, 3H), 3.39 (q, 
2H, J = 7.0Hz), 1.48 (s, 9H), 1.29 (t, 3H, J = 7.0Hz). 13C NMR (126 MHz, CDCl3) δ 156.1, 139.6, 
128.9, 122.8, 120.1, 56.6, 39.7, 29.6, 17.0. HRMS-ESI (m/z): [M+H]+ calcd for C13H21N2O+, 
221.1648; observed, 221.1648. 
NO2-Ph-tBEU: 1H NMR (500 MHz, CDCl3), δ 8.15 (d, 2H, J = 9.0 Hz), 7.50 (d, 2H, J = 9.0 Hz), 
6.68 (br, 1H), 3.42 (q, 2H, J = 7.0Hz), 1.49 (s, 9H), 1.30 (t, 3H, J = 7.0Hz). 13C NMR (126 MHz, 
CDCl3) δ 154.7, 146.1, 142.2, 125.1, 118.6, 57.2, 39.7, 29.4, 17.0. HRMS-ESI (m/z): [M+H]+ calcd 




Binding constant measurement for aryl hindered urea in d-chloroform. 
The binding constant (Keq) was measured through indirect method used previously.3,4 The Keq of 
the hindered urea bond increases with the decrease of the substituents bulkiness. Briefly, the Keq 
of the equilibrium shown in Scheme 6.4 was measured in d-chloroform and the Keq of each aryl 
urea was calculated accordingly (Appendix Figure A34-A45). The results were summarized in 
Table 6.3. 
 
Scheme 6.4. Chemical structure and binding constant measurement of bulky aryl ureas.  
Determination of dissociation constant (k-1) of aromatic hinder ureas. 
N-t-butyl-N-ethyl-N’-aryl urea (tBEU) 
The dissociation constant (k-1) of corresponding hinder ureas were determined through exchange 
experiment. Briefly, a d-chloroform(550 µL) solution of tBEU (0.050 mmol) was mixed with N-
methyl-t-butyl-amine (1 eq). Then the mixture was monitored with 1H NMR. The ratio of the two 
ureas was quantified by integration of the methyl/methylene hydrogen adjacent to the nitrogen 
atom. (Appendix Figure A46-A48) Linear regression of ln(
[𝑐tBEU]
[𝑐tBEU]0
− A) ~ t giving the slope as the 
dissociation constant (k-1), in which A = [ctBEU]/( [ctBEU]+ [ctBMU]).3 (Figure 6.12) 
N,N-diethyl-N’-aryl urea and N-t-ethyl-N-isopropyl-N’-aryl urea. 
Similar method as tBEU was adopted except that 10 equivalent t-butylamine or n-butyl amine was 
used. All the obtained k-1 was summarized in Table 6.3. 
 
122 
Determination of hydrolysis kinetics of hindered aromatic urea bonds (HAU) in d6-DMSO 
at 37 oC by 1H NMR. 
In a typical experiment, tBEU (5 mg) was dissolved in d6-DMSO (475 µL) and H2O (25 µL). The 
clear solution was then placed in NMR instrument at 37 oC. The composition was constantly 
monitored by 1H NMR every 5 minutes. The urea percent was quantified by the peak integration 
ratio of the t-butyl group in the urea (9 H, 1.38-1.43 ppm) over t-butyl+methylene group in the 
amine (11 H, 0.99-1.06 ppm). (Appendix Figure A49-A51) 
HPLC analysis of Ph-tBEU hydrolysis kinetics in 50:50 DMSO-H2O at 37 oC. 
Ph-tBEU stock solution was prepared in DMSO as 2 mg/mL. The solution was diluted with 1:1 
DMSO/buffer to 20 µg/mL (~10-4 M) and incubated at 37 oC. At specified time, the solution was 
analyzed by HPLC to quantify the remaining tBEU content by HPLC standard calibration curve 
(λabs = 264 nm).  
The standard sample of Ph-tBEU was prepared by diluting the above stock solution with 
acetonitrile to a 2 fold serial dilution and analyzed instantly after preparation. The pH 3-11 buffer 
cocktail was prepared by mixing 0.1 M Na2HPO4, (NH4)2CO3, citric acid and adjusted pH using 1 
M NaOH/HCl (aq), monitored by pH meter to 0.1 unit. 
Determination of Ph-tBEU dissociation constant (k-1) in 50:50 DMSO-H2O at 37 oC. 
To a 1:1 DMSO/H2O solution of Ph-tBEU (1 mg/mL) was added t-butyl amine (5 µL, ~10 equiv). 
The clear solution was then incubated in 37 oC shaker. At specified time point, an aliquot of 20 µL 
was diluted with 980 µL 0.1 % TFA-H2O for HPLC analysis. The Ph-tBEU concentration was 
quantified by standard calibration curve. Different from that of hydrolysis experiment, a new peak 
representing exchanged urea (N-t-butyl phenyl urea) showed up and its integrated UV absorption 
area matched the disappearance of the Ph-tBEU (Appendix Figure A47) indicating the reaction 
was exclusively amine exchange with negligible hydrolysis. The dissociation constant and half life 
of the tBEU was calculated through linear regression of ln([tBEU]/[tBEU]0)-t. (Figure 6.15) 











=  𝑘2[𝑪][𝐻2𝑂] (1) 
Since the isocyanate B is an intermediate with very low concentration during hydrolysis, a steady-
state approximation expressed as Equation (2) can thus be deduced: 
𝑘2[𝑪][𝐻2𝑂] + 𝑘1[𝑩][𝑪] = 𝑘−1[𝑨] (2) 
[𝑪] =  
𝑘−1[𝑨]
𝑘1[𝑩] + 𝑘2 [𝐻2𝑂]
 (3) 
When 𝑘2[𝑪][𝐻2𝑂] ≫ 𝑘1[𝑩][𝑪] 
The concentration of C can be simplified as following: 
[𝑪] =  
𝑘−1[𝑨]





The hydrolysis rate of the HAU is 
 𝑟(ℎ𝑦𝑑𝑟𝑜𝑙𝑦𝑠𝑖𝑠) = −
𝑑[𝑨]
𝑑𝑡
= 𝑘2[𝐻2𝑂][𝑪] = 𝑘2[𝐻2𝑂] ×
𝑘−1[𝑨]
𝑘2 [𝐻2𝑂]
=  𝑘−1 [𝑨] (5)  
Which is a first order kinetic with the HAU bond dissociation constant as the apparent hydrolysis 
rate kobs as the urea dissociation is the rate-determining step during hydrolysis. 
Synthesis of MDI- tBEU polymer and stability test under ambient condition. 
4,4’-Methylene diphenyl diisocyanate (MDI) (100 mg, 0.40 mmol) was mixed with N,N'-di-t-
butyl-ethylenediamine (69 mg, 86 µL, 0.40 mmol) in chloroform (300 µL) at room temperature 
for 5 minutes. Then solvent was removed under vacuum pump giving a white powder as polymer. 
The polymer powder was stored in a capped 7 ml scintillation vial without seal. The polymer was 
dissolved and analyzed in d-chloroform by 1H NMR over 2 month. No peaks were observed in 
region δ 6.5-6.9 ppm indicating no hydrolytic aryl amine product in the polymer. 
Determination of pHAU hydrolysis kinetics in water containing organic solvent. 
GPC measurement 
The stored MDI-tBEU polymer powder was dissolved in THF as a 5 mg/mL solution and mixed 
with 5 % v/v buffer cocktail of pH 3, 7, and 11. The clear solution was then incubated at room 
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temperature (25 oC) and the Mw was monitored by THF GPC at room temperature (one 
Phenomenex Phenogel 5 µm column, 103 Å).  
1H NMR measurement 
The polymer was dissolved in 500 µL d7-DMF as 5 mg/mL solution. The obtained solution was 
mixed with 5% (v/v) PBS buffer (pH=1), citric acid-Na2HPO4 buffer (pH=4), PBS (pH=7), 
nothing, respectively. The polymer degradation was monitored by 1H NMR and the urea per cent 
was calculated as the ratio of two peaks at (7.5-7.8 ppm)/(6.7-6.9 ppm). 
Control polymer (MDI-DEU) preparation and degradation in 5% H2O containing DMF at 
37 oC*. 
MDI (1.05 g, 4.2 mmol) was mixed with N, N’-di-ethyl ethylene diamine (488 mg, 4.2 mmol) in 
chloroform (2 mL) at room temperature. White precipitates formed immediately and were 
sonicated for 20 minutes. Then the solvent was removed under vacuum and the polymer was 
obtained as white powder. The polymer was dissolved in DMF as 5 mg/ml solution and mixed 
with 5 % v/v H2O. The clear solution was then incubated at 37 oC and the Mw was monitored by 
DMF GPC at 60 oC.  
 
Synthesis of BTP-HUB-MA 
A chloroform suspension (3 mL) of 2-(4-Aminophenyl)benzothiazole (23 mg, 0.10 mmol) was 
mixed with 15 wt% phosgene toluene solution and refluxed overnight during which the 2-(4-
Aminophenyl)benzothiazole gradually dissolved. The solvent and excessive phosgene was 
removed by pump. The remaining solid was then suspended in DCM (4 mL) and 2-(tert-
butylamino)ethyl methacrylate (22 mg, 24 µL, 0.12 mmol) was added, The yellow suspension 
turned clear within 1 minutes and was concentrated, subject to chromatography (hex:ethyl acetate, 
                                                 
* The MDI-DEU was not well-dissolved in THF so DMF was used as solvent for the degradation study instead. 
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6:1) giving yellow powder as the product (23 mg, yield: 52%). 1H NMR (500 MHz, CDCl3), δ 
8.08 (s, 1H), 8.02 (3H), 7.87 (d, 2H, J = 8.0 Hz), 7.69 (d, 2H, J = 9.0 Hz), 7.46 (dd, 1H, J1 = J2 = 
8.0 Hz), 7.34 (dd, 1H, J1 = J2 = 8.0 Hz), 6.21 (s, 1H), 5.70 (s, 1H), 4.33 (t, 2H, J = 7.0 Hz), 3.56 
(t, 2H, J = 7.0 Hz), 2.00 (s, 3H), 1.50 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 168.46, 168.28, 
156.17, 154.35, 143.02, 135.74, 134.97, 128.38, 127.59, 127.32, 126.27, 124.87, 122.92, 121.61, 
119.50, 64.77, 56.92, 43.26, 29.27, 18.40. HRMS-ESI, (m/z): [M+H]+ calcd for C24H28N3O3S+, 
438.1846; observed, 438.1844. 
Synthesis of BTP-HUB-MA containing hydrophilic cross-linked hindered polyurea gel. 
Poly(ethylene glycol) methyl ether methacrylate (Mw 475, 950 mg, 2.0 mmol), Poly(ethylene 
glycol) dimethacrylate (Mw 700, 70 mg, 0.10 mmol), and DMSO solution (20 µL) of BTP-HUB-
MA (0.2 mg, 0.0004 mmol) and 2,2-Dimethoxy-2-phenylacetophenone (10 mg, 0.04 mmol) were 
mixed and irradiated by UV (365 nm, 40 mW/cm2) for 15 min to yield cross-linked gel G1.  
BT-amine release from organogel G1. 
G1 (50 mg) was placed in 15 mL vial and swelled with H2O (10 mL) at 37 oC for 30 minutes. The 
aqueous suspension was then centrifuged at 6 krpm for 10 minutes. The supernatant was carefully 
removed and the gel was immersed in 5 mL aqueous buffer cocktail of different pH 
aforementioned and was stirred vigorously at 37 oC. At designated time, an aliquot of 600 µL was 
removed and centrifuged at 8 krpm for 5 minutes. 500 µL supernatant was taken for HPLC analysis 
to quantified the 2-(4-Aminophenyl)benzothiazole (BT-amine) (λex = 360 nm, λem = 430 nm) by 
standard fluorescence calibration curve. The experiment was done in triplicate and the results are 
presented as mean value ± standard deviation. 
 
Scheme 6.5. Schematic illustration of the fluorescein containing gel synthesis and release of 






Synthesis of fluorescein methacrylate containing hydrophilic cross-linked polyester gel (G2). 
Poly(ethylene glycol) methyl ether methacrylate (Mw 475, 950 mg, 2.0 mmol), Poly(ethylene 
glycol) dimethacrylate (Mw 700, 70 mg, 0.10 mmol), and DMSO solution (20 µL) of fluorescein 
methacrylate (1.0 mg, 0.0025 mmol) and 2,2-Dimethoxy-2-phenylacetophenone (10 mg, 0.04 
mmol) were mixed and irradiated by UV (365 nm, 40 mW/cm2) for 15 min to yield cross-linked 
gel G2.  
Fluorescein release from organogel G2. 
G2 (145 mg) was placed in 15 mL vial and swelled with H2O (15 mL) at 37 oC for 30 minutes. 
The aqueous suspension was then centrifuged at 6 krpm for 10 minutes. The supernatant was 
carefully removed and the gel was the suspended in 15 mL DI H2O. The gel suspension was then 
separated (1 mL each) into vials, diluted with 4 mL buffer cocktail aforementioned and was stirred 
vigorously at 37 oC. At designated time, an aliquot of 800 µL was removed and centrifuged at 10 
krpm for 10 minutes. 600 µL supernatant was taken for HPLC analysis to quantified fluorescein 
(λex = 440 nm, λem = 532 nm) by standard fluorescence calibration curve. The experiment was done 
in triplicate and the results are presented as mean value ± standard deviation. 
Water vapor degradation of PDI-tBEU polymer film on glass slide.  
PDI-tBEU polymer was synthesized by mixing m-phenylene diisocyanate (143 mg, 0.87 mmol) 
and N, N’-di-tert-butylethylene-diamine (155 mg, 0.87 mmol) in chloroform (400 µL) and stirred 
at room temperature for 1h. The light yellow solution turned viscous indicating the formation of 
high molecular weight polymer. PDI-DEU polymer was prepared similarly using m-phenylene 
diisocyanate (225 mg, 1.4 mmol) and N, N’-di-ethylethylene-diamine (163 mg, 1.4 mmol) in 
chloroform (2 mL). 50 µL of the polymer solution was then mixed with 450 µL chloroform giving 
a 3.3% polymer solution that was then dip-cast on a pre-weighed glass slide (~1*3 cm) and let dry 
under air. Another 500 µL 3.3% polymer solution was cast on the film giving about 20 mg polymer 
as a film on the glass slide. The film on the glass slide was dried under vacuum overnight and then 
placed in a pre-weighed 20 mL vial. Water vapor was generated from a 250 mL round bottom 
flask and introduced to the vial through a rubber tube connected glass pipette. The glass slide was 
treated with the water vapor for 1 h during which the condensed water in the 20 mL vial was 
carefully removed by pipette without agitating the film and the polymer solid peeled from the film. 
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The remaining content in the vial was lyophilized and weighed to calculate the weight loss of the 
film. Each experiment was triplicated to obtain an average and standard error of the results. 
Preparation of Self-healing elastomer. 
In glovebox was mixed methylenediphenyl diisocyanate (MDI, 5.0 g, 20 mmol), polypropylene 
oxide (Mw 425, 4.25 g, 10 mmol), 2,2-dihydroxylmethylpropanol (402 mg, 3 mmol) and DMF 
(2.82 mL, 20 wt% to all component) in 20 mL vial. N,N’-di-t-butylethylene diamine (1.03 g, 1.29 
mL, 6 mmol) was added slowly with mild stirring, during which the MDI gradually dissolved. The 
clear solution was then exposed to ambient atmosphere and poured onto dog-bone shape mold 
(~1mL polymer mixture each) separately with/without DBTDL (5 µL in each mold). The gel was 
incubated at room temperature in desiccators overnight . The gel was peeled off the mold, cut by 
razor blade and then put back for designated time at room temperature and subject to mechanical 
test. Stress–strain experiments were performed on a custom-built, bidirectional screw-driven rail 
table that allows tensile testing of samples with both grips translating simultaneously and in 
opposite directions, keeping the center of mass of the sample stationary. The samples were 
extended at the speed of 0.2 mm/s. Load was measured via a 22 N capacity load cell. 
Synthesis of linear PDI-iPEU polymer. 
To DMF solution (10.9 mL) of N,N’-diisopropylethylenediamine (539 mg, 3.74 mmol) was mixed 
with 1,3-phenylene diisocyanate solid (598 mg, 3.74 mmol). White precipitates were formed and 
the suspension was heated to 50 oC for 3 hours. The mixture was cooled to room temperature and 
precipitated in 40 mL ethyl ether. The polymer was collected by centrifugation, resuspended in 
5mL DCM, precipitated in 40 mL ether again. The polymer was then dried as white powder. (950 
mg, 84% yield). dn/dc: 0.1211, Mn = 25.8 kDa, Mw = 36.3 kDa, PDI = 1.41. 
Water stability of a linear aromatic HUB polymer in ethanol/H2O. 
15 mg PDI-iPEU powder was suspended in 2 mL 8:2 EtOH:H2O solution and stirred at 60 oC. At 
designated time, the suspension was transferred to a 15 mL centrifuge tube and centrifuged at 6 
krpm for 5 min. The supernatant was carefully decanted and the solid was lyophilized to remove 
residue water and ethanol. The remaining polymer was then dissolved in DMF and analyzed by 
DMF GPC or dissolved in d6-DMSO for 1H NMR analysis. The experiment was triplicated and no 
significant polymer weight loss was observed over the course of the study.  
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Synthesis of UV-HUB. 
 
N-isopropyl-o-nitrobenzyl amine was synthesized by mixing o-nitrobenzyl bromide, isopropyl 
amine and K2CO3 in acetone at room temperature. The suspension was filtered to remove inorganic 
salts. The solution was concentrated and subject to column (DCM/Hex 1:1 to Methoanol) giving 
384 mg yellow oil (66% yield) as the product. 1H NMR (500 MHz, CDCl3), δ 7.91 (d, 1H, J = 8.0 
Hz), 7.69 (d, 1H, J = 7.5 Hz), 7.57 (dd, 1H, J1 = J2 = 7.5 Hz), 7.39 (dd, 1H, J1 = 8.0 Hz, J2 = 7.5 
Hz), 3.96 (s, 2H), 1.19 (s, 9H). 
Synthesis of N-t-butyl-N-(2-nitrobenzyl)-N’-butylurea  
N-t-butyl-2-nitrobenzylamine (72 mg, 0.35 mmol) and n-butyl isocyanate (52 mg, 46 µL, 0.52 
mmol) was mixed in methylene chloride (1 mL) for a few minutes. The clear solution was then 
subject to flash chromatography. DCM/MeOH 20:1 giving light yellow powder as the product 
(101 mg, yield 94%). 1H NMR (400 MHz, CDCl3), δ 8.13 (d, 1H, J = 6.8 Hz), 7.70 (2H), 7.47 (m, 
1H), 4.82 (s, 2H), 4.09 (br, 1H), 3.12 (dt, 2H, J1 = 5.7 Hz, J2 = 4.5 Hz), 1.43 (s, 9H), 1.35 (s, 2H), 
1.20 (s, 2H), 0.84 (t, 3H, J = 6.0 Hz). 
UV triggered degradation of N-t-butyl-N-(2-nitrobenzyl)-N’-butylurea (tBNBU). 
In quatz flask was dissolved N-t-butyl-N-(2-nitrobenzyl)-N’-butylurea in 3 mL CDCl3 at 3 mg/mL 
(or 4 mg/mL d3-acetonitrile). The clear solution was irradiated with UV light at 50 mW/cm2. At 
designated time point, an aliquot of 550 μL was taken out and characterized by 1H NMR.  
UV-vis measurement of the N-t-butyl-N-(2-nitrobenzyl)-N’-butylurea upon UV treatment. 
In quatz flask was dissolved the N-t-butyl-N-(2-nitrobenzyl)-N’-butylurea in 5.0 mL acetonitrile 
at 2 mmol/L. The clear solution was irradiated with UV light at 50 mW/cm2. At designated time 
point, an aliquot of 100 μL was taken out and diluted with acetonitrile to 3.0 mL as 0.67 mmol/L 




Table 6.3. Equilibrium constant of aromatic ureas with varying steric hindrance on amine.  
 
Figure 6.12. Linear regression of ln(
[𝑐tBEU]
[𝑐tBEU]0
− A) ~ t.. (A = 
[𝑐tBEU]eq
[𝑐tBEU]0
) Relative concentration of 
TBEU was calculated from 1H NMR integration from Appendix Figure A49-51. 
TMPCA TBIPU TBEU TBMU
13 4.9×102 2.8×104 2.0×105
16 5.4×102 3.0×104 2.1×105
5.6×102 3.6×104 2.6×106 2.0×107





















Figure 6.13. Linear regression of ln(
[𝑐IPEU]
[𝑐IPEU]0
− A) ~ t. (A = 
[𝑐IPEU]eq
[𝑐IPEU]0
) Relative concentration of 
MeO-Ph-DIPU was calculated from 1H NMR integration. 
 
Figure 6.14. Linear regression of ln(
[𝑐IPEU]
[𝑐IPEU]0
− A) ~ t.. (A = 
[𝑐IPEU]eq
[𝑐IPEU]0
) Relative concentration of 
MeO-Ph-IPEU was calculated from 1H NMR integration. 
 











































Table 6.4. Summary of dissociation constants of aromatic hindered ureas in d-chloroform as 
measured by 1H NMR. 
 
Figure 6.15. Hydrolysis of tBEU in d6-DMSO with 5% H2O (v/v) at 37 oC. (a) Hydrolysis kinetics 
of tBEU with various substitution. (b) Apparent hydrolytic constant and half life of the tBEU.  
  
R1 R2 R3 T k-1(h
-1)
MeO Et t-Bu 25 oC 11.2
H Et t-Bu 25 oC 8.9
NO2 Et t-Bu 25 
oC 5.7
MeO i-Pr i-Pr 25 oC 0.035
MeO i-Pr i-Pr 37 oC 0.20
H i-Pr i-Pr 37 oC 0.18
NO2 i-Pr i-Pr 37 
oC 0.22



























pH kobs (h-1) R2 
2.0 0.294 0.999 
3.0 0.182 0.998 
4.0 0.175 0.998 
5.0 0.170 0.999 
6.0 0.170 0.998 
7.0 0.170 0.999 
8.0 0.170 0.999 
9.0 0.183 0.991 
10.0 0.184 0.991 
11.0 0.190 0.991 
k-1 0.169 0.999 
Table 6.5. Summary of first order hydrolytic constant (kobs) and dissociation constant (k-1) of Ph-
tBEU in 1:1 DMSO:buffer at room temperature. 
 
Figure 6.16. k-1 measurement of Ph-tBEU in 50% DMSO-H2O at 23 oC by HPLC. (a) HPLC trace 
of the exchange mixture. The rising peak at 1.7 minutes is the N-t-butyl-N’-phenyl urea and the 
integrated area matched the consumed Ph-tBEU indicating hydrolysis is negligible in the process. 
(b) linear regression of the Ph-tBEU concentration. The calculated k-1 is 0.17 h-1.  
R2 = 0.999
a) b)





















Figure 6.17. (a) Chemical structure of non-degradable linear HUB structure. Note that the N-
substitution is less bulky than tert-butyl group and the polymer is much less dynamic that MDI-
tBEU. (b) Relative molecular weight change of MDI-DEU in 5% H2O-DMF solution at 37 oC.  
6.6. Conclusion 
In summary, we explored various aspects of the dynamic hindered urea chemistry based on our 
previous work on aliphatic HUB dynamicity and self-healing,3 water degradation,4 and malleable 
thermoset.5 We demonstrated for the first time that the aromatic hindered ureas can have hundred 
time higher dissociation kinetics (k-1) than their aliphatic counterpart. The bond equilibrium 
constant (Keq) of N-t-butyl-N-ethyl aromatic ureas is lower than aliphatic ones, which makes 
preparation of high molecular weight linear polymers difficult for N-t-butyl-N-ethyl aromatic 
ureas. Alternatively, N-ethyl-N-isopropyl aromatic ureas have higher Keq and comparable k-1 as the 
aliphatic tBEUs, which makes them promising dynamic materials for material applications. The 
dynamic urea dissociation was further shown to be highly environment dependent based on the 
hydrolysis study – The HUBs exchange slower in polar and hydrophilic solvent. The self-healing 
property of aromatic HUB was also explored in an elastomer. Room temperature self-healing was 
observed with up to quantitative mechanical strength recovery. A water stability study of a linear 
aromatic HUB solid powder showed negligible degradation even in ethanol/H2O mixture and Mw 
increased overtime indicating that the hydrolytic concern for the HUB may be properly addressed 
through rational design of a hydrophobic environment around the HUB. At last, we demonstrated 
as proof-of-concept that UV light can be an efficient trigger to turn the dynamic HUB into 




















permanent covalent bonding. To the best of our knowledge, this is the first example to use light to 
control dynamicity of a reversible chemistry. The underlying mechanism can potentially facilitate 
further design of complex smart materials that require a spatially controlled dynamicity within the 
3D structure. 
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NMR SPECTRA OF NEW COMPOUNDS AND DYNAMIC UREAS* 
A.1 Content of Appendix A  
NMR characterization of new compounds including all drug dimers (Chapter 2-4), chain shattering 
polymers  (Chapter 5) hindered ureas and NMR measurement of hindered urea equilibrium 
constant (Chapter 6) are presented in this section. 
A.2 NMR of new compounds in Chapter 2  
 
 
Figure A1. 1H and 13C NMR of 3-azidopropanol 
                                                 
* Part of this chapter is adapted from the publication: (1) Cai, K.; He, X.; Song, Z.; Yin, Q.; Zhang, Y.; Uckun, F.M.; 
Jiang, C.; Cheng, J. "Dimeric Drug Polymeric Nanoparticles with Exceptionally High Drug Loading and Quantitative 
Loading Efficiency", J. Am. Chem. Soc., 2015, 137, 3458-3461. (2) Cai, K.; Yen, J.; Yin, Q.; Yang, L.; Song, Z.; 
Lezmi, S.; Zhang, Y.; Yang, X.; Helferich, G.; Cheng, J.*, "Redox-Responsive Self-Assembled Chain-Shattering 































Figure A3. 1H 13C NMR of N3-SS-BHA-OTBS 
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A.3 NMR of new compounds in Chapter 3  
 
 









































































Figure A16. 1H and 13C NMR of BE-BHP-OH2. 
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Figure A17. 1H and 13C NMR of BE-CPT2.  
e, h 
f, g 
j, c, h 
q r u 























Figure A19. 1H NMR of Dox-SS-Dox. 
 




Figure A21. 1H NMR of CPT3-SS-N3. 
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A.4 NMR of new compounds in Chapter 4  
 
 
Figure A23. 1H and 13C NMR of hQ-BHP-OTBS. 
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Figure A24. 1H and 13C NMR of hQ-BHP-OH. 











Figure A25. 1H and 13C NMR of hQ-CPT2. 
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Figure A26. 1H and 13C NMR of Boc-OTBS2. 
 











Figure A27. 1H and 13C NMR of Boc-OH2. 
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A.5 NMR of new compounds in Chapter 5  
 
Figure A29. 1H NMR of SS-CSPT 
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Figure A30. 1H NMR of SS-CSPT-PEG 










A.6 NMR of new compounds and measurement of hindered urea equilibrium constants in 
Chapter 6  
 
 

















Figure A34. 1H NMR spectrum of equilibrated mixture of 4-methoxylphenyl-isocyanate and 
TMPCA in CDCl3.  







Figure A35. 1H NMR spectrum of equilibrated mixture of MeO-Ph-TMPCU and TBIPA in 
CDCl3.  








Figure A36. 1H NMR spectrum of equilibrated mixture of MeO-Ph-TBIPU and TBEA in 
CDCl3.  











Figure A37. 1H NMR spectrum of equilibrated mixture of MeO-Ph-TBEU and TBMA in 
CDCl3.  










Figure A38. 1H NMR spectrum of equilibrated mixture of phenyl-isocyanate and TMPCA in 
CDCl3. 
c0 (NCO)= 0.083 mol/L  








Figure A39. 1H NMR spectrum of equilibrated mixture of Ph-TMPCU and TBIPA in CDCl3. 







Figure A40. 1H NMR spectrum of equilibrated mixture of Ph-TBIPU and TBEA in CDCl3. 








Figure A41. 1H NMR spectrum of equilibrated mixture of Ph-TBEU and TBMA in CDCl3. 








Figure A42. 1H NMR spectrum of equilibrated mixture of 4-nitrophenyl-isocyanate and TMPCA 
in CDCl3. 
c0 (NCO)= 0.083 mol/L  







Figure A43. 1H NMR spectrum of equilibrated mixture of NO2-Ph-TMPCU and TBIPA in 
CDCl3. 








Figure A44. 1H NMR spectrum of equilibrated mixture of NO2-Ph-TBIPU and TBEA in CDCl3. 








Figure A45. 1H NMR spectrum of equilibrated mixture of NO2-Ph-TBEU and TBMA in CDCl3. 








































































Figure A51. 1H NMR spectrum of NO2-Ph-tBEU in d6-DMSO with 5% H2O (v/v) at 37 oC.  
  







Figure A52. 1H NMR of MDI-tBEU before and after degradation in 5 % PBS buffer (pH=1) 
containing d7-DMF.  
 
Figure A53.1H NMR of MDI-tBEU before and after degradation in 5 % PBS-citrate buffer (pH=4) 










Figure A54. 1H NMR of MDI-tBEU before and after degradation in 5 % PBS buffer (pH=7) 
containing d7-DMF.  
 
Figure A55. 1H NMR of MDI-tBEU before and after degradation in 5 % PBS buffer (pH=10) 










Figure A56. 1H NMR of MDI-tBEU powder stored in glass vial under ambient condition.. No 


























Figure A58. 1H NMR of N-t-butyl-2-nitrobenzylamine.. 
 
 
Figure A59. 1H NMR of N-t-butyl-N-(2-nitrobenzyl)-N’-butylurea. 
 
